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Abstract
Health supplement products contain ingredients of more than thousand chemicals.
Several of these chemicals may adversely affect human health. Previous studies have
found that consumers are generally unaware regarding the risks of health supplements
and their associated adverse events. In addition, they are unaware of the appropriate
reporting process to relevant authorities should adverse events occur. Moreover, many
healthcare professionals have inadequate knowledge, attitude and practice in health
supplement consumption-related adverse events and their reporting. The purpose of
this research was to measure the health supplement consumption in the population of
Dubai, the adverse events thereof, and the level of knowledge, attitude, and practice
among healthcare professionals about the issue.
This research project comprised two cross-sectional studies. The first was a telephone
survey using computer-assisted personal interviewing carried out among the general
population. The second study was an on-line survey among healthcare professionals
from various private and government healthcare settings in Dubai that sought to assess
their knowledge, attitude, and practice (KAP) toward health supplements. Descriptive
statistics were used to describe the demographic characteristics of the sample using
frequencies and percentages as appropriate. Chi-square, or ANOVA, was used as
appropriate to test for statistical differences. Analyses were conducted using STATA
version 14.2.
In the first survey, among 1,203 participants, 455 (37.8%) reported either current or
previous use of health supplements. Of the 455 users, 389 (85.54%) were
knowledgeable about health supplements and 442 (97.14%) had encountered no
adverse events. Of the 13 (2.86%) who had encountered adverse events, the degree of
severity was either moderate or mild. Most (10, 76.92%) did not know how to report
the adverse event to healthcare professionals. Only 3 (23.08%) had ever reported an
event.
In the second study, 427 healthcare professionals participated to the online survey. Of
these, 78 (18.3%) had a good level of KAP towards health supplements, 166 (38.9%)
had a fair level of KAP, while 183 (42.9%) had a poor level. Job experience of over 6
years resulted in a significant difference (P=0.017) in mean KAP scores. No
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statistically significant differences in scores were found with gender or educational
levels. Significant differences, however, (P=0.001) were found with nationality where
non-UAE national participants had a higher level of KAP than UAE nationals. There
were also significant differences in mean KAP scores between occupational groups,
physicians and pharmacists having higher scores than other healthcare providers.
The findings of this research provide important new knowledge about health
supplement use in Dubai. The findings may be used to develop policies and programs
on health supplements that will help to minimise the risk of adverse events arising
from their use. The results also point out that it is important to institute educational
initiatives to assess any risks related to the use of health supplements. Such initiatives
will help to raise both awareness and knowledge in both the population and healthcare
professionals regarding the use and adverse events of health supplements.

Keywords: Health supplements, Dubai, adverse event, knowledge, attitude, practice.
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)Title and Abstract (in Arabic

استهالك المكمالت الصحية واآلثار الصحية المرتبة في إمارة دبي – اإلمارات العربية
المتحدة :دراسة استقصائية
الملخص

كل منتج مكمل صحي في إمارة دبي يحتوي على العديد من المكونات التي تصل إلى
أكثر من ألف مادة كيميائية في المجموع .العديد من هذه المواد الكيميائية قد يكون لها بعض اآلثار
السلبية مما سيؤثر على صحة اإلنسان .كثير من الدراسات أثبتت أن المستهلكين بشكل عام ال
يدركون عن المخاطر المصاحبة للمكمالت الصحية واآلثار السلبية المرتبطة بها .كذلك ،بعض
المستهلكين ال يدركون كيفية تزويد السلطات المعنية في حال وجودها بأي من األعراض الجانبية
التي يتعرضون إليها .وباإلضافة إلى ذلك ،فإن العديد من المتخصصين في مجال الرعاية الصحية
ليس لديهم المعرفة الكافية ،أو التصور على األعراض السلبية والمصاحبة مع استهالك المكمالت
الصحية.
يهدف هذا البحث إلى إجراء مسح سكاني في إمارة دبي لتحديد نسبة استهالك المكمالت
الصحية من قبل سكان دبي ،واآلثار السلبية والمصاحبة مع استهالك المكمالت الصحية (إذا تم
تحديدها) ومستوى المعرفة والممارسة بين المتخصصين في مجال الرعاية الصحية حول هذه
القضية .الحقا تم استخدام نتائج البحث لتقييم األثر الصحي إلنشاء نظام اليقظة للمكمالت الصحية
في دبي.
أجريت دراسات من خالل توزيع استبيانات للمستهدفين من السكان والمختصين وتم
استخدام المعلومات التي تم جمعها في تقييم األثر الصحي للنظام المراد إنشائه .قام هذا البحث
بملء الفجوة المعرفية الحالية في هذا المجال البحثي في دبي كما ال تتوفر أي معلومات سابقة
بشأن هذا الموضوع في دولة اإلمارات العربية المتحدة.
مفاهيم البحث الرئيسية :المكمالت الصحية ،دبي ،اإلمارات العربية المتحدة ،األعراض الضارة،
المعرفة ،الممارسة ،التصور.
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Chapter 1: Introduction
1.1 Overview
Within the last two decades, consumption of dietary supplements has increased
worldwide, especially in the United States of America (Millen et al., 2004; Slesinski
et al., 1995; Wu et al., 2011). This has raised the awareness and interest of regulatory
organizations, healthcare professionals and researchers (Al-Ahmad et al., 2012).
The World Health Organization (WHO) and the United States (US) Dietary
Supplements Health and Education Act (DSHEA) of 1994 both define dietary
supplements as a product (other than tobacco) that is meant to supplement the diet.
Both organizations include vitamins, minerals, herbs, botanical products, amino acids,
or dietary substances in their definitions. The use of dietary supplements including
herbal supplements is gaining popularity in many developed countries (Aina &
Ojedokun, 2014).
In the Local Order No. (11) of 2003 concerning Public Health and Safety of
the Society in the Emirate of Dubai and its Administrative Resolution No. (30) of 2007,
dietary supplements are referred to as health supplements (HS). These supplements are
strongly related to human health as about 1,000 different chemicals may be included
in the ingredients. These constituents may cause disease or other adverse events by
their chemical reactions with the human body. HS products such as minerals and
vitamins are widely available over-the-counter and are often purchased by consumers
without advice from a healthcare provider. HS products are widely consumed for the
purposes of weight reduction and energy enhancement, among several other reasons
(CPSS, 2015).
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Herbs were the predominant form of healthcare for the world’s population
before the advent of modern medicine and are still common among many underserved
populations (Su & Li, 2011; Rossler et al., 2007). HS products, including herbal
supplements, also have the potential for drug interaction (Izzo & Ernst, 2009; Moyad,
2010; Tsai et al., 2013; Van & Bogers, 2012), which necessitates consumer awareness
and diligence among healthcare professionals in their daily practice (Kemper et al.,
2006; Piening et al., 2012).
HS products play an important role in the general healthcare system of many
developing countries and are rapidly gaining popularity in many developed countries
(Chitturi & Farrell, 2008). WHO estimates that 80% of Asian and African populations
rely on traditional medicine as the primary method to meet their healthcare needs
(WHO, 2008). The scenario in developed countries is very similar with 70% to 80%
of the population using some form of complementary or alternative medicine. Most of
these can be used safely if the public is given the right education and advice (Barnes
et al., 2004). Physicians need to be ready to discuss their use with patients or advise
patients accordingly (Neergheen-Bhujun, 2013).
As HS products have a wide range of possible actions, their effectiveness and
safety for human consumption is of concern. Harmful side effects have been reported
following the use of some types of HS products (Tsai et al., 2013). For example,
Ginkgo Biloba has been implicated in the occurrence of epileptic seizure, and chronic
use of zinc may result in anaemia (Al-Ahmad et al., 2012; Izzo & Ernst, 2009; Shaw
& Palmer, 2003).
Adverse events, such as allergy, drug interactions, heavy metal poisoning,
reactions to adulterants or contaminants and other toxicities, can arise from the product
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itself (Tachjian et al., 2011). When these problems occur, a rational approach to
management with resuscitation, symptomatic, and supportive care is essential. Clinical
features may give clues about the offending agents. HS products that possess
pronounced pharmacological effects or toxic constituents can be inherently poisonous,
and physicians should anticipate problems with such toxicities if they encounter
patients using these products (MOH, 2011).
Also, potentially hazardous interactions between HS products and some
medicines have been reported in the literature including synergistic effects, poisoning,
or inactivation of at least one of the substances (Tsai et al., 2013). For example, St.
John’s Wort is a substance that is used as a HS product to treat mild and moderate
depression. St. John’s Wort can induce liver enzymes and so has the potential to
interact with many narrow therapeutic range medicines that are metabolised through
the liver such as anti-depressants (Van & Bogers, 2012). Some other substances such
as garlic, ginger, and Ginkgo Biloba can induce the risk of bleeding when administered
with anticoagulants (Moyad, 2010).
Many HS products, used singly or in combination, have unknown effects.
Under the DSHEA, the U.S. Food and Drug Administration (FDA) does not mandate
any efficacy and safety assessments of HS products. This is unlike novel medicines
and over-the-counter drugs (USFDA, 2016).
HS products are generally regarded as safe by the USFDA unless proven
otherwise through its Adverse Event Reporting System (AERS). Since 2006, all
manufacturers, packers, distributors and retailers are responsible for reporting serious
adverse events associated with their products, including HS products, to the FDA’s
MedWatch system (Kailin, 2008).
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A study by Frankos et al. (2010) showed that many healthcare professionals
fail to report adverse events related to the use of HS products to the appropriate
authority, as many of them are unaware of the risks and benefits of HS products. Some
researchers have investigated the knowledge, attitudes and practices of physicians in
terms of complementary and alternative medicine, but there has been little focus on
herbal supplements (Clement et al., 2005).

1.2 Statement of Problem
In the United Arab Emirates (UAE) and particularly in Dubai, dietary
supplement products and herbal supplements are combined under a definition called
health supplement products (HS). Currently, there are limited data and information on
HS products and any related adverse events. In addition, unlike the situation in other
developed and some developing countries, in Dubai there is no surveillance or
reporting system for adverse events resulting from HS product use. It is probable that
there are adverse events associated with the consumption of HS products in Dubai.
There is a need, therefore, to investigate the current situation and explore the
possibilities of establishing a reporting system.
In many countries, spontaneous reporting or vigilance systems are the main
means of detecting safety issues associated with HS products. If suspected adverse
events associated with HS products do not reach the system, either through direct
patient reporting or through reporting from healthcare professionals, the detection of
safety issues may be missed or delayed (Gavaza et al., 2011; Piening et al., 2012). This
has important implications for public health protection. It is, therefore, important to
identify the extent of the problem and the underlying causes to inform public health
policy.
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1.3 Research Questions
The following research questions were proposed to achieve the objectives of the
research:
1. What are the prevalence and characteristics of HS product consumption in the
general population of Dubai?
2. Are the consumers of HS products aware of and able to identify HS product
related adverse events?
3. How extensive is consumer knowledge about HS products?
4. Do HS products present any potential risks to human health, and, if so, what
is the level of this risk?
5. What are the knowledge, attitude and practice of healthcare professionals in
Dubai towards HS product related adverse events and the reporting or
notification of such events?
6. What is the level of reporting of suspected HS product related adverse events
in Dubai?

1.4 Research Aim
Previous studies have found that consumers are generally unaware of the risks
of HS products and associated adverse events. In addition, they are unaware of the
appropriate reporting process to the specific authorities in the event of adverse events.
Also, many healthcare professionals do not have adequate knowledge, attitude or
practice in relation to adverse events related to HS product consumption (Qassim et
al., 2014; Ting et al., 2010). In a study among community pharmacists working in the
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cities of Ajman and Sharjah, United Arab Emirates, only 4.9% were found to have
good knowledge of ADRs (Qassim et al., 2014). In a cross-sectional prospective study
conducted among US military physicians, 60% of the physicians observed adverse
events associated with HS and only 18% reported these events. Around 70%
physicians did not know how or where to report the adverse events associated with HS
(Cellini et al., 2013). The prevalence of HS product consumption ranges from 10% to
30% according to Kemper et al. (2006) and around 19% according to Hara et al.
(2011). In the case of Dubai, however, there is no information about the prevalence of
HS product consumption or any related risks. The main aim of this research, therefore,
is to evaluate the public health importance of HS product consumption related adverse
events in the Emirate of Dubai.

1.5 Research Objectives
The research objectives of this research are as follows:
a- To assess the knowledge of HS products, levels of consumption and
occurrence of adverse events in the population of Dubai.
b- To assess the knowledge, attitude and practice (KAP) of healthcare
professionals in Dubai regarding HS products and HS product related adverse
events.
c- To assess the reporting level of HS product related adverse events among
healthcare professionals in Dubai regarding HS products and HS product
related adverse events.
d- To understand the views on the setting up of a surveillance system.
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1.6 Research Significance
HS products are imported and distributed in many countries where premarketing safety and efficacy assessment is not usually a mandatory requirement
(Kailin, 2008). Despite high levels of HS product consumption in many countries,
there are low levels of reporting of related adverse events by consumers, manufacturers
and healthcare professionals (Al-Ahmad et al., 2012). In a free trading country like the
UAE, and especially in Dubai, the availability and consumption of HS products with
established harmful effects is an issue of significant public health importance (CPSS,
2016).
Healthcare professionals have a key role in identifying HS product related risks
and adverse events, but this role may be underdeveloped because of low levels of
knowledge and lack of awareness (Walji et al., 2009). For the first time in the UAE,
this research will provide an assessment of HS product awareness and practice among
both consumers (the general population) and healthcare professionals alike. It will
inform and help policymakers, where necessary, to develop programs for public and
professional education, establish new policies and regulations on HS products and an
adverse event reporting system (CPSS, 2016).

1.7 Organization of the Remainder of Dissertation
The remainder of this dissertation is structured as follows: chapter two reviews
the literature in eleven sections; section one presents introductory statements of the
chapter. Section two presents the diverse definitions of HS products. Section three
provides a review of the literature on the use and demand of HS products in the world
population and discusses the gap in knowledge in the UAE context. Section four
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describes the global regulations for HS products including the current codex aimed at
harmonising food and food supplement rules among all nations of the world. This
section gives an overview of the HS product regulations in the following countries:
USA, Canada, Australia, and UAE (Dubai). Section five considers the safety and
efficacy of HS products including HS product interactions with other food and/or
drugs, or other HS products. This section also discusses the various types of HS
product related adverse events. Section six presents the literature on global adverse
event monitoring systems for HS products including adverse event reporting systems
and post-market surveillance. In addition, it discusses the adverse event monitoring
system of HS products in some leading countries.
Section seven discusses patient disclosure of HS product use information to
healthcare professionals. Section eight identifies the literature on healthcare
professionals’ knowledge, attitude and practice of HS product related adverse events.
Section nine reviews the current literature on the challenges in adverse event data
collection and analysis including the under-reporting of adverse events and the quality
of data collection. Section ten discusses the benefits of having an adverse event
reporting and monitoring system. The last section of this chapter discusses in summary
all related HS concepts in relation to the current research.
Chapter three covers the methods used in this research, namely two crosssectional studies using questionnaires in four sections. The first section presents
introductory statements on the research methods. The second section presents details
of the survey of HS product consumption in the population of Dubai including study
design, study setting, study participants, sampling, sample size, survey instrument, the
actual questionnaire including variables, data management including re-coding and
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interpretation of the variables, statistical analysis, data limitation, and ethical approval
and safeguarding participants. Section three presents similarly on the knowledge,
attitude and practice of HS product related adverse events among healthcare
professionals. The last section provides a summary of all related information regarding
research methods.
Chapter four presents the results from the analysis of the two cross-sectional
studies. Chapter five discusses these findings. It presents a summary for each of the
study objectives that have emerged from the findings and review of the literature. This
chapter also presents the strengths of the study and reviews the limitations of the
research.
Chapter six presents a summary of the previous chapters and the conclusion of
the findings. This chapter also presents the lessons and contribution of the study for
academics and practitioners and makes recommendations for further research.
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Chapter 2: Literature Review
2.1 Introduction
Dietary or health supplements (HS) are widely consumed by people across the
world and their availability in the global market has been increasing in recent years.
They are readily available without prescription and their regulation is not as stringent
as medicines/drugs. Though many HS have a clean safety history, various
reports/studies imply potential safety concerns regarding the quality and use of these
products. Apart from regulating the manufacture and introduction of HS into the
market, it is also important to monitor, collect and analyse the adverse events that may
be caused by HS to improve the safety of HS use.
These products are becoming an integral part of diet plans, mostly in developed
countries. Increasing awareness of essential nutrients and their importance in
maintaining a healthy lifestyle has led to a higher consumption of these supplements
to offset a perceived lack of essential nutrients from normal diets. Over the years,
increasing numbers of products have entered the markets under the label of HS. Today,
HS is an umbrella term used to denote a vast variety of supplements that may include
vitamins, minerals, herbs or other plants, amino acids, enzymes, and fibres among
other products. They are available in various dosage forms and are meant to be
exclusively taken by oral route.
Unlike drugs, for which safety profile is well documented and closely monitored
with established mechanisms, HS are thought to be harmless and safe for consumption
without undergoing vigorous clinical testing. Even though established regulatory and
monitoring policies are in place in many countries, adverse events caused by the
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consumption of HS may not be adequately reported. This results in a potential health
hazard which may go undetected. Lack of awareness about the potential harmful
effects of HS among both consumers and healthcare professionals emphasizes the need
for more effective regulatory and monitoring systems.
The prevailing policies in regulating the consumption of HS in various countries
together with the mechanisms established to identify the potential health risks caused
by HS are discussed here. The limitations of current policies and monitoring systems
and the specific areas which could make health supplement surveillance more
inclusive are also discussed. Dubai, United Arab Emirates (UAE), has an HS market
that is expanding year by year. As a result, there is a need to have proper monitoring
and reporting systems. In this thesis, extensive research has been carried out to review
the regulation and monitoring of HS, the reporting of adverse events in various
countries, the various factors preventing the effectiveness of these systems and the
need to improve existing systems with specific focus on Dubai.
In this chapter, a detailed review of available literature on the following essential
topics was carried out including HS definitions, use of HS in the world population,
global regulations of HS, efficacy, safety and adverse events of HS, global adverse
event monitoring systems for HS, disclosure of HS use to healthcare professionals,
healthcare professionals’ knowledge, attitude and practice on HS related adverse
events, challenges in adverse event data collection process and analysis, and the
benefits of having an adverse drug reaction reporting and monitoring system.
The research questions played a vital role in the selection of the topics for the
literature review.
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After finalising the topics, the literature review was written from access to the
library of the UAE University and Hamadan Bin Mohammed Smart University. Some
of the literature was accessed from the Pubmed on-line library. The literature search
was conducted using a set of key words and phrases suitable for the framework, like
health supplements, dietary supplements, risks of health supplement, use of health
supplement, adverse events of health supplements, global regulation of health
supplements, food supplements, etc. The literature and related topics were reviewed.
Around 87 publications were shortlisted from a total number of 216 as references for
the literature review chapter. This filtration process excluded articles after abstract
review, after full article review and after data abstraction due to weak evidence.

2.2 Health Supplement - Definitions
The definition of HS differs from country to country and the products considered
as HS also differ. The World Health Organization (WHO) and the United States
Dietary Supplements Health and Education Act (DSHEA) of 1994 both define dietary
supplements as products (other than tobacco) that are meant to supplement the diet.
Both include vitamins, minerals, herbs, botanical products, amino acids, and dietary
substances in their definitions (Phua et al., 2009).
The Consumer Products Safety Section (CPSS) of Dubai Municipality defined
HS as products (other than tobacco) complementary to the diet that include one or
more of any dietary ingredient like vitamin, mineral, herb or other botanical, and/or
amino acid ingredients. Additionally, dietary substance is defined as any preparation
that is planned for use by any individual to enhance the diet’s nutritional value by
amplifying the overall dietary intake and in a concentrated dosage form, a metabolite
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preparation, element, extract, or a blend of any of the ingredients mentioned earlier
(CPSS, 2015).
Under Canadian federal regulations, natural health products (NHPs) are
technically a sub-category of drugs. Any substance naturally found in plants, animals,
fungi, algae or microorganisms (regardless of the source used for the supplement) that
is used to diagnose, treat or prevent disease and is suitable for self-care use is
categorized as an NHP in Canada. This category includes vitamins (regardless of
source), minerals, traditional Chinese medicines, Ayurvedic medicines, Native North
American medicines, traditional herbal remedies and homeopathic medicines.
Biologics such as insulin, tobacco and marijuana are specifically excluded from the
NHP definition (Walji et al., 2010).

2.3 Use of Health Supplement in the World Population
The use of HS is increasing worldwide. People around the world consider
supplements to be safer and more effective than conventional medicines. Ready
availability of HS without prescription and extensive advertisements make them the
people’s medicine of choice for many ailments. Supplements are preferred over
conventional medicines for the treatment of digestive conditions, common respiratory
ailments and for weight management (NBJ’s Supplement Business Report, 2012). In
the United States (US) the use of HS is increasing year by year. Statistics show that
65% of the population in 2009, 66% in 2010 and 69% in 2011 were using HS (Gahche
et al., 2011; Council for Responsible Nutrition, 2003).
The demand for HS is also increasing globally. The global HS market was worth
$243 billion in 2014 (Jose, 2015). The number of visits to providers of complementary
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and alternative medicine (CAM) exceeds those to primary care physicians, for annual
out-of-pocket costs of $30 billion. Herbal products constitute the major proportion of
these treatments (Tachjian et al., 2010). In the US, sales of HS reached $28.1 billion
in 2010, a 4.4% growth over 2009 sales. Top supplement categories included:
multivitamins ($4.9 billion), sports nutrition powders and formulae ($2.8 billion), B
vitamins ($1.3 billion), calcium ($1.3 billion), and fish/animal oil ($1.1 billion) (NBJ’s
Supplement Business Report, 2012).
According to recent studies, the use of HS and herbal preparations has also
increased in the Middle East (Mamtani et al., 2015). In Dubai, the demand for and sale
of HS are increasing year by year. The increasing number of HS premises in Dubai
indicates the growing HS market: 690 premises in 2014, 740 premises in 2015, and
800 premises in 2016 (CPSS, 2016). In addition, the increasing number of on-line
applications for importing HS to Dubai, as shown in Table 2.1, supports evidence of
the growth in the market. The HS consignment statistics in Dubai for the years 2012
to 2015 indicate that the number of consignments containing HS imported to Dubai
through Dubai ports increased by 86% from 2012 to 2015 (see Table 2.1 for more
details). This probably relates to increased consumption of HS in Dubai as the
percentage of non-complied HS in Dubai increased from 55% in 2013 to 63% in 2015.
This indicates that a growing number of various, new and non-registered types of HS
are being imported and marketed in Dubai (CPSS, 2016).
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Table 2.1: Health supplement consignments (number, weight) Dubai 2012–2015
Year
2012
2013
2014
2015

Quantity
2019
2448
3224
3752

Gross Weight (Kg)
2,940,877.89
3,790,542.40
4,702,010.22
4,790,351.00

Table compiled by the author from data from Consumer Products Safety Section
Annual Reports 2012-2015.

2.4 Global Regulations of Health Supplements
Despite the belief that HS are safe, these products are pharmacologically active
and therefore have inherent risk. Most countries are aware of the need for regulation
of HS and have regulatory systems for HS. HS are regulated by different authorities
around the world. The policies and procedures of established authorities
internationally and in various countries in terms of HS regulation are discussed in the
following sections.
2.4.1 Codex: harmonising food and food supplement rules
In 1962, the Codex Alimentarius (food code) Commission (Codex) was created
to harmonise health food standards internationally by two United Nation (UN)
Organizations, the Food and Agriculture Organization (FAO) and the World Health
Organization (WHO). Codex comprises more than 150 member countries and
international organizations that meet to exchange information and ideas related to food
safety and trade issues. The members of Codex are also members of WHO and FAO.
Codex Alimentarius is a collection of standards, codes of practice, guidelines, and
other recommendations. It has become the global reference point for consumers, food
producers and processors, national food control agencies, and the international food
trade. Currently, Codex Alimentarius lists more than 200 standards, encompassing
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issues like labelling, additives, methods of analysis and sampling, food import and
export inspection and certification, pesticides in foods, and contaminants. The code
also deals with nutrition and foods for special dietary uses, which includes dietary
supplements. The Codex Committee on Nutrition and Foods for Special Dietary Uses
(CCNFSDU), hosted by Germany, meets every year to study the nutritional problems
referred by the Codex Alimentarius Commission. The committee also considers draft
provisions on nutritional aspects for all foods and develops guidelines, general
principles, and standards for foods for special dietary uses (Das & Sen, 2014).
The CCNFSDU began discussions on the guidelines for vitamin and mineral
food supplements in the 1990s and these were adopted in 2005. The guidelines were
limited only to food supplements that contain vitamins and/or minerals, where these
products are regulated as foods. Although guidelines address the composition of
vitamin and mineral supplements, including sources, safety, purity, and
bioavailability, they only provide criteria for establishing maximum amounts of
vitamins and minerals per daily portion of supplement consumed rather than setting
upper limits for vitamins and minerals in supplements. The packaging and labelling
requirements of vitamin and mineral supplements are also addressed in the guidelines
(Das & Sen, 2014).
These guidelines unfortunately do not address the broad category of dietary
supplements, which includes herbals, amino acids, metabolites, concentrates, and
many other non-essential nutrients. The codex in its current form has limited global
implementation and individual countries have established more effective regulations
on a wider range of food supplements (Das & Sen, 2014).
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2.4.2 United States food and drug administration regulations
In the US, products falling under the definition of HS include vitamins, minerals,
and herbs addressed as dietary supplements and regulated by the Food and Drug
Administration (FDA) within the context of the US Federal Food, Drug, and Cosmetic
Act (FFD&C Act). Dietary supplements are considered food, and there are no
regulatory categories or regulatory definitions to accommodate them separately from
other food ingredients. In respect of dietary supplements, the FDA mainly regulates
the labelling (including the label on the product container and accompanying material)
of the product. The FFD&C Act was amended by US congress many times in the
1990s. These amendments include the1990 Nutrition Labelling and Education Act
(NLEA), the 1994 Dietary Supplement Health and Education Act (DSHEA), and the
1997 Food and Drug Administration Modernisation Act (FDAMA).
The 1994 Dietary Supplement Health and Education Act (DSHEA) regulates
various types of health claims and structural/functional claims that may be made about
dietary supplements.
Health claims in dietary supplements should characterise a relationship between
a food, a food component, or dietary ingredient and the risk of a disease (e.g. adequate
calcium throughout life may reduce the risk of osteoporosis). The FDA authorises
these types of health claims based on an extensive review of scientific literature. Only
NLEA authorised health claims or health claims based on authoritative statements may
be used in the labelling of dietary supplements.
Structural/functional claims describe the role of a nutrient or dietary ingredient
intended to affect the normal structure or function of the human body, (e.g. calcium
builds strong bones). In addition, they may characterise how a nutrient or dietary
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ingredient acts to maintain such structure or function, (e.g. fibre maintains bowel
regularity, or antioxidants maintain cell integrity). Such claims do not need approval
from the FDA, but the manufacturer must have substantiated that the claim is truthful
and not misleading and must submit a notification with the text of the claim to the
FDA no later than 30 days after marketing the dietary supplement with the claim. If a
dietary supplement label includes such a claim, it must state in a disclaimer that the
FDA has not evaluated the claim. The disclaimer must also state that the dietary
supplement product is not intended to diagnose, treat, cure or prevent any disease.
Only a drug can legally make such a claim (Hoadley & Rowlands, 2014).
The FDA established current good manufacturing practice (cGMPs)
requirements for dietary supplements in 2003 which specify detailed conditions for the
preparation, packing, and storing of dietary supplements, and required that dietary
supplements be unadulterated and accurately labelled to meet full safety and sanitation
standards. Furthermore, the Dietary Supplement and Non-prescription Drug Consumer
Protection Act (Public Law 109-462, effective December 2007) was issued and
requires that serious adverse events related to dietary supplements and nonprescription drugs be reported (Fu & Xia, 2014).
2.4.3 Canada regulations
In Canada, dietary supplements are referred to as Natural Health Products
(NHPs) and comprise a group of health products that include vitamin and mineral
supplements, herbal and other plant-based health products, traditional Chinese and
Homeopathic medicines, probiotics and enzymes, and certain personal care products
like toothpastes that contain natural ingredients (Health Canada, 2012a). The Natural
Health Products Regulations (NHPR) under the Canadian Food and Drugs Act
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regulates NHPs. NHPR is implemented by the Natural and Non-prescription Health
Products Directorate (NNHPD) (Health Canada, 2012b). NNHPD requires all NHPs
sold in Canada to have product licenses and the Canadian sites that manufacture,
package, label and import NHPs must have site licenses.
Producers of NNHPs are required to register the product with the NNHPD before
launching the product in the market. The NNHPD may issue a license after evaluating
the submitted documents including a consideration of the safety of the product.
NNHPD follows a three-class system for licensing the product where the review time
for the products are dependent on how much is already known about the benefits and
risks of the products. This system enables quick reviewing and licensing of products
about which there is most knowledge and certainty regarding safety, while complex
applications require more detailed evaluation efforts.
Class 1: This class has the highest level of certainty about the product (how much
is known about the product) and the lowest potential risk. Seventy five percent of
NHPs are in this category. These products are supported by pre-cleared information
(PCI) based on previous NHPD decisions and can receive a license within 10 days of
submission of the application.
Class 2: This class covers moderate certainty of product and moderate risk.
Around 20% to 24% of NHPs are in this class, typically those with at least one claim
or ingredient supported by a PCI. For example, a Class 2 product may be an existing
authorised product with a new claim related to product use. Products falling into this
category will undergo an expedited risk-based review with a target of 30 days.
Class 3: This class covers NHPs with the lowest certainty and highest risk and
comprises about one to five percent of NHPs. In this class, there are no ingredients or
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claims supported by PCI. For example, if a new product is claimed to prevent
rheumatoid arthritis, clinical trial evidence with a full pre-market assessment is the
level of review needed. The current review period for this class is 180 days, but
companies could reduce this time by revising their claims for the NHP to meet the PCI
(Harrison & Nestmann, 2014).
2.4.4 United Arab Emirates - Dubai regulations
HS in Dubai Emirate are controlled by Dubai Municipality through Local
Circular No. (11/2003) for the year 2003 and the Health Supplement Circular dated 24
February 2010. The trading companies who are licensed inside the UAE and have
business related to HS product trading can do HS business in Dubai, but need to
register their product(s) with Dubai Municipality prior to importation or any other
business related practice.
The Consumer Products Safety Section (CPSS) of the Health and Safety
Department is the responsible regulatory authority at Dubai Municipality for HS
products. The CPSS controls HS products in three different areas: HS products
registration, HS product consignment release, and HS product monitoring in Dubai
Emirate through field inspection.
2.4.4.1 Health supplement registration
Companies may register HS products with the CPSS using an on-line system
prior to importation of the product into Dubai. Companies submit documentation for
the products including artwork of the product, free-sale certificate, which is a
certificate that is issued by a related authority in the country of origin of the product
certifying that goods such as food items, cosmetics, biologics, or medical devices are
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legally sold or distributed in the open market, freely without restriction, and approved
by the regulatory authorities in the country of origin (Web Finance Inc., 2016).
Additional documentation includes an ingredient report and an analysis report from
the manufacturer, a related test report from an accredited laboratory and other
supporting documents. The CPSS team then assesses the product documents and its
application. If the product does not raise any concern then the CPSS team will register
the product. If there are concerns then these must be rectified by the company before
re-applying for registration. The validity of registration is 5 years. The company must
renew the registration before the expiry date (CPSS, 2015).
2.4.4.2 Health supplement consignment release
The CPSS team at Dubai ports controls the entry of HS products into Dubai
Emirate. Companies apply through an on-line system for the shipment release with
shipment details and registration details. Inspectors from CPSS consignment release
teams to inspect the shipment and the shipment is released if it meets the required
standards which include the quality of the product, the storage condition during the
shipment and the registration status of the product (CPSS, 2015).
2.4.4.3 Health supplement field inspection
The field inspection team of CPSS monitors the Dubai market through routine
inspections of premises where HS are on sale. Field inspectors inspect the shops and
ensure compliance with regulations including label modifications, use of unapproved
claims and storage conditions. Random sampling and laboratory testing of the
registered products further ensure the quality of the HS products in Dubai (CPSS,
2016).
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2.5 Efficacy, Safety and Adverse Events of Health Supplements
2.5.1 Efficacy of health supplements
The efficacy of HS has been established through years of practice and is now
one of the essential parts of day to day life. Some HS have proven their efficacy
through clinical studies. For example, vitamin D and calcium supplements have been
shown to be beneficial in the prevention and treatment of bone loss and osteoporosis
(Lanham-New, 2008). Similarly, folic acid has been shown to be effective in
preventing certain birth defects such as neural tube defects (Wolff et al., 2009).
Glucosamine containing supplement use has a proven effect in improving locomotor
function and reducing knee pain in osteoarthritis (Kanzaki et al., 2015). Vitamin B12
along with Omega 3 fatty acid were shown to be beneficial in Alzheimer’s disease by
slowing the rate of brain shrinkage in patients with Mild cognitive impairment (Oulhaj
et al., 2016).
2.5.2 Safety of health supplements
As the definition implies, HS are mainly intended to supplement the diet with
one or more dietary ingredients like vitamins, minerals, herbs or other botanical, and/or
amino acid ingredients. The use of HS and herbs was thought to be safe in the past,
but an excessive intake of any nutrient could result in adverse events. There exists a
wide variability in the nature and concentration of the ingredient and the source and
purity of raw material, especially in herbal supplements. This, along with variations in
methods of preparation and a lack of related safety data for human consumption,
highlights the potential safety risks involved in HS consumption. The factors affecting
the safety and the risk of consuming the supplement may vary by product and category.
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For vitamins and minerals, even if they have been established as safe over years of
practice and clinical trials, over-dosage may lead to severe direct toxicity to the
consumers.
The risk of consuming vitamins and minerals increases as the consumed dose
increases. At low dosage, the risk of compromised health due to deficiency is high. At
high dosage, the risk of compromised health due to toxicity is high. As the margins
between the essential amounts and toxicity are narrow, a conventional method of risk
assessment has been established in an Acceptable Daily Intake (ADI) for vitamins and
minerals which is a recommended safe level. This level is established following a
consideration of two risk assessment values, the NOAEL and the LOAEL. NOAEL is
the non-observed adverse event level, which is the maximum dose in acceptable daily
intake. LOAEL is the lowest observed adverse event level. If there are no adequate
data demonstrating a NOAEL, then a LOAEL may be used. Where various adverse
events (or endpoints) occur for a nutrient, the NOAELs (or LOAELs) for these
endpoints will differ. The critical endpoint is the adverse event exhibiting the lowest
NOAEL (i.e. the most sensitive indicator of a nutrient’s adverse events) which ensures
protection against all other possible adverse events (COT, 2003; EFSA, 2006).
NOAEL and LOAEL play a vital role to establish an acceptable daily intake of
vitamins and minerals. NOAEL can be calculated by extrapolating LOAEL from the
dose response curve (one of the most important concepts in pharmacology which
describes the relationship between an effect of a drug and the amount of drug given).
The factor of 3 is commonly used when extrapolating from a LOAEL to a NOAEL for
data derived from studies in experimental animals. This is because the dose levels used
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in such studies are commonly at 3-fold intervals. ADI can be calculated from the below
formula.

ADI =

No Observed Adverse Effect Level
10 (inter species variation) × 10 (inter individual variation)

For example, the LOAEL of Vitamin B6 (pyridoxine) is identified as 50 mg/kg
bw/day based on studies. Uncertainty factor for LOAEL to NOAEL extrapolation was
3. The NOAEL calculated as 16.66 (LOAEL/3). The ADI calculated for Vitamin B6
(pyridoxine) is 16.7 mg/kg bw/day which is equivalent to 10 mg/day for a 60 kg adult.
(COT, 2003).
The referral intake of vitamin C by an adult is in a range of 45-90 mg/d, an
amount needed to prevent scurvy. The maximum level of safe intake (NOAEL) is 1
gram (g). The margin of ADI is larger and it is more than 10 times greater than the
referral intake. A much larger quantity of vitamin C can cause gastrointestinal events
such as osmotic diarrhoea, which occurs at intakes of several grams. In the case of
vitamin A, the referral intake is 600-900 microgram (µg), and evidence exists of
adverse events on bone health at an intake of 1500 µg. Safety and risk assessment
values vary for different vitamins and minerals. A close monitoring of international
safety standards and studies is essential in the safe control of vitamins and minerals
(Mulholland & Benford, 2007).
The established safe range or ADI may not be applicable to all groups. The ADI
may differ with life stage or increased or decreased susceptibility to adverse events.
Nutritional requirements vary because of growth and existing conditions like altered
renal function. A dose that is beneficial for some sub-groups in the population may
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possess potential harmful effects for others. Folate supplementation reduces the
incidence of neural tube defects in the foetus, but may mask the anaemia associated
with vitamin B12 deficiency in older persons, allowing neuropathy, also associated
with the deficiency, to progress undiagnosed.
In terms of herbal supplements, one of the safety issues is heavy metal
contamination. Herbal supplements may be contaminated by heavy metals such as lead
(Pb), cadmium (Cd) and mercury (Hg). This heavy metal contamination increases the
risk for the safe use of herbal supplements. The heavy metal contamination is
influenced by several factors such as occupational contamination, bioaccumulation of
heavy metals in herbs/plants from atmospheric depositions determined by climatic
factors, heavy metal pollutions in soil, contaminated wastewater used for irrigation of
soil on which the herbs are grown, and the degree of maturity of the plant at the time
of harvest (Bentum et al., 2011; Khan et al., 2008). High doses of heavy metal
consumption can cause several diseases. They may be carcinogenic or have adverse
reproductive effects, and they may unfavourably impact on nutrition by displacing
biologically useful metals such as calcium and zinc (Ejeatuluchukwu et al., 2011;
Fasinu & Orisakwe, 2013).
Another safety concern relating to herbal supplements is pesticide residues.
These may contaminate the herbal supplement due to excessive use of pesticides
during the cultivation of the herb and from lack of good agriculture practices (GAP).
Organochlorine pesticide residues have been found in several Chinese herbal plants
cultivated in China and sold in Hong Kong (Leung et al., 2005). Even though safety is
a concern, the use of HS in daily life is increasing and it demands more attention and
control.
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Other serious concerns in the consumption of HS are adulteration and
contamination by various methods. The adulteration of herbal products with
undeclared pharmaceuticals, substitution with exhausted drug and substitution with
artificially manufactured substances along with contamination from different sources
like pollens, dust, moulds and fungi can cause serious adverse events. A study in Hong
Kong published in 2011 shows the severity of the under-recognised problem of
adulteration of Chinese herbal anti-diabetic and diabetic products with undeclared
pharmaceuticals, including both registered and banned drugs (Ching et al., 2011).
When evaluating the safety of the HS, it is important to consider their use by
vulnerable groups. Some groups of the population may be particularly susceptible to
adverse events from the ingredient of a HS. Vulnerable groups are defined as a subpopulation who are more likely to have adverse events or individuals in whom the
specific adverse events identified are more likely serious in comparison with the
general population. Characteristics that contribute to this vulnerability may be
physiological, disease related, or related to other aspects such as lifestyle or therapeutic
interventions. Physiological characteristics include age, genetic predisposition and
specific physiological conditions. Some age groups may be more susceptible to
adverse events from some HS than others. The capacity of the human body to
metabolise the ingredients of HS varies through the life span. HS ingredients that are
normally excreted or altered by kidney or liver function may potentially pose greater
risk to the elderly than to the younger population. This must be considered in the HS
specifically intended for use by the elderly such as HS used for osteoarthritis. Children
have a lower metabolic capacity than adults, which for certain supplements may make
them more susceptible to adverse events. Physiological conditions like pregnancy also
increase the chance of adverse events from HS ingredients. Special concern should be
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given to the teratogenic effects of HS ingredients intended for use in pregnancy (Phua
et al., 2009). A well-known example is the teratogenic effect of high doses of vitamin
A if used in the pre-conception period (Rothman et al., 1996).
In addition to the life stages, disease conditions also alter susceptibility to
adverse events. Disease, or pre-existing conditions including hypertension,
cardiovascular disease, hepatitis, renal disease and diabetes all require special attention
if present in a person contemplating HS use. Hepatitis or renal dysfunction may delay
the metabolism and excretion of the ingredient leading to toxic levels which may lead
to severe adverse events. In diabetic patients, HS may affect insulin and glucose which
could lead to severe metabolic adverse events. All these factors should be taken in to
account to ensure the safe use HS (Phua et al., 2009).
One of the major concerns about the safety of HS is the potential for interaction
between a supplement and other ingested substances like drugs, other dietary
supplements or food. This may result in adverse clinical outcomes due to an increase
or decrease in the level of drugs, dietary supplements or food in the body. Some
examples of these interactions are discussed below.
Calcium carbonate taken as HS may interact with the antibiotic, tetracycline.
This is a direct chemical-to-chemical interaction. The calcium carbonate may bind
with the tetracycline and form an insoluble product. This will reduce or even eliminate
the effect of tetracycline (NAS, 2005).
The use of herbal products forms the bulk of treatments (particularly by elderly
persons who also consume multiple prescription medications for comorbid conditions)
which increase the risk of adverse herb-drug-disease interactions (Tachjian et al.,
2010). The concomitant use of yohimbine bark with guanabenz acetate, a drug used
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for hypertension, may diminish the antihypertensive activity of guanabenz through its
opposing pharmacodynamic effect (Grossman et al., 1993). Ginkgo biloba leaf, used
as an HS for mental alertness, may have an antagonistic effect on platelet activating
factor. If it is ingested with an anti-coagulant like warfarin, it will have an additive
action and may lead to bleeding (Spencer, 2004). St. John’s Wort, used as an HS for
depression, has some proven drug interactions. It may interact with cyclosporine, an
immune suppressant drug and thereby reduce the effect of cyclosporine. The level of
cyclosporine in the blood is controlled by the MDR1-encoded transporter and the
enzyme CYP3A4CYP both of which are affected by St. John’s Wort. This will reduce
the level of the cyclosporine in the blood and may lead to transplanted organ rejection
(Ruschitzka et al., 2000; Borrelli & Izzo, 2009). St. John’s Wort may also interact with
oral contraceptives. Circulating oestrogen levels following oral contraceptive intake
are also regulated in part by the activity of MDR1-encoded transporters so that St.
John’s Wort may lead to reduced levels of oestrogen in the blood level and a reduced
contraceptive effect (Borrelli & Izzo, 2009).
Herbal supplements like cranberry, which is used in blood and digestive
disorders, in co-administration with warfarin may affect CYP2C9 and CYP3A4. This
may lead to an additive action and bleeding may occur (Ge et al., 2014; Mohammed
Abdul et al., 2008). The concomitant use of Echinacea, an HS used as an immune
stimulant to prevent infections like the common cold and flu, with etoposide, a
cytotoxic drug used in the treatment of lung cancer, may produce an interaction and
lead to an increased platelet count. The use of Echinacea is not desirable in patients
taking etoposide or any other chemotherapeutic drug (Bossaer & Odle, 2012).
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All the above mentioned potential HS interactions with drugs shows a clear need
for the consumer to discuss any planned use of HS with their healthcare professionals
to avoid possible adverse events.
2.5.3 Adverse events of health supplements
The World Health Organization (WHO) has defined an adverse reaction as a
response to a drug which is noxious and unintended, and which occurs at doses
normally used in man for the prophylaxis, diagnosis, or therapy of disease, or for the
modification of physiological function (WHO, 2002).
All HS carry risks and benefits. Many of these risks are identified in pre-market
testing and can be managed as expected or with tolerable side effects that are
outweighed by the product's benefits. Adverse events may occur even when a product
is being used as directed. An event may occur within minutes after exposure or it can
take years to develop. Adverse events can range from minor irritations, like a skin rash,
to serious and life threatening events, such as a heart attack or liver damage. Most
often, adverse events are unexpected and are not necessarily indicated on the product
label or on any other information provided with the product (Health Canada, 2011a).
Adverse events associated with vitamins and minerals are usually due to over
consumption compared to the acceptable daily intake (ADI). In this respect, an
important consideration is the dietary pattern of the individual taking the vitamin and
mineral supplementation as diet also contributes towards daily intake. As stated above,
the safe upper level of vitamin C is 1g per day and this can be provided by a single
tablet, 1.69 kilograms (kg) of kiwi fruit or 2.5 litre (L) orange juice. For a person taking
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these levels of vitamin C in their diet, even a vitamin C supplement with a dose less
than 1g may cause adverse events (EFSA, 2006).
The WHO’s Uppsala Monitoring Centre, which pools reports from over 100
countries worldwide, has a database of over four million reports, of which 21,000
involve adverse events caused by herbal and natural products. The complexity of
herbal products starts with the method of cultivation and collection of the herbs. Major
causes of adverse events are the adulteration of herbal products with undeclared
chemicals including potent pharmaceutical substances such as corticosteroids and nonsteroidal anti-inflammatory agents. Major causes and sources of adverse events
associated with herbal products include mistaken or deliberate use of the wrong species
of medicinal plants, incorrect dosing, deliberate over-dosing for a more rapid effect,
heavy metal contamination (during cultivation or manufacturing),the presence of
agrochemical and pesticide residues, the presence of pathogenic microorganisms,
errors in the use of herbal supplements both by healthcare providers and consumers,
and interactions with other medicines (WHO, 2004; Phua et al., 2009).
In 2009, a division of the US Food and Drug Administration (FDA), the Internet
and Health Fraud Team, conducted an internet survey of HS products intended for
sexual enhancement. They found that one third of such supplements that are marketed
as dietary supplements to promote sexual performance and treat erectile dysfunction,
despite having no disclosure of any medicinal content on the label, nevertheless
contained the medicinal ingredient sildenafil, the active ingredient in Viagra (USFDA,
2009).
In Germany, the Deutsches Aerzteblatt International, which is responsible for
the approval of HS products, carried out research in March 2009 which found that
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certain Chinese slimming products, such as slimming tea and slimming herbal
capsules, had been associated with 17 incidents in which the consumer became ill with
symptoms and signs that included vomiting, arterial hypertension, headache, malaise,
nausea, chest pressure, dyspnea, tachycardia, insomnia and high fever. The herbal
products subsequently underwent chemical analysis in which sibutramine, a medicinal
slimming ingredient, was found. Every capsule of the herbal product contained twice
the recommended daily dose of sibutramine. Sibutramine is now a banned ingredient
even in medicinal products due to its potential to cause serious side effects (Müller et
al., 2009).
In 2001, the FDA issued warnings and an import alert that herbal products are
unsafe if they contain or are suspected to contain aristolochic acid (USFDA, 2001). A
cohort study of 105 patientsat a Belgian clinic found that rapidly progressive
nephropathy developed after they had been administered an herbal weight-loss product
containing aristolochic acid (Nortier et al., 2000). Because of a suspected association
between aristolochic acid and urothelial carcinoma, 39 patients with end-stage renal
disease underwent prophylactic removal of the kidneys and ureters. Urothelial
carcinoma was diagnosed in 18 of them. Aristolochic acid nephropathy has been
reported in eight other countries, and associated urinary tract cancer has been reported
in two (Arlt et al., 2002). The International Agency for Research on Cancer classifies
products containing the aristolochia species as human carcinogens (Heinrich, 2003).
The toxicological evidence of the risks associated with aristolochic acid is strong. In
1982, tumours were rapidly induced in rats at low doses (Wang et al., 2011).
Aristolochic acid is among the most potent two percent of the carcinogens in the
Carcinogenic Potency Database (Gold et al., 2005). It is mutagenic, forms DNA
adducts in humans, and is carcinogenic in mice. In rabbits, aristolochic acid induces
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nephrotoxic effects, the same DNA adducts in kidney as in humans, and urothelial
tumours (Arlt et al., 2002).
Patients are increasingly using herbal products for purportedly preventative and
therapeutic purposes. Some products have direct effects on the cardiovascular or
homeostatic system, whereas others have indirect effects through interactions with
medications that could lead to serious consequences. Common herbal remedies that
produce adverse events on the cardiovascular system include St. John’s Wort,
motherwort, ginseng, gingko biloba, garlic, grapefruit juice, hawthorn, saw palmetto,
danshen, echinacea, tetrandrine, aconite, yohimbine, gynura, liquorice, and black
cohosh (Tachjian et al., 2010).
In a study conducted in 2012 which evaluated the use of supplements containing
ephedra, which has been temporally associated with sudden death, 48 cases of those
with known supplement use were compared to 144 age, gender, and socioeconomicmatched controls in a 1:3 case control design. Of the 48 sudden deaths temporally
associated with supplement use, the underlying cause of death was fatal atherosclerotic
coronary disease in 18 (37.5%), sudden unexplained death in 16 (33.3%), and
hypertrophic cardiomyopathy in 6 (12.5%). In subjects ≥35 years of age, and known
to be taking supplements, there was a significant increase in mortality due to sudden
unexplained death (relative risk = 5.1 [95% confidence interval, 1.4–18.7]). This study
concluded that atherosclerotic coronary disease and idiopathic sudden death are
common etiologies of death when taking supplements (Appel et al., 2012).
HS products are gaining popularity throughout the world and the expanding HS
market in Dubai mirrors this consumption. As previously discussed, the consumption
of any pharmacologically active substance may have potentially harmful effects. There
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are also the additional dangers of adulteration, contamination, drug-HS or HS-HS
interactions to consider as these raise significant health issues. As the consumption of
HS products may have potentially deleterious effects on human health, there arises a
need for this issue to be duly addressed.

2.6 Global Adverse Event Monitoring Systems for Health Supplements
The following sections present details of various worldwide monitoring systems
in use regarding HS product related adverse events.
2.6.1 Adverse event reporting systems and post market surveillance
Some countries have established adverse event monitoring systems for HS.
Regardless of the pre-market requirements like notification, registration and premarket approval, the most effective safety assessment measure is post-market
surveillance. Monitoring product performance in the market place through collection
and investigations of consumer inquiries, complaints, and adverse reactions is the most
effective means of assuring quality and safety.
Adverse event reporting is a system that requires the reporting of adverse events
associated with a product to the appropriate authority. This is a regulatory requirement
in some countries. Post-market surveillance goes beyond this requirement to ensure
the overall quality and consistency of products in addition to managing company
liability by monitoring the performance and safety experience for a given product in
the market place. Post-market surveillance is a broader field, incorporating the
collection and analysis of consumer inquiries and complaints, in addition to adverse
events, and using this information to resolve issues and ensure continuous
improvement. Some leading companies which carry out post-market surveillance for
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their products may be in a better position to provide quality and safety assessments
than the regulators (Shao, 2014; Frankos et al., 2010).
Many countries have an established pharmacovigilance system for the
identification of the hazards associated with drugs. Spontaneous reporting systems for
suspected adverse drug reactions (ADRs) continue to be an essential part of
pharmacovigilance. Any information on a new or known adverse event that might be
potentially caused by a medicine and that necessitates further investigation is
considered as signal. Signals are generated from several sources such as spontaneous
reports, clinical studies, and the scientific literature. Signal detection is the process
that aims to find, as soon as possible, any indication of an unexpected drug safety
problem which may be either new ADRs or a change of the frequency of ADRs that
are already known to be associated with the drugs involved. The results of this
surveillance exercise tend to arouse suspicions and should always be followed up by
thorough investigations.
Causality or relatedness assessment evaluates whether the detected adverse
event is probably caused by the specific product. Causality assessment tools can be
broadly classified as expert judgment/global introspection, algorithms and
probabilistic methods (Bayesian approaches) and comprises, among others, the
evaluation of temporal relationships, dechallenge/rechallenge information, association
with or lack of association with underlying disease, presence or absence of a more
likely cause, and biologic plausibility (DSRU, 2017; EMA, 2014; Agbabiaka et al.,
2008). In adverse event reporting systems, the agencies receive reports of adverse
events from customers, healthcare professionals or companies. Respective regulatory
agencies utilise the information for signal detection, not causality analysis. Regulators
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do not individually rate or score individual reported adverse events. Rather, they
consider all incidents in totality, in context, to identify signals. Agricultural or
manufacturing errors, product contamination, and tampering are examples of issues
that can be identified through the collection of adverse events (Shao, 2014).
A robust post-market surveillance system involves comprehensive investigation
of quality and adverse reaction incidents. This includes collection, documentation, and
categorising of incidents followed by causality analysis and corrective action or risk
mitigation efforts, where applicable. This process falls outside the scope of most
mandatory adverse event reporting requirements. For the handling and mitigating of
consumer complaints related to product quality, some regulatory agencies have
incorporated requirements into Good Manufacturing Practice (GMP) regulations. For
example, in the United States, the FDA has promulgated requirements for complaint
handling in the current GMP regulation published in 2007 (USFDA, 2016).
2.6.2 Adverse event monitoring systems in leading countries
Adverse event monitoring systems for HS vary greatly around the world. In some
countries, reporting is practiced voluntarily by some companies and provided by
healthcare professionals. Some countries have established specific requirements for
adverse event reporting. Adverse event monitoring systems in selected countries are
described in the following section.
2.6.2.1 USA monitoring system
In December 2006, the US Congress passed the Dietary Supplement and Nonprescription Drug Consumer Protection Act, requiring manufacturers of dietary
supplements and OTC drugs to report to the FDA all serious adverse events they
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receive within 15 business days and to maintain records of all adverse events they
receive for up to six years. The law defines a serious adverse event as death, a lifethreatening experience, an inpatient hospitalisation, a persistent or significant
disability or incapacity, a congenital anomaly or birth defect, or an event that requires
appropriate medical judgment that may jeopardise the patient or subject and may
require medical or surgical intervention to prevent one of the outcomes listed in this
definition. In addition, this law mandates that the name and address of a party (e.g., a
manufacturer, packer, distributor, or retailer) responsible for collecting information
about adverse events should appear on the label of a non-prescription drug (also known
as an OTC drug) or a dietary supplement (USFDA, 2016).
An adverse event reporting system has been established called MedWatch. By
law, companies must report serious adverse events to the FDA within 15 days through
the MedWatch system using form FDA 3500A. The label of the product should be
attached with the form. Moreover, if the party learns of any new medical information
related to a serious adverse event report submitted in the previous 12 months, it must
be passed on to the FDA within 15 business days of receiving that information.
Consumers and healthcare professionals can also report adverse events
associated with HS voluntarily through the MedWatch system using the same form.
The receipt by the FDA of reports of minor adverse events in this way from consumers
may lead to signal generation. In addition, clinicians who may find some interaction
of HS with drugs during patient treatment should also report these interactions through
Medwatch form 3500A. Reports are assigned with a unique identification number and
forwarded to a Centre for Food Safety and Applied Nutrition (CFSAN) reviewer who
evaluates the report and characterises the relationship of the dietary supplement to the
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reported adverse event. Sometimes even reports of minor adverse events can be a
signal that a serious adverse event could arise from using a dietary supplement. The
reviewer may contact the person who filed the adverse events to obtain more
information and may do a scientific background review of the adverse events, whether
it is associated with the HS or not. If the signals of adverse events indicate a relation
with the intake of the HS, the FDA will act, including product withdrawal from the
market (Frankos et al., 2010).
2.6.2.2 Canada monitoring system
Health Canada requires NHP licensees to report all serious worldwide adverse
events (AE) arising from the product within 15 working days (Shao, 2014).
Health Canada assesses NHP for safety, effectiveness and quality before they
can be licensed for sale in Canada. Health Canada monitors the safety profile of all
health products sold in Canada to ensure that the benefits of using them continue to
outweigh the risks that may be associated with their use (Health Canada, 2011b).
NHPD controls NHPs after product approval through post-market activities
including the Adverse Reaction (AR) reporting system. Along with other medical
device problem reporting reports, the MedEffect Canada website supports the
reporting of AR associated with NHPs. Canada has an established post-market
surveillance system run jointly by NHPD and the Marketed Health Products
Directorate (MHPD) (Harrison & Nestmann, 2014).
Consumers and healthcare professionals may report adverse events of NHP
products to the Canadian Vigilance System through MedEffect Canada by telephone,
on-line or by mail using a consumer side effect reporting form. HC evaluates the
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signals associated with the adverse events and the safety profile of the product and, if
needed, may recall the product from the market. The MedEffect Canada system allows
consumers, patients and healthcare professionals to report an adverse event or side
effect thereby generating new safety information of NHP products. Consumers and
healthcare professionals may search for advisories, warnings and recalls in the Recalls
and Safety Alerts Database of MedEffect Canada (Health Canada, 2011a).
2.6.2.3 Australia monitoring system
In Australia, HS are categorized as Complementary Medicines (CM) and
controlled by the Therapeutic Goods Administration (TGA). Australia has a
pharmacovigilance system, Therapeutic Product Vigilance, that requires the reporting
of adverse events of CMs in the absence of specific requirements for CMs. TGA
mandates by law that the sponsor or manufacturer of the product should report AEs
within 15 working days. If it is a critical, significant safety issue, the sponsor should
report within 72 hours from the time of awareness of the issue by any personnel of the
sponsor. Consumers and healthcare professionals may also report adverse events of
CM through an on-line form on the TGA website. Each adverse events report received
by the TGA is entered into a database and continually evaluated by TGA staff to
identify potential emerging problems for detailed investigation. TGA staff carry out
detailed investigation and if they identify a safety concern associated with the product,
TGA may take regulatory action including recalling or suspending of the product from
the market (TGA, 2016).
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2.7 Disclosure of Health Supplement Use to Healthcare Professionals
Patients’ disclosure of HS consumption to healthcare professionals is one of the
factors contributing to the safe use of HS. Drug/HS interaction may lead to major
adverse events and demands the attention of healthcare professionals to avoid this. The
disclosure rate of complementary and alternative medicine (CAM), which also
includes HS, varies from 23-70% and one of the reasons for this is that practitioners
did not need to know about their patients’ CAM use, and the fact that the practitioners
did not ask (Robinson & McGrail, 2004). One study shows that 69% patients did not
inform the physician about their dietary supplement use excluding vitamins (Gardiner
et al., 2006). Without specific prompting or questioning, consumers of natural products
may not disclose their use of such product to primary healthcare professionals. It is
helpful if the healthcare professional adopts a pro-active approach and routinely
includes questions about health supplement use, but this does not usually happen
(Busse et al., 2005). There is concern about a negative response from healthcare
professionals: they do not ask, and the perception is that because healthcare
professionals work within a biomedical framework, they have less knowledge of CAM
(Robinson & McGrail, 2004). Nutritional supplements are often considered safe and
natural, and consumers are not aware of the possibility of HS/drug interactions (Bebeci
et al., 2015). The regulatory authorities should pay more attention to educating
consumers about the complications of the concomitant use of HS and drugs and the
need for disclosure of HS use to healthcare professionals. This could be done through
public information campaigns and continuing professional education for healthcare
professionals to ensure that both consumer and professional are aware of HS,
especially herbal supplements (Samojlik et al., 2013).
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2.8 Healthcare Professionals’ Knowledge, Attitude and Practice on Health
Supplement Related Adverse Event
Herbs and other dietary supplements are among the most commonly used
complementary medical therapies. Clinicians, however, generally have limited
knowledge and confidence to communicate regarding herbs and dietary supplements.
Educational interventions and institutional policies are needed for healthcare
professionals in relation to herbs and dietary supplements to improve the quality of
patient care (Kemper et al., 2006).
The unprecedented global increase in the use of herbal remedies is set to continue
apace well into the foreseeable future. This raises important public health concerns,
especially as it relates to safety issues including adverse events and herb/drug
interactions. Most Western-trained physicians have very limited knowledge of the
risks and benefits of this healthcare modality. Therefore, evaluation of healthcare
professional knowledge would identify appropriate intervention strategies to improve
physician-patient communication in this area (Clement et al., 2005).
A survey conducted in Maharashtra, India, found that a lack of knowledge
prevented healthcare professionals from advising their patients on herbs and herbal
preparation in a positive way. The authors recommended that the medical curriculum
should include training in the use of scientific and evidence-based research on herbal
medicines. Physicians must become more educated about the safe and effective use of
herbs. Asking patients about supplement use during an initial medical history should
be made a central component of patient care and medication use monitoring (Ghia &
Jha, 2013).
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In a cross-sectional prospective study of US military physicians, 60% of the
physicians observed adverse events associated with HS, but only 18% reported these
events. Approximately 70% of physicians did not know how or where to report adverse
events associated with health supplements. A gap in information of HS and adverse
events reporting is identified in the study. A centralised adverse event reporting system
could serve to identify potentially harmful HS for further evaluation. Health
professionals need to remain vigilant for adverse events associated with HS use and
should be better informed on how to report them (Cellini et al., 2013).
A study carried out among doctors working in a teaching hospital in Lagos,
Nigeria underlined the fact that there are gaps between knowledge and ADR reporting.
For the long-term improvement of ADR reporting, it is very important that these gaps
be filled by improved training in pharmacovigilance and risk perceptions of drugs.
Healthcare professionals should be made aware that ADR reporting is considered an
integral part of the clinical activities of doctors (Oshikoya & Awobusuyi, 2009).
Another descriptive cross-sectional study conducted among oncology
practitioners, including medical and allied medical personnel, in Doha, Qatar drew
attention to the need to integrate an educational and training program regarding CAM
practices and usage to enhance cancer patient management and ensure a more holistic
and efficient cancer treatment for patients (Hassan, 2015).
A survey of attitudes and knowledge of HS among US and Canadian pharmacists
recommended that pharmacists need to have additional training in HS, that there
should be increased regulation of HS, and that there should be an improvement in the
quality of information on HS. In addition, the survey data indicated that pharmacists
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do not perceive their knowledge of HS to be adequate and that they do not routinely
document, monitor, or inquire about patient use of HS (Kwan et al., 2006).
A study in Gujarat, India, found that community pharmacists’ knowledge of the
terminology of ADR and awareness of the national pharmacovigilance centre was 65%
and 63%, respectively. In addition, 60% of community pharmacists assumed that all
herbal products were free from ADRs (Rathod & Panchal, 2014).
In a study among community pharmacists working in the emirates of Ajman and
Sharjah, United Arab Emirates, only 4.9% were found to have good knowledge of
ADRs. Moreover, the study concluded that knowledge of ADRs and their reporting
were also found to be inadequate. Community pharmacists, however, showed a
positive attitude towards ADR reporting and felt that they had an important role to play
in ADR reporting. Notwithstanding, community pharmacists were unenthusiastic
about reporting ADRs that might be caused by over-the-counter drugs (OTC) (Qassim
et al., 2014). In a study of the knowledge, attitude and the practice of
pharmacovigilance among healthcare professionals in a teaching hospital in north
India, fewer than 40% of healthcare professionals knew how to report ADRs (Bajaj &
Kumar, 2013).
A cross-sectional survey of community pharmacists in Riyadh, Saudi Arabia
discussed the most common hurdles that prevent community pharmacists from
discussing the use of HS. These included a lack of time due to other obligations
assigned to the community pharmacist (46%), a lack of reliable resources (30.3%), a
lack of scientific evidence that supports herbal medicine use (15.2%), and a lack of
knowledge of herbal medicines (13.4%). The study also pointed out that further steps
must be taken to increase awareness in pharmacists of adverse drug reaction reporting
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systems and to improve the curricula and continuous education programs to address
herbal products and related issues (Al-Arifi, 2013).
A further survey among pharmacists in Virginia and North Carolina in 1998
concluded that pharmacists with previous continuing education in herbal medications
were more knowledgeable of these products (Chang et al., 2007).
In most developing countries, healthcare professionals and, especially, doctors
are the principal contributors of adverse event reports (Heinrich, 2003). Usually, a high
number of doctors have the correct understanding regarding adverse events and know
what should be reported. Nurses, however, know better about where to report adverse
events (Rehan et al., 2012). Under-reporting of adverse drug events by prescribers is a
common problem. The underreporting of ADRs among health professionals is
attributed to various factors including the knowledge and practice of health
professionals regarding reporting (Kamtane & Jayawardhani, 2012).
The under-reporting of ADRs, caused by both prescription and OTC drugs, is
widespread in both developed and developing countries. The lack of awareness of the
available pharmacovigilance systems and insufficient knowledge of ADRs are major
reasons. Studies show that increased knowledge correlates to higher ADR reporting
(Qassim et al., 2014). Despite health care professionals having the right attitude and
willingness to report ADRs, it is mostly the lack of knowledge or unawareness that
results in under-reporting. Healthcare professionals need education and formal training
in herbal medicines, where to source herbal information and how to evaluate it to
makeinformed decisions prior to making recommendations and providing patient
information. Continuing education programs, conferences and seminars would assist
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healthcare professionals in increasing and updating their knowledge base in herbal
medicines (Al-Arifi, 2013).

2.9 Challenges in Adverse Event Data Collection Process and Analysis
The reporting process of adverse events is based on a voluntary system that helps
in distinguishing vulnerable groups and generating safety indications. Such a system,
however, also has major disadvantages like under-reporting and sub-optimal data
quality which limits efforts to establish an effective adverse event monitoring system
for HS. Under-reporting may negatively affect signal detection and may result in
under-estimation of the size of a problem. The quantity along with the relevance of
case reports and the quality of data are important in signal detection (WHO, 2012).
The following section briefly discusses the challenges of adverse event data collection.
2.9.1 Under-reporting of adverse event
A study was conducted to evaluate how well the FDA’s adverse event reporting
system for dietary supplements functions as a consumer protection tool. It estimated
that the FDA receives under 1% of reports of all adverse events associated with dietary
supplements. The study further suggested that factors that may contribute to underreporting are many consumers presume supplements to be safe, use these products
without the supervision of a healthcare professional, and may be unaware that the FDA
regulates them (DHHS, 2001). Under-reporting of adverse events may be for the
following reasons. A lack of consumer awareness of the importance of reporting
adverse events of HS or even about the unavailability of a reporting system. Even if
the reporter is aware of the system, a lack of familiarity with the form or a lack of
clarity about the required information might deter submission. Patients are often
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reluctant to report the use of alternative treatments to their healthcare providers. Some
consumers believe HS are inherently safe since they are natural, and consumers
therefore fail to make a connection between the use of a dietary supplement and its
adverse events and, as a result, do not report it. Neither is there a clear, common
understanding of what constitutes an adverse event. For example, for some, only death
or permanent disability qualify, while others include discomfort leading to absence
from work or admission to an emergency room for treatment of a symptom such as
dehydration. Nor is the recording of the history or asking about HS use a routine part
of medical history in either emergency room or follow-up ambulatory visits (Oria,
2008).
Apart from the above-mentioned reasons, the introduction of a dietary
supplement, media attention, and the level of educational or regulatory activity
recently presented could be other factors that indirectly affect the report rate. There are
many psychological and professional issues that contribute to under-reporting.
Healthcare professionals fear that ADR reporting may reflect negatively on their
competence or even attract litigation. Even although it is essential that all suspected
adverse reactions be reported, healthcare professionals are sometimes reluctant to
report them because of doubts regarding the causal role of the drug (WHO, 2012).
Under-reporting of ADRs is widespread and a remains a daunting challenge in
pharmacovigilance (PV). There are patient-related reasons for UR like failure to
recognise ADR or the inability to link the ADR with a drug.
2.9.2 Quality of data collected
The quality of information reported depends on the reporter’s judgment as well
as familiarity with medical reporting, signs, and symptoms. Forms filled by consumers
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often include incomplete or inaccurate information about an adverse event. Consumers
may lack the information to complete the form with the correct medical terms and
standard codes for data entry of adverse event reporting. The form may not collect data
about brand name, dose, and other products or medications being taken concomitantly
(Oria, 2008).
The 2001 OIG report highlighted the difficulties presented by poor data quality.
Adverse event report data were categorised as suboptimal, specifically providing
limited medical information, limited information on products and manufacturers,
limited information about the consumer, and limited ability to analyse trends. The
report found that in 1999, the FDA recorded only 400 adverse events from dietary
supplements through MedWatch 3500A forms. Of those, medical records were
unavailable in 58% of cases, ingredients could not be determined in 32%, and there
was no patient follow-up information available for 27% (DHHS, 2001). The user
guidance recently issued on how to fill in the MedWatch 3500A forms improve this
situation by helping those reporting adverse events to submit accurate and appropriate
information.
These challenges can be overcome by raising the awareness of consumers about
the adverse events reporting system. An on-line reporting system could reduce errors
with HS associated adverse events reports. If information about the use of HS and
adverse events can be collected by healthcare professionals as part of their daily
practice and they can report this using correct medical terminology to the adverse
events monitoring system, this would raise the quality of reports to the authority and
would improve the process of generating signals for the analysis of adverse events
(Oria, 2008)
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2.10 Benefits of Having Adverse Drug Reaction Reporting System
ADRs have a major impact on public health and are an important cause of
hospital admissions. An ongoing ADR monitoring and reporting program can provide
benefits to the organization, pharmacists, other healthcare professionals and, more
importantly, to patients. These benefits include (but are not limited to) the following:
providing an indirect measure of the quality of pharmaceutical care through
identification of preventable ADRs and anticipatory surveillance for high-risk drugs
or patients, complementing organizational risk management activities and efforts to
minimise liability, assessing the safety of drug therapies, especially recently approved
drugs, measuring ADR incidence, educating healthcare professionals and patients
about drug effects and increasing their level of awareness regarding ADRs, providing
quality-assurance screening findings for use in drug-use evaluation programs, and
measuring the economic impact of ADR prevention as manifested through reduced
hospitalisation, optimal and economical drug use, and minimised organizational
liability (ASHP, 1995).
The impact assessment proposal for Directive of the European Parliament and
of the Council for the amendment of pharmacovigilance system clearly states the
benefits and positive outcomes of having a surveillance or adverse event monitoring
system. The document states that 30% of the adverse events associated with drugs and
medical substances may be preventable. They assume that they can reduce the health
burden by enhancing the European pharmacovigilance system including early
detection of fatal adverse reactions, fast implementation of EU-wide decisions on the
safety labelling of medicines, clear warnings like not to prescribe a certain medicine
to a certain at-risk group of patients, or not to prescribe together two medicines
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dangerous in combination, to reach 10% of preventable ADRs in an optimistic scenario
and 1% in a conservative scenario (EUROUPA, 2008).
Five percent of total hospital admissions are associated with ADRs and about
5% of hospitalised patients suffer ADR. Another study has highlighted the public
health importance of ADRs by estimating that ADRs caused over 100,000 hospital
deaths in the United States in 1994 (EUROUPA, 2008).
A proactive and robust pharmacovigilance system could reduce mortality and
morbidity, prevent potential disabilities, and improve access to safe and effective
medicines for unmet medical needs. The importance of pharmacovigilance/ADR
monitoring systems in reducing or preventing drug induced human suffering cannot
be understated. Still, the very purpose might be undermined by under-reporting or poor
quality of data. The factors contributing to these may vary, but are a potential risk to
patient safety and may result in an increased financial burden. Through customer
awareness programs and continuing medical education for healthcare professionals,
ADR reporting can be made efficient. The establishment of a proactive
pharmacovigilance system reduces not only the ADR economic burden but also
considerably reduces mortality and morbidity (EUROUPA, 2008; Pirmohamed et al.,
2004).

2.11 Summary
This chapter compiled information regarding the consumption of HS and the
existing rules and regulations that were exercised in different countries. Various
surveys mentioned here implicate the existence of misconceptions about the safety of
HS, among both consumers and healthcare professionals. Many developed countries
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have various monitoring systems in place to tackle the issue of lack of awareness and
under-reporting of adverse events. The quality of data collected is of prime importance
and educating healthcare professionals is an important step in this direction. It might
be noted that the increasing HS consumption among the Dubai population also
significantly increases the potential risks that might be related to HS. The role of CPSS
at Dubai Municipality in promoting the safe use of HS through import regulations and
field inspections was discussed in this chapter. Apart from the HS import data at CPSS,
no studies exist, to date, to establish the extent of HS consumption in Dubai and the
occurrence of adverse events, if any, that might be caused by their use. This warrants
the need for an extensive study to assess the wide spread use of HS and to educate
health professionals and consumers about their safe use. The information collected
could be of high significance and could also justify the creation of an ADR reporting
system for HS, which in turn could promote the safe use of HS in Dubai.
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Chapter 3: Methods
3.1 Introduction
This chapter describes the methodology and research design used in the study.
The study aims to evaluate the public health importance of HS product consumption
related adverse events in the Emirate of Dubai. The study aims to fulfill the following
objectives: measure both healthcare professionals’ and the Dubai population’s
knowledge of HS products, the levels of consumption of HS by the Dubai population,
and the incidence of adverse events in the Dubai population. The study additionally
aims to identify the level of KAP among Dubai healthcare professionals regarding HS
products, any related adverse events, and the reporting of such events.
To find answers to the research questions of the research, the study included the
following two cross-sectional surveys: a survey of HS products consumption in the
population of Dubai, and a survey of healthcare professionals to assess knowledge,
attitude and practice of HS product related adverse events.

3.2 Study 1: Survey of Health Supplement Use in the Dubai Population
3.2.1 Study design
A cross-sectional study design was used to determine the prevalence and
characteristics of HS product consumption in Dubai and to study HS product adverse
events among consumers. The sampling units were households. A new survey tool was
developed based on earlier studies with similar objectives, as shown in Figure 3.1.
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Figure 3.1: Process of questionnaire development

3.2.2 Study setting
This population-based survey included both nationals and non-nationals resident
in all areas of Dubai in 2016. The population of Dubai is approximately 2.1 million
(DSC, 2014). Dubai Statistic Centre provided the necessary mobile phone numbers for
all registered residents in Dubai. Data collection took place between 1 May 2016 and
1 July 2016.
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3.2.3 Study participants/population
All residents of Dubai aged 16 and above who were willing to participate were
included in the study. In addition, participants had to be willing to disclose their height
and weight so that their body mass index (BMI) could be calculated. This was needed
to assess HS consumption which is BMI dependent.
3.2.3.1 Population contact database
The co-operation with an established and experienced survey institution was
important in this research process as the survey required skilled expertise resources.
Dubai Statistical Centre (DSC), a Government of Dubai entity, was selected as the sole
official source for the collection, analysis and publication of statistical information and
data in the Emirate of Dubai, UAE. Joint meetings with the DSC team were held to
clarify the survey objective, questionnaire outline, survey team constitution and
timeframe (DSC, 2014).
DSC maintains a regularly updated central database of the contact telephone
numbers of all Dubai residents with a fixed landline, and individual mobile telephone
numbers.
3.2.4 Sampling
Sampling is one of the most important parts of the survey. A survey is only as
good as the quality of its sample. The sample design and the implementation were
carried out with the utmost care to avoid possible mistakes. Both nationals and nonnationals were included for a more accurate cross-sectional representation of the Dubai
population and, additionally, to maximise generalizability (UN, 2008).
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The DSC central database was used in the making of the sampling frame from
which geographical areas, households and individuals were selected for sampling
purposes. The sample frame covered Dubai geographically and socio-economically
(CPSS, 2015) and formed six areas, three in Deira and three in Bur-Dubai.
Stratified sampling was used. Contacts were randomly selected avoiding any
duplication that might negatively affect the validity of the result. Pre-survey
evaluations, tests and pilot surveys were carried out. Sampling procedure was
monitored and the survey was conducted appropriately.
For the purposes of statistical gathering and cost efficiency, the DSC population
database was organized geographically and divided into regions. In total, six regions
were selected as survey areas for data collection (DM, 2015), three in Deira and three
in Bur-Dubai. Area One, Deira, included Al-Qusais and Al-Muhaisina where nonnationals mainly resided. Area Two, Diera, included Mirdif, Al-Mizhar and Al-Warqa
where mainly nationals resided. Area Three, Diera, included Hor-Al-Ans and AlBaraha where both nationals and non-nationals resided. Area Four, Bur-Dubai,
included Al-Karama and Satwa where non-nationals mainly resided. Area Five, BurDubai, included Jumeira and Umm-Suqeim where mainly a mixture resided. Area Six,
Bur-Dubai, included Al-Quoz and International City where mainly non-nationals
lived. The area selection considered the following factors that might influence the
survey: the extent and representation of Dubai emirate, Nationals Vs non-nationals in
residential areas, and socio-economic status (CPSS, 2015).
The Dubai geographic map constructed by Planning and Survey Departments of
Dubai Municipality (DM) was used. Dubai households were divided almost equally
into six geographically defined areas. The agreed sample size determined for this study
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was 1,200 individuals. The targeted respondents for the survey were Dubai residents,
randomly selected from contacts in the DSC database. The database contained
necessary information for this survey including name of the house owner, gender,
employment status, income range, landline number, house number, several mobile
numbers of house residents, area number, and number of residents, etc. (DSC,
2014).The populations of the selected areas were of similar sizes. The sample size per
area was proportional to the population of the area. Sampling was completely random
within the population of the areas. In each of the six areas, 200 random households
were selected using SPSS software, version 20. Each house was registered with mobile
numbers ranging from one to maximum 20 different numbers. Mobile numbers for
each house were selected randomly. Respondents aged only 16 years or older were
included for the purposes of this study. This age detail was not available from the DSC
database. Upon enquiry with both Etisalat and Du, the only two mobile phone service
operators in the UAE, mobile numbers were not issued to individuals aged under 21
years. Four researchers were therefore hired. They were given random mobile numbers
to call, explain the purpose of the survey and ask about ages. Individuals found to be
under 16 were subsequently excluded. Another random number from the same house
was chosen. About 6,200 mobile numbers were contacted during the three-month
period prior to data collection. It would be helpful in future studies if DSC contained
this age-related information in their database.
In each selected household, researchers negotiated with respondents regarding
their agreement to complete a telephone interview. Interviews were then successfully
concluded. Where contact was not made and interviews were not successfully
concluded, researchers would call the same number a maximum of three times over
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three consecutive days. In the event of failure to contact, another random sample from
the same house was selected.
3.2.5 Sample size
As the prevalence of HS product consumption may range from 10% to 30%
according to Kemper et al. (2006) and around 19% according to Hara et al. (2011), it
was estimated that there may be approximately a 30% prevalence of HS product
consumption among both nationals and non-nationals in Dubai.. The required sample
size was calculated as alpha=0.05, the desired precision of the confidence interval set
to 5%, the population size of nationals and non-nationals in Dubai was 200,000 and
1,900,000, respectively, and the non-response rate to such surveys was estimated to be
12% from previous similar surveys (DSC, 2014).
The sample size was calculated using computer software called OpenEpi.
Sample size and power were selected. The size of population was entered as 2,100,000.
The expected frequency was entered as an estimate of the true prevalence (30%
according to Kemper et al., 2006). The margin of error was set to no more than 3%.
The sample size was equal to 1,067 with 95% confidence level. A 12% increase in the
sample size was calculated to overcome the non-response rate expected from previous
studies in which the total sample size was 1,200.
3.2.6 Survey tool
The survey tool used for this study was a questionnaire. The following describes
the process of the survey tool development including the literature/expert review,
producing ane-form, reviewing, pilot testing and changes, and the translation of the
final questionnaire. This section also presents the questionnaire administration
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including the recruitment and training of researchers, the process of the interview, and
the ensuring and checking of data quality.
3.2.6.1 Questionnaire development
The process of questionnaire development included some critical stages as
illustrated in Figure 3.1.
Literature/expert review: A primary draft version of the questionnaire was
developed as a Microsoft Word document based on previous research and input from
professionals and experts in the field of HS products. The draft questionnaire was
reviewed by PhD Research Committee Members at United Arab Emirates University.
Producing e-form questionnaire: Upon successful review by the UAEU, the
draft questionnaire was submitted to the DSC for digital transfer into an electronic
version allowing CAPI researchers to conduct telephonic surveys. DSC was a survey
partner in this research. The questionnaire was completed by DSC on 17 June 2015.
E-form questionnaire review: The e-form questionnaire was reviewed by a
panel of information technology specialists at DSC. Thirty HS specialists from the
Consumer Products Safety Section of DM worked with researchers. They checked
accessibility, order of questions, and spelling.
Changes in the questionnaire: Upon receiving feedback from information
technology specialists, Consumer Products Safety Section HS specialists, and the
researchers regardingchanges to the questionnaire, the DSC was asked to modify the
numbering of the questions and pages, to replace the field name, Sex, by Gender,
replace the term Surveillance by Reporting, add a progress bar at the top of the survey
page, show notification if a mandatory question was not answered, change the
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formatting, order and context of some questions and answers, and link some questions
to each other, and end the questionnaire at certain answers.
Pilot testing: After discussion, the DSC made the required amendments and
CAPI was ready to use by 23 July 2015. The pilot study was started on 27 July 2015
aiming to achieve 120 responses. By the 4 August 2015, 74 responses had been
received from non-nationals and 60 responses from nationals. This pilot study did not
identify any further problems or technical issues with the questionnaire.
Translation: In Dubai, the local language of communication is Arabic, and nonnationals mainly speak English. The questionnaire was therefore produced in both
Arabic and English. Translation was carried out to the highest level by the Arabspeaking researcher involved in the survey. The translated questionnaire was proofchecked by language experts at Dubai Municipality. The translated questionnaire was
corrected with required changes after proof reading, tests and pilot surveys (UN,
2008).
Questionnaire approval: The final version of the questionnaire was approved
and made available for data collection. The questionnaire was subsequently approved
by the Social Sciences Research Ethics Committee at UAE University, an authorised
agent able to issue approval to students/researchers wishing to conduct social science
related research in the UAE.
3.2.6.2 Questionnaire administration
The questionnaire administration process included certain stages such as
recruitment and training of researchers, process of the interview, instructions to
researchers, and ensuring and checking the data quality.
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Recruitment and training of researchers: To ensure the quality of the survey,
two teams of researchers/interviewers were hired at DSC for the telephonic survey.
One team was Arabic speaking experts and assigned to do the survey for nationals who
mainly speak Arabic. The second team was multi-lingual experts who speak both
Arabic and English. They were assigned to do the survey for non-nationals. This
arrangement increased the quality of communication and helped in clarifying such
things as medical terms mentioned in the survey.
One key element of the survey was training. The training process started before
the survey and continued during the entire data collection process. During selection of
the interviewers, the qualification of a Bachelor degree was listed as a requirement.
Training sessions for the interviewers were conducted for supervisors and the
coordinators at the DSC to make sure that everyone associated with the survey were
clear about their role and the aim of the survey. Training methods included role-play
in interviews with various scripts. The training process motivated the interviewers and
their practical suggestions were accepted. This training improved the overall quality
of the data collection (UN, 2005).
Process of the interview: Survey implementation requires great attention to
obtain quality data. The entire survey process was monitored in real time by the writer
and problems were addressed as they arose. The supervisor/interviewer ratio was 1:5.
Input from the telephonic survey were entered on the specially created Microsoft Excel
file during the survey itself (UN, 2005).
A principal concern was how to increase the response rate. It was assumed that
unemployed respondents may be more available between 11 AM and 1 PM, and for
employed respondents, it was assumed that they may be more available between 3 PM
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and 6 PM. This method of approach was successful and increased the response rate in
the survey.
Ensuring and checking data quality: The quality of the survey is vital and
ensures accuracy, reliability and validity of the results. To ensure quality, World
Health Organization (WHO) guidelines were followed using World Health Survey
(WHS) (UN, 2005). To achieve the maximum quality, the following principles were
adopted: quality standards which need to be adhered to each step of survey, quality
assurance procedures ongoing throughout the survey from preparation and sampling
through to data collection and data analysis and on to report writing, and evaluation of
the quality assurance procedures (UN, 2005).
In the survey procedure, great attention was paid to quality in every respect.
Random participants, for example, were re-surveyed to check the quality and veracity
of their original answers. Of the 1,200 residents surveyed, 40 were re-surveyed.
The survey was conducted through CAPI and designed such that, if data were
missing, interviewers would be alerted, allowing the survey to be completed correctly
and with confidence.
The research outcome is entirely based on data from the survey. To ensure the
quality of data collected, it was important to obtain accurate data timely. After
sampling and before starting the survey, call sheets were provided for each telephone
number. The interviewer could make notes related to the survey. These notes might
play a vital role in the quality of survey itself. In the event, call sheets did indeed play
an important role in the data collection by: recording the status of each telephone
number participating in the survey, providing helpful information to the next
interviewer like convenient time to call back, seeking attention for feedback and
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supervision if needed, and marking the number of attempts with time and response,
and recording the outcome of each telephone number enquiry (including completed
interviews, refusals etc.) (UN, 2005).
This call sheet worked as a cover page to the questionnaire for each telephone
number used in the survey. Upon completion of the questionnaire, data were directly
input into the computer using user-friendly software, Epidata. To minimize errors in
transferring data, a special data entry team was created from the interviewer team,
supervised by one of the supervisors from the survey team.
3.2.7 The questionnaire
The following sections present a summary of the survey tool, its various sections,
variables, questions, related scales and coding.
3.2.7.1 Questionnaire sections: summary
A questionnaire (Appendix A) composed of six sections was used to measure
HS product consumption and other required variables in the study population. The
section, as shown in Table 3.1, asked about demographic information including age,
gender, marital status, nationality, occupation, health insurance coverage, income,
education, weight and height. All data were nominal except age, height, and weight
which were interval. Additionally, income was presented as an ordinal scale. Height
and weight were used to present the Body Mass Index (BMI). All data were used to
measure the demographic characteristic.
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Table 3.1: Population demographic data, scales & variables
Question

Scale

Age

Interval

Gender

Nominal

Marital status

Nominal

Nationality

Nominal

Occupation

Nominal

Health insurance coverage

Nominal

Income

Ordinal

Education

Nominal

Weight (kg)

Interval

Height (cm)

Interval

Variables measured

Demographic - characteristics

The section on health and lifestyle, as shown in Table 3.2, assessed the general
health status of the responder including allergies, clinic visits during the previous year,
chronic diseases, consumption of drugs and smoking habit. All data were nominal
except for clinic visits and smoking habit which were presented as ordinal scale. All
data were used to measure health and lifestyle.
Table 3.2: Population health and lifestyle, scales & variables
Question

Scale

Having any allergy

Nominal

Specifying the type of allergy

Nominal

Frequency of visiting a doctor in the past 12 months
Whether been diagnosed with chronic medical
condition

Ordinal
Nominal

Whether taken prescription drugs in the past month

Nominal

Smoking status

Ordinal

Variables
measured

Health and
life style
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The section, as shown in Table 3.3, focused on HS consumption and comprised
questions covering the following points: knowledge of HS, HS consumption including
duration, frequency, number and amount, discontinuation of HS consumption,
categories, forms and names of HS consumed, ingredients of HS consumed, reason for
consuming HS and location of purchasing HS. All data were categorical except for
duration of using HS which was presented as ordinal scale. All data were used to
measure the HS use except the question - Do you know what HS are?- which was used
to measure consumer knowledge regarding HS.
In the section Information about HS Products, as shown in Table 3.4, questions
covered the following points: the identity of the person, if any, who recommended HS
to the responder, the frequencies of prescribing HS by healthcare professional, HS
information source, opinion about information on label including product information
and nutritional facts, label information of concern to the responder and, finally, the
level of compliance with label recommendations. All data were nominal except for
frequency of HS prescribed for the consumer by healthcare practitioner, which was
presented as ordinal scale. All data were used to measure consumer knowledge
variable on HS.
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Table 3.3: Health supplement consumption, scales & variables
Question

Scale

Knowing what HS are

Nominal

Reasons for taking HS

Nominal

Reasons for discontinuing HS

Nominal

Ever using HS

Nominal

Duration of using HS

Ordinal

Frequency of using HS

Nominal

Which HS categories been using

Nominal

Variables measured
Consumer
knowledge on HS

Consumption
characteristics

Which HS forms been used

Nominal

Which HS ingredient been using

Nominal

Where purchasing HS

Nominal

How many HS products been using

Ordinal

Enter the full name of HS including brand
name

Nominal
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Table 3.4: Information about health supplement, scales & variables
Question

Scale

Variables
measured

Who advised you to take HS

Nominal

Times HS prescribed by healthcare practitioner

Ordinal

Where seeking HS product information

Nominal

Whether finding sufficient information on HS
label

Consumer
Nominal

knowledge on
HS

Whether nutrition information on HS useful

Nominal

Which label information concerns you

Nominal

Whether following recommended label
information

Nominal

The section Adverse Events Related to Health Supplement Consumption, as
shown in Table 3.5, asked whether the responder had experienced any adverse event
related to HS use. If the respondent answered yes, further questions enquired about the
nature, severity, frequency and onset time of the adverse events reported. There are
also questions about the exact relation between the adverse event and the HS
consumed, and what HS product is confirmed or suspected to have caused the adverse
event. Finally, in this section, the responder is asked about the resolution of the adverse
event and any period of hospitalisation that was necessary. All data were nominal
except for severity of the adverse events, frequency of encountering adverse events,
and onset time of adverse events which were presented as ordinal scale. All data were
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used to measure the variable of level of experiencing an adverse event, potential
deleterious effects on human health in the Dubai population, except for healthcare
practitioner investigation on HS consumption at any visiting time, and the resolution
of the adverse event.
The section Reporting Adverse Events, as shown in Table 3.6, asked whether
the responder had reported an adverse event related to HS and, if so, how this was
done. A final question asked for the responder’s opinion about establishing a reporting
system for any adverse event related to HS.
All data were nominal except for practice of population on establishment of a
reporting system of adverse events related to HS consumption, which was presented
as ordinal scale. All data were used to measure the reporting of suspected HS-related
adverse events, except for establishment of a reporting system of adverse events
related to HS consumption, which was used to measure the consumer knowledge on
HS variable.
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Table 3.5: Adverse event related to health supplement use, scales & variables
Question
Whether experiencing any AE related to HS
use
Which AE of HS use been ever experienced
Severity of the AE
Frequency of encountering AE due to HS use

Scale

Variables measured

Nominal

Nominal
Ordinal
Ordinal

Onset time of AE after consuming HS

Ordinal

How was the relation between HS
consumption and the AE confirmed

Nominal

Which of the HS you have used was
suspected/confirmed to cause the AE

Nominal

When visiting your healthcare practitioner
for any reason, whether asked you about
your HS consumption

Nominal

How did the AE resolve

Nominal

Potential deleterious
effects of HS on
human health

Reporting of
suspected HS-related
AE

Table 3.6: Reporting adverse event, scales & variables
Question
Have you ever informed your physician
about your HS use

Scale

Variables measured

Nominal

Have you ever reported an AE related to HS
use

Nominal

Where did you report the AE

Nominal

What do you think about the establishment of
a reporting system of AE related to HS use

Ordinal

Reporting of
suspected HS-related
AE

Consumer knowledge
on HS
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3.2.7.2 Variables
The dependent variables within the population-based survey include
consumption rate, consumer knowledge of HS, the level of experiencing adverse event,
and the potential deleterious effects on human health in the Dubai population. The
independent variables or correlates include: age, gender, marital status, nationality,
occupation, health insurance, income, education level, and BMI.
For the three dependent variables, knowledge of HS was defined as an
affirmative answer to Q2 - Do you know what HS are? HS use was defined as an
affirmative answer to Q23 - Have you ever used HS? and ever having had an HS
adverse event was defined as an affirmative answer to Q41 - Have you ever
experienced an adverse event from HS?
3.2.8 Data management
Data were managed through SPSS version 20. All data were coded in such a way
as to interpret the variables.
3.2.8.1 Re-coding and interpretation of the variables
Some of the variables were re-coded during the analysis. For instance, the
nationality category was re-coded as Emirati, Middle East/ North Africa, South Asia,
East Asia/ Pacific, Central Asia/ Europe, Africa, Western Europe/ North America/
Australia, and Latin America/ Caribbean. Also, the HS ingredients categories were
merged together and re-coded within four different main categories. Moreover, the
forms of HS categories of drinks, liquids, caplets, granules, lozenges, and gels were
merged and re-coded into one category. Finally, the HS current and past consumption
categories were merged into a re-coded ever used category.
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Question 29, - HS ingredient have you used? - had a large answer list of 60
different ingredient names. This was re-coded in terms of risk assessment module
classification into four main categories of low, medium, high, and extreme ingredients’
overall risk estimation.
The risk assessment process for the presence of some ingredients in HS products
began with hazard identification, the hazards being the ingredients in the supplement
products, as shown in appendix B. Some ingredients can induce certain risks to human
health under certain conditions or at certain doses.
The hazard characterisation based on associated risks in response to
dose/response relationship and the probability of adverse outcomes include short-term
toxicity from reported side effects, long-term toxicity from evidence-based published
sources, interactions of food and/or drugs, contamination with toxicants such as heavy
metals, and pesticide residue. The risk characterisation within the risk assessment
module was calculated as the multiple of the likelihood and severity of the adverse
events related to the ingredient. To calculate the risk score, a risk matrix was adopted.
The risk matrix had four ranges for severity, as shown in appendix C.
The risk score range was low, medium, high and extreme. As many of the
ingredients had several risk factors, either in the impact field or in the probability field,
the risk scoring method field was used as a calculation to obtain an overall impact
value. This value was then used along with the probability to determine the score used
to evaluate project risk. The overall impact value was calculated using average impact.
The overall impact was determined by calculating the average of all impact values.
As per above mentioned method, the associated risk(s) with the ingredient in
terms of short-term toxicity, long-term toxicity, interactions of food/drugs,
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contamination with heavy metals, and pesticide residue are shown in appendix D for
each individual ingredient.
Table 3.7 presents a summary of all the above-mentioned ingredients as
classified, according to the induced risk, into low, medium, high and extreme risks in
which Glandular extract (Hadayer & Schaal, 2016; Gangwar et al., 2015; CPSS, 2015),
yohimbe (NIH, 2016; CPSS, 2015; Wongkrajang et al., 2014) was considered as a
potential for extreme risk.

Table 3.7: Ingredients overall risk estimation
Level of

Ingredient(s)

risk
Low

Bilberry, Methylsulfonyl Methane, Garlic, Oxymatrine, Creatine,
Folic Acid, Vitamin B6, Potassium, Vitamin B12, Vitamin E, Zinc,
Grape Seed Extract, Siberian Ginseng, Lecithin, L-Carnitine,
Morinda Citrifolia, Lycopene

Medium

Alfalfa, Saw Palmetto, Tryptophan, Amino Acids, Iron, Spirulina,
Calcium, Magnesium, Vitamin C, Caffeine, Echinacea, Chondroitin,
Vitamin D, Glucosamine, Cayenne Pepper, Vitamins A & D,
Cimicifuga Racemosa, Parsley, Pygeum Africanum, Ginkgo Biloba,
Panax Ginseng, L-Cysteine, L-Methionine, Lysine, Chromium,
Lutein, Royal Jelly, Bee Pollen, Guarana, Kelp, Fructus Cynosbati,
Ginger, Liquorice, Melatonin

High

Gentian, Ephedra, Selenium, Conjugated Linolenic Acid, St. John’s
Wort, Damiana Folia, Fish Oils

Extreme

Glandular Extract, Yohimbe
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3.2.9 Statistical analysis
Data were exported from the computer application as a Microsoft Excel 2010©
spreadsheet and analyses were conducted using STATA version 14.2. Data were
cleaned prior to analysis. Data were nominal, interval (for age, height, weight, and
BMI) or ordinal. Answers to the following questions were ordinal data: Q11 Income,
Q17 Frequency of visiting a doctor, Q20 Smoking, Q25 Duration of HS use, Q35
Frequency of HS been prescribed by practitioner, Q43 Severity of adverse events, Q44
Frequency of encountering adverse events, Q45 Onset time of adverse events, Q54
Practice of establishing a reporting system. Descriptive statistics were used to describe
the demographic characteristics of the sample using frequencies (percentages) or
means (standard deviation) as appropriate. If differences were found between subgroups of the sample (age, gender, educational status, nationality, etc.), these
differences were tested for statistical significance using chi-square test for categorical
variables and ANOVA for continuous variables. The distribution of the characteristics
of the study population for each of the outcome variables was tabulated. Again, for
characteristics that are categorical variables, frequencies and percentages are shown,
and for characteristics that are continuous variables, means are shown. Chi-square test
or ANOVA was used as appropriate to test for statistical differences. Simple logistic
regression analysis was performed to assess the association between HS use (outcome
variable) and selected correlates (independent variables). The variables having p value
<0.10 were included in a stepwise logistic regression model to identify the independent
factors associated with HS use. The confidence interval of 95% and p value <0.05 were
used to determine statistical significance.
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3.2.10 Data limitations
Bias is the expected difference between an estimated characteristic of a
population and that population’s true characteristic. Bias may occur in any step of the
research. In this research, care was taken to minimise the risk of bias as much as
possible.
Information bias: To collect accurate data from the respondents, researchers
must be able to understand and identify possible errors in the design of the
questionnaire as a research tool. Any errors in the questionnaire design may be
considered as information bias and researchers should be able to prevent or minimise
this kind of bias.
In the current survey, attention was paid to or even ting any errors arising during
the questionnaire preparation stage. Possible biases in the questionnaire were
identified like complex questions, double-barrelled questions, and short questions
which might not be accurately answered in the population-based survey and an
upcoming healthcare professional survey. The questionnaire was limited to the scope
of the research questions. In the e-mail survey, respondents tended to choose the first
few options from the list (primary bias) and in the telephonic survey, respondents were
more likely to answer the later options (recency bias). To minimise this bias, the
number of options was reduced and the order of options randomized.
In the population-based survey, the questionnaire was designed in such a way as
to afford the interviewer an easy means of conducting it while offering respondents an
easy means of responding to questions. The use of technical and complicated clinical
terms was kept to a minimum for ease of understanding.
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To minimise bias, the questionnaire was evaluated by HS experts at Dubai
Municipality. The questionnaire underwent pre-testing and was modified accordingly.
In the population-based survey, stratified sampling was used to minimise the
bias associated with sampling. One of the challenging areas in bias was the use of
landline phone numbers or mobile phone numbers to conduct the survey. Mobile
phones alone were selected for the survey. Many peoplecarry their mobile phones with
them for long periods of time daily, and a mobile number may be used as an individual
identifier. This minimised the bias associated with a landline phone survey where
several people in the same household might use the same number with a resultant
difficulty arising in identifying specific individuals.
Interviewer bias: Interviewer bias was considered a concern in telephonic
surveys. During the survey, an interviewer might communicate with the respondent in
such a way as to obtain a tailored answer. This might lead to unreliable results.
Interviewers should have enough knowledge of the questionnaire to be able to
communicate with respondents clearly and succinctly to obtain a truthful and accurate
answer.
In the telephonic survey for this research, there was a possibility of serious
interviewer bias. As interviewers read the questions to the respondent, answer choices
were offered. In one question, a large list of answer options was offered. The list was
so long that interviewers compromised the question and answer by failing to make all
options clear. This was spotted and rectified during the pilot survey. All interviewers
were further trained in scientific terminologies included within the survey. This
training program improved surveyor skills and minimized the incidence of errors.
Interviewers were selected from employees of DSC. They underwent a smart training
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program to improve their knowledge of the questionnaire and to enhance their survey
skills.
Non-response bias: Non-response bias is the error which may occur due to nonresponse of contacted individuals. If steps are not taken to prevent non-response bias,
the result of the survey may be biased in a way that the opinion of the respondents does
not reflect the actual opinion of the source population.
In the population-based survey, care was taken to minimize non-response bias.
As discussed in the sampling section, six areas were randomly chosen for sampling.
Where there was no response from the respondent, attempts to contact were made over
the three following days. Where respondents were unwilling to participate or nonresponsive, another random sample was chosen to continue the survey.
To reduce the non-response rate, it was assumed that unemployed people, as
shown in DSC directory based on employment status, might be more availablefrom 11
AM to 1 PM, and, similarly, employed people might also be more available from 3
PM to 6 PM. Contact was therefore arranged accordingly for the telephonic survey.
3.2.11 Ethical approval and safeguarding participants
The consent and information details were given to respondents prior to starting
the survey.
3.2.11.1 Informed consent
Informed consent, for the purposes of this study, included a participant computer
generated dedicated identification number. Informed consent also included the title of
the project and the main researcher’s name. It also explained that the study would take
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place at the United Arab Emirates University, College of Medicine & Health Sciences,
School of Public Health, Al-Ain, UAE, and that participation in the study would take
up to 30 minutes: five minutes for set-up/explanation, around 20 minutes for the
questionnaire itself, and five minutes for a discussion with the researcher afterwards.
In addition, it included the following: an easily understood information sheet dated 5th
March 2015 and designed in such a manner as to allow participants to ask questions
of the interviewer, an explanation that participation in the survey was voluntary and
that participants were free to withdraw at any stage, confirmation that information and
opinions provided during the survey would be kept strictly confidential and used only
for research purposes, confirmation that names and details would not be linked to this
survey and would not be identified in any report/publication, and consent to agree to
take part in the study.
This information was provided to the participant verbally, by phone. Participant
decision to continue with the survey was deemed consent.
3.2.11.2 Information for participants
The nature and purpose of the survey, as shown in appendix E, were fully
explained to participants verbally, by phone. Prospective respondents were cordially
invited to take part in the research study. The purpose of the study was
comprehensively explained to them. Prospective respondents were given ample time
to consider the invitation. A confidentiality code was assigned to each prospective
respondent.
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3.2.11.3 Ethics review
A Research Ethics Review Form, available at UAE University website, was
completed and submitted to Al Ain Medical District Social Sciences Research Ethics
Committee at UAE University. Approval to conduct the study was received in June
2015.

3.3 Second study: Knowledge, Attitude and Practice of Health Supplements
Related Adverse Event Among Healthcare Professionals
3.3.1 Study design
A cross-sectional study design was also used in the second study to assess
knowledge, attitude and practice (KAP) regarding HS products among healthcare
professionals including physicians, pharmacists in hospitals and clinics, both public
and private, and community pharmacies. To be included in the study, healthcare
professionals had to be employed as such for at least three months. A questionnaire
was devised for this survey using the same principles adopted in the questionnaire for
the population-based study, as shown in Figure 3.1.
3.3.2 Study setting
The survey was carried out in public or private hospitals and pharmacies in
Dubai.
3.3.3 Study participants/population
The study population comprised all physicians in all specialties and all
pharmacists and assistant pharmacists registered with DHA, with a minimum of three
months’ experience and who worked in public orprivate hospitals, clinics or healthcare

76
centres. The inclusion criteria included individuals who were employed in DHA or
any other governmental or private health sector who had registration with DHA.
Individuals who worked in other free zone health sectors and not registered with DHA
were excluded from the study. Additionally, any individual on work probation was
excluded.
3.3.4 Sampling
DHA provided the e-mail contact details for all registered physicians and
pharmacists working at DHA. Data were collected during the period 2 May 2016 to 23
November 2016. Dubai Municipality additionally provided e-mail contact details for
all private pharmacies in Dubai (CPSS, 2015) as well as e-mail contact details for
managers at private hospitals and clinics in Dubai. Data for these sectors were
collected from 3 May 2016 to 23 November 2016.
3.3.5 Sample size
The latest published numbers of physicians working in public hospitals and
clinics in Dubai was 1,096 (DSC, 2012) and the latest published numbers of physicians
working inprivate hospitals and clinics in Dubai was 1,288 (DSC, 2012). The number
of registered pharmacists in Dubai was 3,155 (DHA, 2014) yielding a total of N=
5,539. All physicians and pharmacists registered with DHA were contacted for this
survey. To calculate a sample size for this survey, a pilot study was used. A
questionnaire was sent to 85 physicians and pharmacists and 83 replied, producing a
response rate of 97%. The questions on which the sample size calculation was based
were:
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1. Do you know about adverse events of HS?
2. Do you sell/prescribe/dispense any HS at practice site?
3. Do you think it is important to report all adverse events of HS products?
The knowledge of physicians regarding HS products was recorded as 15%
according to Clement et al. (2005) and 70% according to Kemper et al. (2006).
According to the Dubai pilot study, the levels of knowledge, attitude, and practice
(KAP) for healthcare providers towards HS products were 78%, 78%, and 74%. The
alpha=0.05 and, as per the results of the pilot study, the level of KAP was estimated
as 50%. It was expected that the proportions of respondents answering yes to the above
questions 1, 2 and 3 would be around 50%, 50% and 50%. The alpha level is set to 5%
and has a 95% confidence interval. The precision (D) of the 95% CI is fixed at 5% so
that the width of the 95% CI will be at maximum 10%. According to the assumptions
and with 5,000 physicians and pharmacists registered with DHA, a sample size of
n=385 was needed to guarantee the desired precision, assuming a non-response rate of
around 3%.
3.3.6 Survey tool
In terms of questionnaire development, this survey underwent a similar process
as the previous survey. It included the phases of literature/expert review, producing eform questionnaire, e-form questionnaire review, and changes in the questionnaire.
Upon receipt of feedback and comments, DSC made the necessary amendments and
activated the survey link on 23 July 2015. The translation process was similar to that
used in the first survey.
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3.3.6.1 Pilot testing
This pilot study was started on 27 July 2015 in two private hospitals. This was
because of a delay in receiving approval to conduct the survey in public healthcare
settings. By 4 August 2015, 83 respondents had completed the questionnaire
satisfactorily and no problems had been reported. The results of this pilot study were
used to calculate the required sample size for the second survey.
3.3.6.2 Questionnaire administration
This survey was designed to be self-completed by respondents through a webbased electronic link sent to respondents’e-mails addresses.
Ensuring and checking data quality: In this e-mail-based survey, the
questionnaire was designed to be particularly user-friendly and easily understood. The
format was compatible for computer, tablet and mobile phone use.
3.3.7 The questionnaire
The following sections present a summary of the survey tool, its different
sections, variables, questions, related scales and coding.
3.3.7.1 Questionnaire sections: summary
A questionnaire composed of four sections was developed to assess healthcare
professionals’ KAP of HS products, related adverse events and other required
variables. This survey was performed electronically by an on-line link sent by e-mail.
The first section, as shown in Table 3.8, asked about demographic information
(age, gender, marital status, nationality, employment status, title, years of job
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experience, insurance coverage and education). All data were nominal except for age,
which was interval. Work experience was presented as ordinal scale. All data were
used to measure demographic characteristics.
In the second section, as shown in Table 3.9, a set of questions was developed
to measure the level of knowledge of HS products and adverse events. Questions
highlighted the following aspects: HS product general information and whether they
were harmless or not, whether reporting systems existed, whether there were reporting
systems in their workplace, whether respondents knew to whom to report an adverse
event, and information on continuous education (articles, training, etc.) related to
adverse events of HS products. All data in this section were nominal. The data
collected in this section were used to measure the knowledge variable.
Table 3.8: Healthcare professionals’ demographic data, scales & variables
Question

Scale

Age

Interval

Gender

Nominal

Marital status

Nominal

Nationality

Nominal

Employment status

Nominal

Title

Nominal

Work experience

Ordinal

Insurance coverage

Nominal

Education

Nominal

Variables measured

Demographic - characteristics

The third section, Practice, as shown in Table 3.10, included the following: types
and forms of HS prescribed and/or dispensed, a system to record HS use, discussing
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HS use with patients/customers and information sources for these discussions, adverse
events encountered in relation to HS consumption, their types and how they are dealt
with. All data were nominal except for frequent HS discussion with patients, frequent
encountering HS related adverse events and frequent recording HS adverse events,
which were presented as ordinal scale. The data collected in this section were used to
measure the practice variable.
Table 3.9: Healthcare professionals’ knowledge scales & variables
Question

Scale

Variables
measured

Do you know what HS are?

Nominal

List as many HS as you can.

Nominal

Do you agree with the statement that HS are

Nominal

harmless?
Do you know about adverse events of HS?

Nominal

List as many adverse events of HS as you can.

Nominal

Do you know what surveillance system is?

Nominal

Do you know about any existing surveillance

Nominal
Knowledge

system in the UAE?
Do you know about any adverse event reporting

Nominal

system in your organization?
Do you know to whom you can report adverse

Nominal

event?
Have you received continuing education on HS?

Nominal

Have you read a scientific article related to

Nominal

adverse events of HS in the last 6 months?
Have you ever received training on reporting
adverse event?

Nominal
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Table 3.10: Healthcare professionals’ practice scales & variables
Question

Scale

Variables
measured

Do you sell/prescribe/dispense any HS at practice site?

Nominal

Which type of HS do you usually prescribe/ dispense?

Nominal

Which form of HS do you usually prescribe/ dispense?

Nominal

Do you have a system to record HS use?

Nominal

How often discussing HS use with patients?

Ordinal

Topic of discussion about HS use with patients?

Nominal

Which of HS information sources are helpful for patients?

Nominal

Barriers limiting discussing HS with patients?

Nominal

Ever experienced HS related AE in patients?

Nominal

How frequently encountered AE related to HS use?

Ordinal

What was the AE?

Nominal

How often have you recorded HS AE?

Ordinal

Which authority/personnel you report HS AE?

Nominal

Is AE reporting form available when you are at the job of

Nominal

prescribing/dispensing medicines to the patients?

Practice
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In the last section, Attitude, as shown in Table 3.11, questions relate to the
reporting of adverse events related to HS. These included reasons for not reporting an
adverse event and the importance of reporting such events. For some questions,
participants selected their answers from a five-point ordered scale. All data were
ordinal except for reason of reporting/not reporting adverse events and the importance
of reporting, which were nominal. Data collected in this section were used to measure
the attitude variable.
Table 3.11: Healthcare professionals’ attitude scales & variables
Question

Scale

Variables
measured

You report HS related adverse events to the higher

Ordinal

authority/personnel.
What is the reason if you don’t/wouldn’t report an

Nominal

adverse event?
Do you think it is important to report all adverse events

Nominal

of HS?
What do you think about the establishment of a

Ordinal

surveillance system of adverse events related to HS
consumption?
Are you concerned about legal problems of reporting

Ordinal

an adverse event?
Do /would you feel confident when reporting an
adverse event?

Ordinal

Attitude
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3.3.7.2 Variables
In this survey, the dependent variables were: healthcare professionals’
knowledge of HS adverse events, attitude to HS adverse events, practice related to HS
adverse events, and reporting level of adverse events. The independent variables or
correlates included: age, gender, marital status, nationality, employment status, job
category, work experience, insurance coverage, and educational level.
3.3.8 Statistical analysis
In this study two approaches (descriptive and analytical) were used for data
analysis.
Descriptive approach: first of all, the frequencies and percentages for all
questions (variables) in the study questionnaire were determined. We reported the
percentage of each demographic characteristics, the frequency and the percentage of
each question related to healthcare professional’s knowledge of HS and the frequency
and the percentage of each question related to HS adverse events reported by
respondents. We also reported the frequency and the percentage of each question
related to healthcare professionals’ practice with respect to selling, prescribing or
dispensing HS, and types of HS and dosage, record keeping and discussions with
patients/consumers. The frequency and the percentage of each question related to
respondents’ experience of HS adverse events was reported. The second part in
statistical analysis plan illustrates the assessment of the knowledge, attitude and
practice (KAP) of healthcare providers towards HS. In this regard two measures were
calculated: The overall knowledge, attitude and practice score: (knowledge, attitude
and practice (KAP) score toward HS related adverse event were assessed by 10-item
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questions. A scoring mechanism was used to understand overall KAP level. Each
correct answer was given one score, and the range of the score varied between 0 (with
no correct answer) to 10 (for all correct answers). Respondents with all correct
response get a maximum of 10 points; higher points indicate good knowledge. Based
on total score, a score of 70% and above was judged to be good, 50%-69% fair and
<50% poor.
Analytical approach: this part of statistical analysis was designed to determine
the differences in participants’ responses in term of demographic. Before running the
comparisons, the normality of our dependent variable (KAP score) among the groups
of independent variables were tested by visual inspection of their histogram, Q-Q plot
and box plot. The results showed that the data were approximately normally
distributed. In total three tests were used to find the associations between KAP scores
and selected socio-demographic factors (independent t-test, ANOVA and Pearson
correlation).
The independent t-test used when we have one continuous (scale) dependent
variable (mean KAP score) and one categorical independent variable with two level
(gender, nationality, marital status, employment status, work experience and
education). The one way ANOVA used when we have one continuous (scale)
dependent variable (mean KAP score) and one categorical independent variable with
more than two level (occupation). Pearson correlation used when we have one
independent variable (mean KAP score) and one independent variable (age). Here both
variables are continuous variable.
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3.3.9 Data limitations
In the healthcare professional survey, sampling was done from the total number
of pharmacists and physicians registered with Dubai Health Authority (DHA), the
local health governing body in Dubai. All pharmacists and physicians working at DHA
received an e-mail with a link to a web-based questionnaire from the Head of the
Human Resources Department at DHA inviting them to participate in the survey.
Pharmacists and physicians working in the private sector in Dubai received the
questionnaire link from their management identified through Dubai Municipality
database details of private healthcare providers. This minimised the selection bias
related to low response in the healthcare professional survey. There was no incidence
of interviewer bias as the survey was completed directly by the respondent without the
supervision or help of an interviewer. There was, however, the possibility of a high
non-response rate. The tailored design method involving multiple communication with
respondents to amplify the response rate was utilised in this research. Reminder emails were sent to non-respondents every two weeks from the start of the survey. This
reduced the non-response rate.
3.3.10 Ethical approval and safeguarding participants
Every physician and pharmacist registered with DHA was contacted by e-mail
by the Head of the Human Resource Department at DHA inviting them to participate
in the survey. Healthcare professionals in the private sector were contacted through
their managers. The e-mail contained a link to the web-based questionnaire (see
Appendix F).
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3.3.10.1 Informed consent
The nature and purpose of the study were explained within the first page of the
survey and if participants continued to the following page this was taken as their
consent to participate in the study.
Around 14 communication e-mails with DHA were made to circulate the survey
to government healthcare professionals. The first e-mail was dated 2 May 2016, and
the last follow-up reminder e-mail was dated 23 November 2016. DHA circulated the
survey link to all government hospitals and medical centres in the Emirate of Dubai
by e-mail on 2 May 2016. The on-line survey took a long time to reach completion
due to the onerous workloads of the healthcare professionals.
Healthcare professionals in the private sector received the survey link by e-mail
from their management sourced from Dubai Municipality database. Contact numbers
were issued. Reminder e-mails were sent every month from the start of survey on 3
May 2016 until 23 November 2016. At the end of the survey, a message of thanks was
issued to all respondents. No incentives were offered for completing the survey.
Around 15 e-mails were issued to private sector managers, then circulated to
pharmacies, clinics and hospitals. The first e-mail was sent on 3 May 2016 and the last
follow-up was on 23 November 2016.
A total of 500 pharmacies registered in Dubai Municipality database received a
survey link sent by the official e-mail of consumer products safety section at Dubai
Municipality. The first e-mail was sent on 4 May 2016 and a reminder e-mail was sent
on 23 June 2016.
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3.3.10.2 Information for participants
Informed consent contained a dedicated participant identification number. It also
included the title of the project, Survey of Healthcare Professionals’ Knowledge,
Attitude and Practice of Health Supplement Products Related Adverse Events, and the
main researcher’s name, all as shown in appendix G. It was explained that the study
would take place at United Arab Emirates University, College of Medicine & Health
Sciences, School of Public Health located in Al-Ain, UAE and that participation in
this study would take 15 minutes. In addition, it contained an explanatory information
sheet dated 5 March 2015. Participation was voluntary and participants were free to
withdraw at any stage. Information provided was strictly confidential. Names and
details would not be linked to this survey and would not be identified in any
report/publication. It also contained a statement of participant’s agreement to take part
in the study.
This information was delivered to participants on the first page of the on-line
questionnaire. Continuing the survey was deemed agreement to participate and acted
as signature of the consent form.
3.3.10.3 Ethics review
Approval to conduct this study was received in June 2015 from the University
Student Research Committee at DHA.

3.4 Summary
This chapter discussed the main two surveys used to achieve the objectives of
this research. All related sampling and sample size were discussed. Statistical analysis
was used to measure dependent variables in the population-based survey including
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consumption rate, consumers’ knowledge on HS, level of experience of adverse events
and to measure the dependent variables of healthcare professional knowledge, attitude,
and practice of HS adverse events, and reporting level of adverse events.
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Chapter 4: Results
The following section describes the demographic information of the two surveys
and display the main results.

4.1 Results of Survey of Health Supplements Consumption in Dubai
Population
4.1.1 Participants’ demographic characteristics
The demographic information of participants is shown in Table 4.1. A total
number of 1,203 participated in the survey. The average age of respondents was 39.2
± 9.1 SD. The participants were predominantly male (n=1002, or 83.3%). Most of the
participants were married (n=1039, or 86.4%). South Asians (n=579, or 48.1%)
constituted the largest ethnic group in the study, followed by Middle East/ North Africa
(n=301, or 25.0%), UAE (n=142, or 11.8%), Western Europe/ North America/
Australia (n=94, or 7.8%), East Asia/ Pacific (n=41, or 3.4%), Africa (n=32, or 2.7%),
Central Asia/ Europe (n=12, or 1.0%), and Latin America/ Caribbean (n=2, or 0.2%).
Most of the respondents in the survey were employed (n=1123, or 93.3%) and 41.5%
(n=499) had an income in the range of 5,000-<10,000AED, 319 participants (26.5%)
earned between10,000-20,000AED, 221 participants (18.4%) had an income higher
than 20,000 AED. 164 participants (13.6%) earned less than 5,000 AED.
Educational qualifications of the participants also varied. Nearly half of the
participants (48.7%, 586) held graduation certificates, 269 were post graduates
(22.4%), 139 were high school education holders (11.5%), 76 non-high school
education holders (6.3%), 68 diploma holders (5.7%), 46 higher diploma holders
(3.8%), and 19 PhD holders (1.6%). Most participants had health insurance coverage
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(n= 1028, or 85.5%). Average height was 171.3 centimetres ±8.9 SD. Average weight
was 78.7 kg ±15.3 SD. Average body mass index was 26.8 kg/m2 ±4.4 SD. There were
546 (45.4%) overweight respondents (25-29.9 kg/m2), 431 (35.8%) of normal weight
(<25 kg/m2) and 226 (18.8%) were obese (≥30 kg/m2). 862 participants (71.7%) were
non-smokers, 183 were current regular smokers (15.2%), 108 were current occasional
smokers (8.9%) and 50 were past smokers (4.2%).
Of the total participants, 115 (9.6%) had an allergy, mainly to aerosols or
perfume. Allergy to drugs accounted for 21 participants (1.7%). Allergy to dust
accounted for 22 participants (1.8%). 106 had diseases (8.8%), mainly diabetes
mellitus (n= 69, or 5.7%) and hypercholesterolemia (n= 31, or 2.6%).
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Table 4.1: Characteristics of population based survey participants (N=1203)
Variables
Age – years
Gender

Marital Status

Nationality

Occupation

Income (AED)

Education

categories
Male
Female
Married
Single
Divorced
Widow
Emirati
Middle East/North Africa
South Asia
East Asia/Pacific
Central Asia/Europe
Africa
Latin America/Caribbean
Western Europe/North America/Australia
Employed
Unemployed
Student
Retired
<5000
5000-<10000
1000020000
>20000
< High school
High school
Diploma
Higher Diploma
Bachelor
Master
PhD

Health insurance coverage
Height – cm
Weight – kg
Body Mass Index – kg/m2
Normal (<25)
Body Mass Index – cat kg/m2
Overweight (25-29.9)
Obese (≥30)
Non-smoker
Past smoker
Smoking status
Current occasional
Current regular
Any allergy
Drug allergy
Aerosol & perfume allergy
Contact allergy
Dust allergy
Others
Diabetes Mellitus
High cholesterol levels
Diseases
Cardiovascular disease
Cancer

n/Avg
39.2
1002
201
1039
150
9
5
142
301
579
41
12
32
2
94
1123
60
9
11
164
499
319
221
76
139
68
46
586
269
19
1028
171.3
78.7
26.8
431
546
226
862
50
108
183
115
21
23
7
22
26
69
31
5
1

%/SD
±9.1
83.3
16.7
86.4
12.5
0.7
0.4
11.8
25.0
48.1
3.4
1.0
2.7
0.2
7.8
93.3
5.0
0.7
0.9
13.6
41.5
26.5
18.4
6.3
11.5
5.7
3.8
48.7
22.4
1.6
85.5
±8.9
±15.3
±4.4
35.8
45.4
18.8
71.7
4.2
8.9
15.2
9.6
1.7
1.9
0.6
1.8
2.2
5.7
2.6
0.4
0.1
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4.1.2 Use of health supplements among the participants in Dubai population
The use of the HS among participants varied, as shown in Table 4.2. Around 748
(62.2%) participants had never used HS and 455 (37.8%) participants had used HS at
least once. Among these 455 participants, 377 were currently using and 138 had
consumed HS in the past.
The purpose of HS consumption among the 455 participants who had a history
of HS usage was as follows: 301 (66.1%) used HS to improve health, 45 (9.9%) male
participants used HS for body building, 11 (2.4%) female participants used HS during
pregnancy, 31 (6.8%) used HS to prevent diseases, 27 (5.9%) used HS for diet
supplementation, 24 (5.3%) used HS for maintaining weight, 18 (4.0%) used HS for
energy boosting and the rest of the participants for other reasons.
The duration of HS usage among the 455 known HS consumers was as follows:
189 (41.5%) used HS for a month, 165 (36.3%) consumed HS anywhere between one
to five years, 52 (11.4%) used HS for less than a month, and 45 (9.9%) used HS for
more than five years. A breakdown of duration of usage among past and current users
was also available. Duration of HS use among the current users varied as follows: 118
(37.2%) used HS for a month, 136 (42.9%) used HS between one to five years, 21
(6.6%) used HS for less than a month, and 40 (12.2%) used HS for more than five
years. Among the past users, 71 (51.5%) used HS for a month, 29 (21.0%) used HS
for one to five years, 31 (22.5%) used HS for less than a month, and five (3.6%) used
HS for more than five years.
Of the 455 participants, 288 (63.3%) were daily users, 116 (25.5%) used HS for
one to four times in a week, 22 (4.8%) used HS for one to three times in a month, and
17 (3.7%) consumed seasonally. The number of HS used by the 455 participants
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differed. While 388 (85.3%) participants used one to two types of HS, 59 (13.0%) used
three to five types, six (1.3%) participants used six to 10 types, and two participants
(0.4%) had a history of using more than 10 types of HS.
The reasons for discontinuing HS use were mainly allergy, skin disease, and cost.
Participants who used HS (n=455) mainly purchased them from pharmacies (88.3%).
The remaining purchase sources were from clinics (9.9%) and nutrition shops (6.7%).
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Table 4.2: Use of health supplement among population of Dubai (N=1203)
Variables
HS use
Ever used (Including current and past users)
Current
Past
Never
Reasons for using HS
To improve health
Body building (Male only)
Diseases prevention
Diet supplementation
Weight management
Energy
Pregnancy (Female only)
Immunity booster
To prevent cold
Ageing
Anaemia
High blood pressure
High cholesterol
Digestive
Other
Reasons for discontinuing HS
Allergy
Skin disease
Cost
Duration of HS use, overall
Less than a month
Month
1-5 years
More than 5 years
Do not know
Duration of HS use, Current users
Less than a month
Month
1-5 years
More than 5 years
Do not know
Duration of HS use, Past users
Less than a month
Month
1-5 years
More than 5 years
Do not know
Frequency of HS use
Seasonally
<1 a month
1-3 times a month

N
1203

n (%)
455 (37.8)
317 (26.3)
138 (11.5)
748 (62.2)

455
301 (66.1)
45 (9.9)
31 (6.8)
27 (5.9)
24 (5.3)
18 (4.0)
11 (2.4)
8 (1.8)
8 (1.8)
5 (1.1)
4 (0.9)
3 (0.7)
5 (1.1)
6 (1.3)
8 (1.7)
4 (0.3)
4 (0.3)
3 (0.2)
455
52 (11.4)
189 (41.5)
165 (36.3)
45 (9.9)
4 (0.9)
317
21 (6.6)
118 (37.2)
136 (42.9)
40 (12.2)
2 (0.6)
31 (22.5)
71 (51.5)
29 (21.0)
5 (3.6)
2 (1.5)
454
17 (3.7)
9 (2.0)
22 (4.8)
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Table 4.2: Use of health supplement among population of Dubai (N=1203)
(Continued)
Variables
1-4 times a week
Daily
Number of HS use
1-2 supplements
3-5 supplements
6-10 supplements
>10 supplements
Purchasing of HS
Pharmacy
Clinic
Nutrition shop
Gym
Super market
Other

N

n (%)
116 (25.5)
288 (63.3)

455
388 (85.3)
59 (13.0)
6 (1.3)
2 (0.4)
455
402 (88.3)
45 (9.9)
29 (6.7)
12 (2.6)
5 (1.1)
9 (2.0)

4.1.3 Knowledge of consumers on health supplements
The knowledge or source of information about HS among consumers of HS in
Dubai is shown in Table 4.3. Among the 455 participants who had ever used HS, 212
(46.6%) were prescribed HS, 204 (44.8%) were self-advised HS, 49 (10.8%) were
advised by healthcare professionals, 35 (7.7%) advised by friends and/or relatives, 30
(6.6%) advised from the internet, and 10 (2.2%) from other sources, like
advertisements.
The participants sought information about HS from various sources. Of the 455
participants who had ever used HS, 274 (60.2%) found out information about HS from
pharmacies, 145 (31.9%) from the internet, 129 (28.3%) from physicians, 39 (8.6%)
from a relative and/or friend, four (0.9%) from other sources and none of them from
government centres. Most participants, 355 (78.0%) who had ever used HS, responded
in the survey that the labelling information of the HS was very informative, 68 (14.9%)
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responded somewhat informative and 28 (6.1%) responded that they did not read the
label. Very few responded that it was not informative (0.9%).
Most of the participants were concerned about the labelling information of HS.
They checked the labelling information before use. From the labelling information,
they were more concerned about of the ingredients, durability, adverse events,
indications, precautions and dosing information. Nutrition information on the label
was useful for most participants (94.7%). Of the 455 participants who had ever used
HS, 334 (73.4%) always and 64 (14.1%) often followed recommended labelling
information.
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Table 4.3: Knowledge/sources of information about health supplement (N=455)
Variables
Who advised to take HS
Self
Friend/Relative
Advertisement
Internet
Prescribed
Health professional
Other
From where do you seek HS information
Pharmacy
Physician
Product helpline
Internet
Relative/Friend
Government centre
Other
Sufficient information on the label
Do not read the label
Not informative
Somewhat informative
Very informative
Type of label information of HS concerns
Ingredients of supplement
Indications of supplement
Dosage of supplement
Adverse events of supplement
Durability of supplement
Dietary sources of supplement
Claims of supplement
Precautions of supplement
Dosing instructions of supplement
No information concerns
Nutrition information on the label is useful
Do you follow recommended label information?
Never
Sometimes
Often
Always

N
455

n (%)
204 (44.8)
35 (7.7)
5 (1.1)
30 (6.6)
212 (46.6)
49 (10.8)
5 (1.1)

455
274 (60.2)
129 (28.3)
10 (2.2)
145 (31.9)
39 (8.6)
0 (0.0)
4 (0.9)
455
28 (6.1)
4 (0.9)
68 (14.9)
355 (78.0)
375 (82.4)
245 (53.9)
237 (52.1)
291 (64.0)
312 (68.6)
226 (49.8)
199 (43.7)
233 (51.2)
227 (49.9)
41 (9.1)
431 (94.7)
455
22 (4.8)
35 (7.7)
64 (14.1)
334 (73.4)
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4.1.4 Forms and ingredients of health supplements
Forms and ingredients of HS used by the participants are shown in Table 4.4.
Vitamins were the most commonly used HS among the participants (87.9%). Both
minerals and sport nutrition were consumed by 48 participants each (10.5%). Herbal
products and dietetic foods were used by nine participants each (2.0%). Five
participants (1.1%) used energy drinks and 12 (2.6%) used miscellaneous types. The
most widely used dosage form was tablet, at 85.5%. Capsules were taken by 53
participants (11.7%). HS in powder form was used by 46 participants (10.1%) and 16
participants (3.5%) used drinks/ liquids/ caplets/ granules/ gels etc.
Ingredients of HS used by the participants in the survey were as follows: 195
(42.9%) vitamin D, 104 (22.9%) vitamin E, 104 (22.9%) vitamin A & D, 58 (12.7%)
calcium & vitamins, 56 (12.3%) vitamin B12, 52 (11.4%) vitamin C, 45 (9.9%)
vitamin B6, 27 (5.9%)amino acids, 32 (7.0%) fish oil, 24 (5.3%) calcium &
magnesium, 20 (4.4%) vitamin E multi component, 14 (3.1%) zinc.14 (3.1%) were
unaware of ingredients. The remainder responded with miscellaneous ingredients.
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Table 4.4: Forms and ingredients of health supplement (N=455)
Variables
Categories of HS
Vitamins
Minerals
Herbal products
Sports nutrition
Energy drinks
Dietetic food
Miscellaneous
Forms of HS
Tablets
Capsules
Powder
Drinks/Liquids/Caplets/Granules/Lozenges/Gels
Ingredients of HS
Vitamin D
Vitamin E
Vitamin A & D
Calcium & Vitamins
Vitamin B12
Calcium
Vitamin C with/without rose
Vitamin B6
Fish oil
Amino acids
Calcium & Magnesium
Vitamin E multicomponent
Zinc/zinc gluconate
Magnesium
Folate/Folic acid
Potassium
Carnitine
Alfalfa
Chondroitin
Creatinine
Other
Do not know about ingredient

N
455

n (%)
400 (87.9)
48 (10.5)
9 (2.0)
48 (10.5)
5 (1.1)
9 (2.0)
12 (2.6)

455
389 (85.5)
53 (11.7)
46 (10.1)
16 (3.5)
455
195 (42.9)
104 (22.9)
104 (22.9)
58 (12.7)
56 (12.3)
52 (11.4)
48 (10.5)
45 (9.9)
32 (7.0)
27 (5.9)
24 (5.3)
20 (4.4)
14 (3.1)
7 (1.5)
6 (1.3)
6 (1.3)
5 (1.1)
1 (0.2)
2 (0.4)
7 (1.5)
14 (3.1)
14 (3.1)
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4.1.5 Adverse events of health supplements
Adverse events of HS are as shown in Table 4.5. Of the 455 participants who
had ever used HS, 442 (97.1%) had experienced no adverse events from HS use. 13
participants (2.9%) had experienced adverse events from HS use. Of these 13
participants, six graded their experience of adverse events as mild (46.1%), five
(38.5%) graded their experience of adverse events as moderate, while two (15.4%)
graded their experience of adverse events as severe. Additionally, of these 13
participants, two (15.4%) had frequent adverse events, nine (69.2%) experienced
adverse events only once and for two (15.4%) adverse events occurred occasionally.
Among these 13 participants, two (15.4%) self-confirmed a co-relation of HS
with an adverse event and one (7.7%) confirmed the co-relation by physician. Of these
13 participants, four (30.8%) suspected or confirmed that vitamins had caused the
adverse event while one (7.7%) suspected or confirmed slimming tea as the cause. For
most of the participants (76.9%), the adverse event resolved after discontinuing
supplement intake. Two participants (15.4%) discontinued intake ofthe supplement on
medical advice and for one participant (7.7%) intake was discontinued after treatment.
Of these 13 participants, only a few reported the adverse events and only to their
physician (23.1%). Regarding the establishment of an adverse event reporting system
for HS, 550 (45.7%) participants responded as unsure about any benefit deriving there
from, 464 (38.6%) responded as definitely beneficial and 163 (13.5%) responded as
somewhat beneficial. These results show that most participants expressed that the
establishment of an adverse event reporting system for HS would be beneficial.
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Table 4.5:Adverse events of health supplements (N=455)
Variables
Adverse events from HS
Type of AE
Abdominal pain
Dermatitis
Diarrhoea
Constipation
Urticaria
Other
Severity of AE from HS
Mild
Moderate
Severe
Frequency of AE from HS
Once
Occasionally
Frequently
Onset time of AE
< 1 hour
1 hour – 1 day
> 1 day
Relation between HS use and AE confirmed
Self
Physician
Lab
Clinic
HS suspected/confirmed to cause AE
Vitamins
Slimming tea
How did the AE resolve?
Self-discontinuing the supplement
Discontinuing the supplement after medical advise
Treatment
Ever reported AE
Where did you report AE
Physician
Benefits of establishing AE reporting system
Definitely not beneficial
Not beneficial
Unsure
Somewhat beneficial
Definitely beneficial

N
455
13

n (%)
13 (2.9)
1 (7.7)
2 (15.4)
2 (15.4)
2 (15.4)
3 (23.1)
3 (23.1)

13
6 (46.1)
5 (38.5)
2 (15.4)
13
9 (69.2)
2 (15.4)
2 (15.4)
13
5 (38.5)
3 (23.1)
6 (46.1)
13
2 (15.4)
1 (7.7)
0 (0.0)
0 (0.0)
13
4 (30.8)
1 (7.7)

13
3

10 (76.9)
2 (15.4)
1 (7.7)
3 (23.1)
3 (100.0)

1203
15 (1.3)
11 (0.9)
550 (45.7)
163 (13.5)
464 (38.6)
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4.1.6 Factors associated with health supplement use
Table 4.6 shows the bivariate analysis in which HS use dependent variable is
tabulated against independent variables. The mean age of the participants who used
HS was 38.9 ± 9.0 SD. There was no effect of age on HS use (P=0.307). There was an
effect shown of gender on HS use (P<0.001). Females were more likely to be HS users
(133 users among 201 respondents, 66.2%) compared to males (322 users out of 1002
respondents, 32.1%). There was no effect of marital status on HS use (P=0.051). Single
and divorced/widowed respondents were more likely to report HS use. There was an
effect seen of nationality on HS use (P<0.001). Persons of Latin America/ Caribbean/
Western Europe/ North America/ Australia origin were more likely to be users.
Persons of South Asian origin were less likely to report use. There was an effect seen
of employment status on HS use (P=0.003). There was an effect seen of income on HS
use (P<0.001). Those with incomes over 10,000 AED per month were more likely to
be users compared to those on lower salaries.
Educational attainment was also significantly associated with HS use (P<0.001).
Those educated to higher diploma level and above were more likely to report HS use
compared to those of lower educational attainment. Health insurance was significantly
associated with HS use (P=0.017). Those with health insurance were more likely to
report HS use. Those with an allergy were also more likely to report HS use (P=0.008).
Similarly, those who had visited a doctor and those taking medicines were more likely
to report HS use. However, body mass index, smoking, and self-reports of medical
conditions were not associated with HS use.
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Table 4.6: Factors associated with health supplement use
Variables

Age – years
Gender
Male
Female
Marital Status
Married
Single
Divorced/Widow
Nationality
Emirati
Middle East/ North Africa
South Asia
East Asia/ Pacific/ Central Asia/
Europe
Africa
Latin America/ Caribbean/ Western
Europe/ North America/ Australia
Occupation
Employed
Unemployed
Student/Retired
Income
<5000 AED
5000-<10000 AED
10000-20000 AED
>20000 AED
Education
< High school
High school
Diploma
Higher Diploma
Bachelor
Master/ PhD
Health insurance coverage
Body Mass Index – kg/m2
Body Mass Index – cat
Normal (<25 kg/m2)
Overweight (25-29.9 kg/m2)
Obese (≥30 kg/m2)

All
N

Non-users
(N=748) n
(%)
39.4±9.1

P
Value

1203

Users
(N=455) n
(%)
38.9±9.0

1002
201

322 (32.1)
133 (66.2)

680 (66.9)
68 (33.8)

<0.001

1039
150
14

379 (36.5)
69 (46.0)
7 (50.0)

660 (63.5)
81 (54.0)
7 (50.0)

0.051

142
301
579
53

68 (47.9)
144 (47.9)
141 (24.4)
28 (52.8)

74 (52.1)
157 (52.1)
438 (75.6)
25 (47.2)

<0.001

32
96

14 (43.7)
60 (62.5)

18 (56.3)
36 (37.5)

1123
60
20

413 (36.8)
35 (58.3)
7 (35.0)

710 (63.2)
25 (41.7)
13 (65.0)

0.003

164
499
319
221

33 (20.1)
149 (29.9)
153 (48.0)
120 (54.3)

131 (79.9)
350 (70.1)
166 (52.0)
101 (45.7)

<0.001

76
139
68
46
586
288
1028
1203

13 (17.1)
39 (28.1)
18 (26.5)
22 (47.8)
245 (41.8)
118 (41.0)
403 (39.2)
26.9±4.5

63 (82.9)
100 (71.9)
50 (73.5)
24 (52.2)
341 (58.2)
170 (59.0)
625 (60.8)
26.7±4.3

<0.001

431
546
226

165 (38.3)
198 (36.3)
92 (40.7)

266 (61.7)
348 (63.7)
134 (59.3)

0.496

0.307

0.017
0.348
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Table 4.6: Factors associated with health supplement use (Continued)
Variables

Smoking status
Non-smoker
Past smoker
Current occasional smoker
Current regular smoker
Any allergy
Drug allergy
Aerosol & perfume allergy
Contact allergy
Dust allergy
Others
Visited a doctor in last 12
months
Did not visit doctor in last 12
months
Less than monthly
1-3 times a month/At least once a
week
Diseases
Diabetes Mellitus
High cholesterol levels
Cardiovascular disease
Medicines
Analgesic
Anti-biotic
Anti-diabetic
Anti-hypertensive
Cholesterol lowering
Vitamins
Anti-allergic
Other

All
N

Users
(N=455) n
(%)

Nonusers
(N=748) n
(%)

P
Value

862
50
108
183
115
20
20
7
23
14

326 (37.8)
27 (54.0)
34 (31.5)
68 (37.2)
57 (49.6)
13 (65.0)
7 (35.0)
2 (28.6)
7 (30.4)

536 (62.2)
23 (46.0)
74 (68.5)
115 (62.8)
58 (50.4)
7 (35.0)
13 (65.0)
5 (71.4)
16 (69.6)

0.059

322

79 (24.5)

243 (75.5)

<0.001

806
75

342 (42.4)
34 (45.3)

464 (57.6)
41 (54.7)

69
31
31
226
41
28
31
14
10
12
8
24

25 (36.2)
9 (29.0)
14 (45.2)
115 (50.9)
17 (41.5)
15 (53.6)
17 (54.8)
6 (42.9)
4 (40.0)
9 (75.0)
3 (37.5)
16 (66.7)

44 (63.8)
22 (71.0)
17 (54.8)
111 (49.4)
24 (51.5)
13 (46.4)
14 (45.2)
8 (57.1)
6 (60.0)
3 (25.0)
5 (62.5)
8 (33.3)

0.008
0.129
0.152
0.252
0.040

0.779
0.352
0.393
<0.001
0.309

The association between HS use as an outcome variable and selected population
characteristics as independent variables is summarized in Table 4.7. There was
positive association of HS use with female gender, higher income, higher educational
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level, having health insurance, being a past-smoker, having an allergy, more frequent
doctor visits, taking prescribed medications and HS knowledge.
There was a negative association of HS use with being married and Emirati,
Middle East/North Africa or South Asian nationality. After adjustment in the
multivariate model, the positive association with female gender, higher income, being
a past-smoker, having an allergy, more frequent doctor visits, taking prescribed
medications and HS knowledge and the negative association with South Asian
nationality and Emirati nationality remained (Table 4.8).
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Table 4.7: Crude odds ratios for HS use, cross-sectional study of HS use and HSrelated adverse events, Dubai, 2015 (N=1203)
Variables
Age – years

All
N

Users
N (%)

1203

38.9±9.0

COR
(95%CI)
0.99 (0.981.01)
1
4.13 (3.005.69)**
1
0.67 (0.480.95)*
1.17 (0.393.51)
0.55 (0.330.93)*
0.55 (0.340.88)*
0.19 (0.120.30)**
0.67 (0.341.33)
0.47 (0.211.05)
1

Gender

Male
Female

1002
201

322 (32.1)
133 (66.2)

Marital Status

Single
Married

150
1039

69 (46.0)
379 (36.5)

Divorced/ Widow/ Widower

14

7 (50.0)

Emirati

142

68 (47.9)

Middle East/ North Africa

301

144 (47.8)

South Asia

579

141 (24.3)

East Asia/Pacific/Central
Asia/Europe
Africa

53

28 (52.8)

32

14 (43.7)

Latin
America/Caribbean/Western
Europe/North America/Australia
Employed

96

60 (62.5)

1123

Unemployed

60

Student/Retired
<5000 AED
5000-<10000 AED

20
164
499

>10000-20000 AED

319

>20000 AED

221

< High school
High school

76
139

Diploma

68

Higher Diploma

46

Bachelor

586

Master/PhD

288

413 (36.8) 1.08 (0.432.73)
35 (58.3) 2.60 (0.917.44)
7 (35.0)
1
33 (20.1) 1
149 (29.9) 1.69 (1.102.59)*
153 (48.0) 3.66 (2.355.68)**
120 (54.3) 4.72 (2.967.50)**
13 (17.1) 1
39 (28.1) 1.89 (0.943.81)
18 (26.5) 1.74 (0.783.90)
22 (47.8) 4.44 (1.9310.20)**
245 (41.8) 3.48 (1.876.47)**
118 (41.0) 3.36 (1.776.39)**

Nationality

Occupation

Income

Education
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Table 4.7: Crude odds ratios for HS use, cross-sectional study of HS use and HSrelated adverse events, Dubai, 2015 (N=1203) (Continued)
Variables

All
N

Users
N (%)

Yes

1028

403 (39.2)

No
Normal (<25 kg/m2)
Overweight (25-29.9 kg/m2)

175
431
546

52 (29.7)
165 (38.3)
198(36.3)

Obese (≥30 kg/m2)

226

92 (40.7)

Non-smoker
Past smoker
Current occasional smoker

862
50
108

326 (37.8)
27 (54.0)
34 (31.5)

Current regular smoker

183

68 (37.2)

Any allergy

Yes

115

57 (49.6)

Visited a doctor
in last 12
months

No
Did not visit doctor in last 12
months
Less than monthly

1081
322

395 (36.5)
79 (24.5)

806

1-3 times a month/ At least
once a week
Yes

75

No
Yes

1134
31

No
Yes

1172
31

No
Yes

1172
226

No
No
Yes

977
174
1029

342 (42.4) 2.27 (1.703.03)**
34 (45.3) 2.55 (1.514.29)**
25 (36.2) 0.93 (0.561.94)
430 (37.9) 1
9 (29.0)
0.67 (0.301.46)
446 (38.1) 1
14 (45.2) 1.37 (0.662.80)
441 (37.6) 1
115 (50.9) 1.94 (1.452.60)**
340 (34.8) 1
19 (10.9) 1
436 (42.7) 6.00 (3.67 –
9.81)**

Health
insurance
BMI – cat

Smoking status

Diabetes
Mellitus
High cholesterol

Cardiovascular
disease
Prescribed
Medicines
Knowledge of
HS

Notes. *P<.05 **p<.01

69

COR
(95%CI)
1.53 (1.082.16)*
1
1
0.92 (0.711.19)
1.11 (0.801.54)
1
1.93 ()
0.75 (0.491.16)
0.97 (0.701.35)
1.71 (1.162.51)*
1
1
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Table 4.8: Adjusted odds ratios for HS use, cross-sectional study of HS use and HSrelated adverse events, Dubai, 2015 (N=1203)
Variables
AOR (95%CI)
Gender
Male
Female
Nationality
Emirati
Middle East/North Africa
South Asia
East Asia/Pacific/Central Asia/Europe
Africa
Latin America/Caribbean/Western Europe/North America/
Australia
Income
<5000 AED
5000-<10000 AED
>10000-20000 AED
>20000 AED
Allergy
Yes
No
Smoking status
Non-smoker
Past smoker
Current occasional smoker
Current regular smoker
Visited to a doctor in last 12 months
Did not visit doctor in last 12 months
Less than monthly
1-3 times a month/ At least once a week
Prescribed Medicines
Yes
No
Knowledge of HS
Yes
No

1
3.26 (2.264.70)**
0.55 (0.30-1.00)*
0.66 (0.39-1.12)
0.51 (0.28-0.93)*
1.16 (0.53-2.52)
0.50 (0.21-1.22)
1

1
1.18 (0.71-1.98)
1.83 (0.98-3.41)
2.41 (1.20-4.83)*
1.75 (1.14-2.66)*
1
1
2.39 (1.274.48)**
0.85 (0.52-1.36)
0.93 (0.64-1.36)
1
1.37 (0.96-1.94)
1.86 (1.02-3.39)*
1.47 (1.04-2.06)*
1
3.91 (2.266.76)**
1

Notes. Stepwise regression method was applied to identify significant correlates
(p<0.10) of HS use *P<0.05 , **p<0.01
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4.1.7 Factors associated with adverse events
The factors associated with adverse events of HS are as shown in Table 4.9. The
average age of participants who experienced an adverse event was 39.3. There was no
effect of age found on the occurrence of an adverse event (P=0.533). Male participants
experienced adverse events more than female participants. Of the 322 male
participants, 11 (3.4%) experienced adverse events. Of the 133 female participants,
only two (1.5%) experienced adverse events. There was no effect of gender on the
occurrence of an adverse event (P=0.363).
Of the 379 married participants, only 10 (2.6%) and of the 69 single participants,
only three (4.3%) experienced adverse events. Among the seven divorced/ widowed
participants, none experienced adverse events. There was no effect of marital status on
the occurrence of an adverse event (P=0.538).
In terms of nationality, of the participants, three UAE nationals (4.1%), five
Middle East/ North Africa nationals (3.5%), two South Asia nationals (1.4%), one
African national (7.1%) and two Latin America/ Caribbean/ Western Europe/ North
America/ Australia nationals (3.3%) experienced adverse events. No East Asia/
Pacific/ Central Asia/ Europe national participant experienced adverse events. There
was no effect of nationality on the occurrence of an adverse event (P=0.467).
Among 413 employed, 35 unemployed and seven students or retired
participants,12 (2.9%) from employed, and one (2.9%) from unemployed participants
experienced adverse events. No student or retiree experienced adverse events. There
was no effect of occupation on the occurrence of an adverse event (P=1.0).
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Participants who had an income greater than 10,000 to 20,000 AED experienced
more adverse events: eight participants (5.2%) of 153. Four participants (3.3%) had an
income greater than 20,000 AED and one participant (0.7%) had an income of between
5,000 and 10,000 AED experienced adverse events. No participant experienced an
adverse event and had an income less than 5,000 AED. There was no effect of income
on the occurrence of an adverse event (P=0.088).
In terms of educational level, of the total 13 recorded adverse events, one was
experienced by a participant who had a diploma, seven were experienced by
participants who had a bachelor’s degree, and five were experienced by participants
who were of post graduate level. There was no effect of education on the occurrence
of an adverse event (P=0.667).
Among the 455 participants who had ever used HS, 403 had insurance cover. Of
the 13 participants who experienced adverse events, 12 had insurance coverage. There
was no effect of insurance coverage on the occurrence of an adverse event (P=1.0).
The adverse events rate was higher in participants with normal body mass index (BMI)
(<25 kg/m2), seven of 165 (4.2%). The BMI mean was 27.1 ± 2.1 SD. BMI showed no
effect on the occurrence of an adverse event (P=0.922).
The smoking status of the participant did not play a role in the occurrence of
adverse events. Of this group, eight non-smokers (2.5%), two past smokers (7.4%),
two current regular smokers (2.9%) and one current occasional smoker (2.9%)
experienced adverse events. Smoking status showed no effect on the occurrence of an
adverse event (P=0.321).
In terms of allergic status, of the 57 participants who had an allergy, only two
experienced an adverse event (3.5%). Of the 455 participants who had ever used HS,
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13 were allergic to drugs. Of these, two experienced adverse events (15.4%). There
was an effect of drug allergy on the occurrence of an adverse event (P=0.049).
Of the participants who experienced adverse events, nine (2.6%) who had visited
a doctor, saw a doctor in a frequency of less than a month. Two (5.9%) who had visited
a doctor one to three times a month/ at least once a week, saw a doctor in a frequency
of one to three times a month/ at least once a week. Two (2.5%) who did not visit a
doctor in the last 12 months, did not see a doctor in the last 12 months. There was no
effect of visiting the doctor on the occurrence of an adverse event (P=0.449).
Participants who experienced an adverse event did not suffer from any common
major disease like diabetes mellitus, high cholesterol levels or cardiovascular disease.
There was no effect of disease on the occurrence of an adverse event (P=1.0).
Participants who experienced an adverse event and who were taking medicine
numbered five (4.3%). There was no effect of taking medicines on the occurrence of
an adverse event (P=0.329).
4.1.8 Factors associated with health supplement knowledge
Table 4.10 shows the association between knowledge of HS and selected sociodemographic and other characteristics of respondents where knowledge is defined by
an affirmative answer to the question: Do you know what health supplements are?
Overall, 1,029 (86%) respondents knew what HS were. There was a significant
positive association between knowledge and female gender. Those of south Asian
nationality, on lower income, with lower educational attainment, lacking health
insurance and who had not visited a doctor were less likely to report familiarity with
HS.
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Table 4.9: Factors associated with adverse events
Variables
Age – years
Gender
Male
Female
Marital Status
Married
Single
Divorced/Widow/er
Nationality
Emirati
Middle East/ North Africa
South Asia
East Asia/ Pacific/ Central
Asia/ Europe
Africa
Latin
America/Caribbean/Western
Europe/North
America/Australia
Occupation
Employed
Unemployed
Student/Retired
Income
<5000 AED
5000-<10000 AED
10000-20000 AED
>20000 AED
Education
< High school
High school
Diploma
Higher Diploma
Bachelor
Master/PhD
Health insurance coverage
Yes
No
Body Mass Index – kg/m2
Body Mass Index – cat
Normal (<25 kg/m2)
Overweight (25-29.9 kg/m2)
Obese (≥30 kg/m2)
Smoking status

All
N
455

Adverse events n
(%)

No adverse events
n (%)

P Value

38.0±5.0

38.9±9.1

0.533
0.363

322
133

11 (3.4)
2 (1.5)

311 (96.6)
131 (98.5)

379
69
7

10 2.6()
3 (4.3)
0 (0.0)

369 (97.4)
66 (95.6)
7 (100.0)

68
144
141
28

3(4.1)
5(3.5)
2(1.4)
0(0.0)

65 (95.6)
139 (96.5)
139 (98.6)
28 (100.0)

14
60

1(7.1)
2(3.3)

13 (92.9)
58 (96.7)

413
35
7

12 (2.9)
1 (2.9)
0 (0.0)

401 (97.1)
34 (97.1)
7 (100.0)

0.538

0.467

1.000

0.088
33
149
153
120

0 (0.0)
1 (0.7)
8(5.2)
4 (3.3)

33 (100.0)
148 (99.3)
145(94.8)
116 (96.7)
0.667

13
39
18
22
245
118

0 (0.0)
0 (0.0)
1 (5.6)
0 (100.0)
7 (2.9)
5 (4.2)

13 (100.0)
39 (100.0)
17 (94.4)
22 (100.0)
238 (97.1)
113 (95.8)
1.00

403
52
1203

12 (3.0)
1 (1.9)
27.1±2.1

391 (97.0)
51 (98.1)
26.9±0.2

165
198
92

7 (4.2)
3 (1.5)
3 (3.3)

158 (95.8)
195 (98.5)
89 (96.7)

0.922

0.321
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Table 4.9: Factors associated with adverse events (Continued)
Variables
Non-smoker
Past smoker
Current occasional smoker
Current regular smoker
Any allergy
Drug allergy
Aerosol & perfume allergy
Contact allergy
Dust allergy
Visited a doctor in last
12 months
Did not visit doctor in last
12 months
Less than monthly
1-3 times a month/At least
once a week
Diseases
Diabetes Mellitus
High cholesterol levels
Cardiovascular disease
Medicines

All
N
326
27
34
68
57
13
7
7
7

Adverse events n
(%)
8 (2.5)
2 (7.4)
1 (2.9)
2 (2.9)
2 (3.5)
2 (15.4)
0 (0.0)
0 (0.0)
0 (0.0)

No adverse
events n (%)
318 (97.5)
25 (92.6)
33 (97.1)
66 (97.1)
55 (96.5)
11 (84.6)
7 (100.0)
2 (100.0)
7 (100.0)

79

2 (2.5)

77 (97.5)

342
34

9 (2.6)
2 (5.9)

333 (97.4)
32 (94.1)

9
25
14
115

0 (0.0)
0 (0.0)
0 (0.0)
5 (4.3)

9 (100.0)
25 (100.0)
14 (100.0)
110 (95.7)

P
Value

0.654
0.049
1.00
1.00
1.00
0.449

1.00
1.00
1.00
0.329
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Table 4.10: Factors associated with health supplement knowledge
Variables

All
(455)

No Knowledge
(n=174) n (%)

P
Value

1203

Knowledge
(n=1029) n
(%)
39.3±0.3

Age – years
Gender
Male
Female
Marital Status
Married
Single
Divorced/Widow/er
Nationality
Emirati
Middle East/North Africa
South Asia
East Asia/Pacific/Central
Asia/Europe
Africa
America/Caribbean/Western
Europe/Australia
Occupation
Employed
Unemployed
Student/Retired
Income
<5000 AED
5000-<10000 AED
10000-20000 AED
>20000 AED
Education
< High school
High school
Diploma
Higher Diploma
Bachelor
Master/PhD
Health insurance coverage
Yes
No
Body Mass Index – kg/m2
Body Mass Index – cat
Normal (<25 kg/m2)
Overweight (25-29.9 kg/m2)
Obese (≥30 kg/m2)

38.7±0.7

0.365
<0.001

1002
201

837 (83.5)
192 (95.5)

165 (16.5)
9 (4.5)
0.282

1039
150
14

884 (85.1)
131 (87.3)
14 (100.0)

155 (14.9)
19 (12.7)
0 (0.0)

142
301
579
53

131 (92.3)
287 (95.3)
443 (76.5)
48 (90.6)

11 (7.7)
14 (4.7)
136 (23.5)
5 (9.4)

32
96

31 (96.9)
89 (92.7)

1 (3.1)
7 (7.3)

1123
60
20

954 (84.9)
57 (95.0)
18 (90.0)

169 (15.1)
3 (5.0)
2 (10.0)

<0.001

0.067

<0.001
164
499
319
221

85 (51.8)
440 (88.2)
296 (92.8)
208 (94.1)

79 (48.2)
59 (11.8)
23 (7.2)
13 (5.9)

76
139
68
46
586
286

26 (34.2)
102 (73.4)
60 (88.2)
41 (89.1)
542 (92.5)
258 (89.6)

50 (65.8)
37 (26.6)
8 (11.8)
5 (10.9)
44 (7.5)
30 (10.4)

<0.001

<0.001
1028
175

431
546
226

897 (87.3)
132 (75.4)
26.8±0.1

131 (12.7)
43 (24.6)
26.3±0.3

362 (84.0)
468 (85.7)
199 (88.1)

69 (16.0)
78 (14.3)
27 (11.9)

0.104
0.367
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Table 4.10: Factors associated with health supplement knowledge (Continued)
Variables
Smoking status
Non-smoker
Past smoker
Current occasional smoker
Current regular smoker
Any allergy
Yes
No
Visited to a doctor in last
12 months
Did not visit doctor in last
12 months
Less than monthly
1-3 times a month/At least
once a week
Diseases
Diabetes Mellitus
Yes
No
High cholesterol levels
Yes
No
Cardiovascular disease
Yes
No
Medicines
Yes
No

All
(455)

Knowledge
(n=1029) n (%)

No Knowledge
(n=174) n (%)

862
50
108
183

733 (85.0)
43 (86.0)
89 (82.4)
164 (89.6)

129 (15.0)
7 (14.0)
19 (17.6)
19 (10.4)

P
Value
0.320

0.323
115
1081

102 (88.7)
922 (85.3)

13 (11.3)
159 (14.7)
<0.001

322

230 (71.4)

92 (28.6)

806
75

732 (90.8)
67 (89.3)

74 (9.2)
8 (10.7)

0.156
69
1134

55 (79.7)
974 (85.9)

14 (20.3)
160 (14.1)
0.299

31
1172

29 (93.5)
1000 (85.3)

2 (6.5)
172 (14.7)
0.073

31
1172

30 (96.8)
999 (85.2)

1 (3.2)
173 (14.8)
0.233

226
977

199 (88.1)
830 (84.9)

27 (11.9)
147 (15.1)

Respondent knowledge of HS stratified by information source (prescription
advice) is shown in Table 4.11. The impact of information source on knowledge of HS
among different demographic variables was investigated by askingthe participants
who had advised them to take HS. A statistically significant difference was found in
the knowledge between males and females when the information sources were selfrecommendation and prescription (P˂0.001), (P=0.004), respectively. A similar
pattern of results was observed in employment status (P=0.004), (P=0.001) and
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education level (P˂0.001), (P˂0.001), respectively. Age of the respondents also
showed a statistically significant difference in knowledge when the sources of
information were relatives and healthcare personnel (P=0.011), (P˂0.006),
respectively.
The nationality of the respondents also showed a statistically significant
difference in knowledge when the source of information was self-recommendation
(P=0.014), relatives (P=0.029), prescription (P˂0.001), and healthcare personnel
(P˂0.001). Moreover, a statistically significant difference was found in the knowledge
of respondents and their monthly income when the information sources were
prescription (P=0.010) and healthcare personnel (P=0.026). A similar pattern of results
was observed in health insurance coverage variable (P=0.022), (P=0.030),
respectively. BMI, as a continuous variable, showed a statistically significant
difference in the knowledge of HS when the information source was selfrecommendation (P=0.043). Also, when BMI was converted and categorised, a
statistically significant difference was found in the knowledge of the respondents when
the information source was the internet (P=0.027). In relation to smoking status,
respondents showed a significant difference in the knowledge of HS when they
obtained their information from the internet (P=0.022).
Regarding visiting the doctor in the last 12 months, respondents showed a
statistically significant difference in the knowledge of HS when the source of
information towards HS was self-recommendation (P=0.008), internet (P=0.001) and
prescription (P=0.014). Among co-morbidities (chronic medical conditions)
respondents suffering from only diabetes mellitus showed a statistically significant
difference in the knowledge of HS when the source of information towards HS was
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prescription (P=0.002). When the respondents were asked about medication history, a
statistically significant difference in the knowledge of HS was observed among the
respondents when the sources of information towards HS were self-recommendation
and prescription (P˂0.001), (P˂0.001), respectively. Conversely, there was no
statistically significant difference in the knowledge of HS in other demographic
specifications (marital status, allergy history) and source of information towards HS.

Table 4.11: Knowledge by prescription advice
Variables

All
(455)

Self
(n=204)

Age – years
Gender
Male

455

n (%)
38.9±0.6

Female
Marital Status
Married

133

Single/Divorced/Widow/er
Nationality
Emirati
Middle East/North Africa
South Asia
East Asia/Pacific/Central Asia/Europe

69

Africa
America/Caribbean/Western
Europe/Australia
Occupation
Employed
Other
Income
<5000 AED

322

P
Value

0.995
<0.001

162
(50.3)
42 (31.6)

Relative
(n=35)
n (%)
35.1±4.5

0.011
0.445

27 (8.4)

170
(44.9)
34 (44.7)

Internet
(n=30)
n (%)
37.3±1.3

0.328
0.303

27 (7.1)

n (%)
39.2±9.7

0.511
0.004

Health
professional
(n=49)
n (%)
42.2±1.3

0.839
42 (11.1)

31 (40.8)

7 (9.1)
<0.001

<0.001

68
144
148
28

27 (39.7)
60 (41.7)
56 (39.7)
20 (71.4)

9 (13.2)
12 (8.3)
4 (2.8)
4 (14.3)

4 (5.9)
10 (6.9)
5 (3.5)
4 (14.3)

38 (55.9)
67 (46.5)
82 (58.2)
3 (10.7)

2 (2.9)
24 (16.7)
3 (2.1)
4 (14.3)

14
60

8 (57.1)
33 (55.0)

2 (14.3)
4 (6.7)

0 (0.0)
7 (11.7)

4 (28.6)
18 (30.0)

2 (14.3)
14 (23.3)

413
42

194
(47.0)
10 (23.8)

33

9 (27.3)

0.004

0.759

0.097

0.001

1.000

33 (8.0)

30 (7.3)

182 (44.1)

45 (10.9)

2 (4.8)

0 (0.0)

30(71.4)

4 (9.5)

0.156

0.701
1 (3.0)

0.293
2 (6.1)

0.010
23 (69.7)

0.006
0.373

17 (12.8)
0.266

0.139

P
Value

32 (9.9)

181 (47.8)

4 (5.3)
0.029

P
Value

76 (57.1)
0.609

26 (6.7)

8 (10.5)

Prescribed
(n=212)

136 (42.2)

6 (4.5)
0.343

0.014

P
Value

24 (7.5)

8 (6.0)
1.00

379

P
Value

0.026
2 (6.1)
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Table 4.11: Knowledge by prescription advice (Continued)
Variables

All
(455)

Self
(n=204)

5000-<10000 AED
>10000-20000 AED
>20000 AED
Education
≤ Higher Diploma

149
153
120

67 (45.0)
75 (49.0)
53 (44.2)

92

29 (31.5)

Bachelor
Master/PhD
Health insurance coverage

245
118

101 (41.2)
74 (62.7)

Yes
No
Body Mass Index – kg/m2
Body Mass Index – cat
Normal

403
52

165

71 (43.0)

Overweight
Obese
Smoking status
Non-smoker
Past smoker
Current occasional smoker

198
92

82 (41.4)
51 (55.4)

326
27
34

135 (41.4)
15 (55.6)
19 (55.9)

Current regular smoker
Any allergy
Yes
No
Visited to a doctor in last 12
months

68

35 (51.5)

P
Value

Relative
(n=35)
10 (6.7)
13 (8.5)
11 (9.2)

<0.001

0.043
0.069

0.123

31 (7.7)
4 (7.7)
25.9±1.0

0.157
0.089

19
(11.5)
11 (5.6)
5 (5.4)

27 (47.4)
176 (44.6)

Health
professional
(n=49)
8 (5.4)
22 (14.4)
17 (14.2)

<0.001

17 (6.9)
7 (5.9)

123 (50.2)
37 (31.4)

22 (9.0)
16 (13.6)

0.558
28 (6.9)
2 (3.9)
25.6±0.8

0.089
0.027

0.022
180 (44.7)
32 (61.5)
26.9±4.4

0.885
0.126

103 (52.0)
39 (42.4)

20 (10.1)
8 (8.7)
0.155

0.742

9 (13.2)
0.693

183 (46.3)
28 (49.1)
0.001

0.695
0.604

36 (11.0)
2 (7.4)
2 (5.9)

31 (45.6)
1.000

3 (5.3)
37 (6.8)

48 (11.9)
1 (1.9)
26.7±0.6
21 (12.7)

160 (49.1)
11 (40.7)
10 (29.4)

1 (1.5)

0.030

70 (42.4)

0.022

P
Value

0.385
11 (12.0)

1.00

0.062

P
Value

52 (56.5)

21 (6.4)
5 (18.5)
3 (8.8)

31 (7.9)
4 (7.0)
0.008

0.967

0.096

5 (7.3)

Prescribed
(n=212)
72 (48.3)
59 (38.6)
58 (48.3)

18
(10.9)
8 (4.0)
4 (4.3)

21 (6.4)
5 (18.5)
4 (11.8)
0.690

P
Value

6 (6.5)

1.00

0.128

57
395

Internet
(n=30)
7 (4.7)
15 (9.8)
6 (5.0)

11
(12.0)
19 (7.8)
5 (4.2)
0.326

184 (45.7)
20 (38.5)
27.4±0.3

P
Value

1.00
6 (10.5)
43 (10.9)

0.014

0.137
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Table 4.11: Knowledge by prescription advice (Continued)
Variables

All
(455)

Self
(n=204)

P
Value

Relative
(n=35)

Did not visit doctor in last 12
months
Less than monthly
1-3 times a month/At least once a
week
Diseases
Diabetes Mellitus
Yes
No
High cholesterol levels
Yes
No
Cardiovascular disease
Yes
No
Medicines
Yes
No

79

47 (59.5)

9 (11.4)

342
34

146 (42.7)
11 (32.3)

21 (6.1)
5 (14.7)

25
430

7 (28.0)
197 (45.8)

9
446

2 (22.2)
202 (45.3)

14
441

5 (35.7)
199 (45.1)

115
340

35 (30.4)
169 (49.7)

0.099

P
Value

Internet
(n=30)
13
(16.5)
14 (4.1)
3 (8.8)

0.244
0 (0.0)
35 (8.1)

0.196

1.00

<0.001

170 (49.7)
17 (50.0)

40 (11.7)
5 (14.7)

0.002

0.606
0 (0.0)
49 (11.0)

0.276
9 (64.3)
203 (46.0)

0.830
8 (7.0)
22 (6.5)

0.502

0.089

0.613

0.381
0 (0.0)
49 (11.1)

<0.001
73 (63.5)
139 (40.9)

P
Value

1 (4.0)
48 (11.2)

205 (46.0)
7 (77.8)

0 (0.0)
30 (6.8)
0.156

5 (4.3)
30 (8.8)

25 (31.7)

Health
professional
(n=49)
4 (5.1)

3.96

0.614

P
Value

19 (76.0)
193 (44.9)

0 (0.0)
30 (7.0)

0 (0.0)
35 (7.9)

Prescribed
(n=212)

1.000
0 (0.0)
30 (6.7)

0 (0.0)
35 (7.9)
0.591

P
Value

0.407
39 (11.5)
10 (8.7)
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4.1.9 Risk assessment of health supplement use
Respondents’ HS use were assigned a risk score based on the activity of the
ingredient and the frequency of use. Scores ranged from one to a maximum of 12. Data
were available to assign scores to 408 HS users in this way. Scores were then arranged
into three categories or tertiles. Tertile one represented HS use with the lowest risk,
tertile two represented HS use with an intermediate risk, while tertile three represented
HS use with the highest risk. Overall, 148 (36.3%) of participants consumed HS with
ingredients within the lowest risk tertile, 219 (53.7%) of participants consumed HS
with ingredients within the intermediate risk tertile, and 41 (10.1%) of participants
consumed HS with ingredients within the highest risk tertile. HS use in each risk tertile
is shown in Table 4.12 by selected socio-demographic and other characteristics of the
respondents.
Gender, income, smoking status, having allergy, having high cholesterol, HS
capsule-form consumption, purchasing from clinic are significantly associated with
HS risk. Compared to males, females were more likely to consume HS in the
intermediate risk tertile. Those earning between 5,000 and 10,000 AED were more
likely to be in the higher risk categories. Past smokers, those who consumed their HS
in capsule-form and those who obtained their HS from a clinic were more likely to be
in the high risk tertile, while those with an allergy or high cholesterol were more likely
to be in the low risk tertile, although numbers were small.
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Table 4.12: Health supplement risk tertile by characteristics of participants
Variables

All
Age – years
Gender

Marital Status

Male
Female
Married

Nationality

Other
Emirati
Non-Emirati

Occupation

Employed

Income (AED)

Education

Health insurance coverage

BMI – kg/m2 (cat)

Smoking status

Any allergy

Visited to a doctor in last 12
months

Other
<5000
5000-<10000
10000-20000
>20000
≤ Higher
Diploma
Bachelor

Lowest
Tertile
n%
148
(36.3)
39.0±8.7
120
(42.4)
28 (22.4)
131
(38.8)
17 (24.3)
27 (41.5)
121
(35.3)
134
(36.6)
14 (33.3)
16 (55.2)
33 (25.8)
54 (39.1)
45 (39.8)
38 (46.9)

Highest
Tertile
n%
41 (10.1)

P
Value

129
(45.6)
90 (72.0)
174
(51.5)
45 (64.3)
35 (53.9)
184
(53.6)
192
(52.5)
27 (64.3)
12 (41.4)
77 (60.2)
71 (51.5)
59 (52.2)
35 (43.2)

34 (12.0)

<0.001

7 (5.6)
33 (9.8)

0.064

19 (8.5)

8 (11.4)
3 (4.6)
38 (11.1)

0.239

40 (10.9)

0.148

1 (2.4)
1 (3.4)
18 (14.1)
13 (9.4)
9 (8.0)
8 (9.9)

0.042

0.093

No
Normal
Overweight

30 (28.9)
136
(25.5)
12 (37.7)
51 (38.6)
62 (32.3)

Obese
Non-smoker

35 (41.7)
95 (33.0)

Past smoker
Current
occasional
Current regular
Yes (n=53)
No (n=352)

8 (33.0)
15 (50)

124
(55.6)
60 (57.7)
189
(63.8)
30 (52.3)
70 (53.0)
105
(54.7)
44 (52.4)
167
(58.0)
10 (41.7)
12 (40.0)

30 (45.5)
29 (54.7)
117
(33.2)
23 (34.3)

30 (45.5)
20 (37.7)
199
(56.5)
39 (58.2)

6 (9.0)
4 (7.5)
36 (10.2)

0.013

5 (7.5)

0.524

119
(37.8)
6 (23.1)

163
(51.7)
17 (65.4)

33 (10.5)

Master/PhD
Yes

No doctor
visits in last 12
months
Less than
monthly
At least once a
month/week

80 (35.9)

Middle
Tertile
n%
219
(53.7)

14 (13.5)
36 (10.6)
5 (10.0)
11 (8.3)
25 (13.0)
5 (6.0)
26 (9.0)

0.261

0.261

0.049

6 (25.0)
3 (10.0)

3 (11.5)
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Table 4.12: Health supplement risk tertile by characteristics of participants
(Continued)
Variables

Diabetes Mellitus

Yes
No

High cholesterol

Yes (n=8)
No (n=400)

Cardiovascular disease

Yes
No

Medicines

Yes (n=109)
No (n=299)

Adverse events

Yes (n=13)
No (n=395)

Forms of
HS

Purchase
of HS

Advise of
using HS

Tablet

Yes (n=349)

Capsule

No (n=59)
Yes (n=47)
No (n=361)

Powder

Yes (n=40)
No (n=368)

Pharmacy

Yes (n=360)

Clinic

No (n=48)
Yes (n=43)
No (n=365)

Lowest
Tertile
n%
10 (43.5)
138
(35.8)
7 (87.5)
141
(35.3)
4 (30.8)
144
(36.5)
32 (29.4)
116
(38.8)
8 (61.5)
140
(35.4)
130
(37.2)
18 (30.5)
10 (21.3)
138
(28.2)
16 (40.0)
132
(35.9)
133
(36.9)
15 (31.3)
16 (37.2)
132
(36.2)
7 (25.0)
141
(37.1)
66 (37.7)
82 (35.2)

Nutrition shop

Yes (n=28)
No (n=408)

Self

Yes (n=175)
No (n=233)

Friend/Relative

Yes (n=27)
No (n=381)

Internet

Yes (n=22)
No (n=386)

Prescribed

Yes (n=198)

11 (40.7)
137
(36.0)
7 (31.8)
141
(36.5)
76 (38.4)

No (n=210)

72 (34.3)

Yes (n=45)
No (n=363)

13 (28.9)
135
(37.2)

Health
Professional

Middle
Tertile
n%
11 (47.8)
208
(54.0)
1 (12.5)
218
(54.4)
8 (61.5)
211
(53.4)
68 (62.4)
151
(50.5)
5 (38.5)
214
(54.2)
189
(54.1)
30 (50.9)
21 (44.7)
198
(54.9)
22 (55.0)
197
(53.5)
193
(53.6)
26 (54.2)
18 (41.9)
201
(55.1)
17 (60.7)
202
(53.2)
87 (49.7)
132
(56.7)
15 (55.6)
204
(53.4)
11 (50.0)
208
(53.9)
106
(53.5)
113
(53.8)
27 (60.0)
192
(52.9)

Highest
Tertile
n%
2 (8.7)
39 (10.1)

P
Value

0 (0.0)
41 (10.3)

0.010

1 (7.7)
40 (10.1)

0.914

9 (8.3)
32 (10.7)

0.103

0 (0.0)
41 (10.4)

0.144

30 (8.6)

0.055

11 (18.6)
16 (34.0)
25 (6.9)

<0.001

0.760

2 (5.0)
39 (10.6)

0.588

34 (9.4)

0.474

7 (14.6)
9 (20.9)
32 (8.8)

0.041

4 (14.3)
37 (9.7)

0.366

22 (12.6)
19 (8.1)

0.222

1 (3.7)
40 (10.5)

0.616

4 (18.2)
37 (9.6)

0.424

16 (8.1)

0.381

25 (11.9)
5 (11.1)
36 (9.9)

0.550
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Figure 4.1 shows a flow chart of the total number of participants in the n survey.
Among a total of 1203 participants 455 consumed HS of whom 13 experienced adverse
events. Of those who experienced adverse events, three visited a healthcare centre
which proved the adverse event to be associated with the consumption of HS. All three
reported the adverse events.

Figure 4.1: Structure of observed outcomes for population survey

4.2 Results of Second Study: Cross-Sectional Study Among Healthcare
Professionals
This cross-sectional study was conducted among physicians and pharmacists in
Dubai both registered with Dubai Health Authority and those working in the private
sector. A total of 427 participants responded to the on-line questionnaire. Of those,
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205 (48%) were pharmacists, 49 (11.47%) were physicians and 173 (40.5%) were
other healthcare professionals.
4.2.1 Demographic characteristics
Among the 427 respondents, there was a relative equality of numbers in terms
of gender: 221 (51.75%) were male and 206 (48.2%) were female. Mean age was 35.43
(SD ±8.43) with a range of 22-67. The socio-demographic characteristics of
participants are shown in Table 4.13.
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Table 4.13: Demographic characteristics of healthcare professionals
Demographic
Age
Mean age ± S.D
Gender
Male
Female
Nationality
Emirati
Middle East/North Africa
South Asia
East Asia/Pacific
Central Asia/Europe
Africa
Western Europe/North America/Australia
Not specific
Marital status
Married
Single
Divorced
Widow
Employment status
Government
Private
Self-employed
Occupation
Specialised physician
Physician
Pharmacist
Assistant pharmacist
Other
Work experience
1-2 years
3-4 years
5-6 years
Less than 1 year
More than 6 years
Insurance coverage
Yes
No
Education
Graduate
Post graduate

N (%)
(22 -67)
(35.43±8.43)
221 (51.75%)
206 (48.2%)
69 (16.2%)
47 (11%)
260 (60.8%)
32 (7.5%)
1 (0.23%)
12 (2.8%)
2 (0.46%)
4 (0.93%)
315 (73.77%)
103 (24.12%)
6 (1.41%)
3 (0.7%)
161 (37.7%)
264 (61.8%)
2 (0.5%)
32 (7.5%)
17 (4.0%)
192 (45.0%)
13 (3%)
173 (40.5)
62 (14.5%)
60 (14.1%)
47 (11.0%)
19 (4.4%)
239 (56.0%)
405 (94.8%)
22 (5.2%)
273 (63.9%)
154 (36.1%)
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4.2.2 Knowledge on health supplements
Table 4.14 summarises healthcare professionals’ knowledge of HS, HS safety,
HS adverse events and adverse event reporting. Of the participants, 352 (82.4%) knew
what HS are and 183 (42.9%) believed HS to beharmless. Around half, 192 (45.0%)
knew what a reporting system was, but fewer could identify reporting systems either
within the UAE or within their organization. Around 40% had attended educational
sessions on HS and read journal articles, but only about a quarter knew how to report
adverse events or had training on the process.
Table 4.14: Descriptive data on healthcare professional’s knowledge
Knowledge on HS
Do you know what HS are (n=427)
Do you agree with the statement that HS are harmless
(n=427)
Do you know what reporting system is (n=427)
Do you know about any existing reporting system in
the UAE (n=192)
Do you know about any AE reporting system in your
organization (n=427)
Do you know to whom you can report an AE (n=427)

Have you ever received any continuing education on
HS products (n=427)
Have you read a scientific article related to AE of HS
in the last 6 months (n=427)
Have you ever received training on how to report an
AE (n=427)

Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No
Yes
No

N (%)
352 (82.4%)
75 (17.5%)
183(42.9%)
244 (57.1%)
192 (45.0%)
235 (55%)
68 (35.4%)
124 (64.6%)
96 (22.5%)
331 (77.5%)
112 (26.2%)
315
(73.77%)
191 (44.7%)
236 (55.3%)
189 (44.3%)
238 (55.7%)
108 (25.3%)
319 (74.7%)

Table 4.15 shows that around two-thirds of respondents (277, 65%) reported that
they knew of adverse events associated with HS use and could list common adverse
events.
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Table 4.15: Health supplement adverse events reported by respondents
Adverse events
Do you know about adverse events of HS
(n=427)

Yes
No

Adverse event
Abdominal pain

Adverse events (n=277)
N (%)
Adverse event
179 (64.6%)
Headache

Anorexia

57 (20.57%)

Hypertension

Anxiety

59 (21.29%)

Hypotension

Chest pain

32 (11.55%)

Convulsions

27 (9.74%)

Muscle
cramping
Muscle pain

Dermatitis

65 (23.46%)

Nausea

Diarrhoea

179 (64.6%)

Palpitations

Dizziness

93 (33.57%)

Pyrexia

Dyspnea

25 (9.02%)

Sedation

Edema

45 (16.24%)

Tingling

Fatigue

70 (25.27%)

Urticaria

Hair loss

61 (22.02%)

Vomiting

N (%)
277
(64.9%)
150
(35.1%)
N (%)
120
(43.32%)
84
(30.32%)
47
(16.96%)
54
(19.49%)
35
(12.63%)
169
(61.01%)
89
(32.12%)
13
(4.69%)
58
(20.93%)
25
(9.02%)
94
(33.93%)
150
(54.15%)

Among the 191 healthcare professionals who reported that they have received
one or more types of continuing education on HS products, 120 (63%) reported that
they had official training courses, 118 (62%) reported that had workshops on product
orientation, and 108 (56%) reported their continuing education on HS products through
electronic learning.
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4.2.3 Practice towards health supplements
Table 4.16 summarises healthcare professionals’ practice with respect to selling,
prescribing and dispensing HS, types of HS and dosage, record keeping and
discussions with patients/consumers.
A total of 232 respondents (54.3%) prescribed or dispensed HS. Most commonly
these were vitamins, herbal supplements, and minerals. Tablets (n=165, or 71.12%),
soft gels (n=160, or 68.96%), capsules (n=151, or 65.08%), chews/gummies (n=128,
or 55.17%), chewable tablets (n=126, or 54.31%) and caplets (n=126, or 54.31%) were
the most identified formulations. 41.81% of the participants stated that they had a
system to record HS use. Most respondents (195, 85%) always or often discuss HS use
with their patients/customers and product effect is the most discussed topic. The
Internet was the most used source of information on HS. Literacy was cited as the most
important barrier limiting discussion between practitioners and patients/customers.
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Table 4.16: Descriptive data on healthcare professionals’ practice
Practice
Sell/prescribe/dispense HS at practice
site (n=427)
Types of HS prescribed (232)

Dosage forms of HS prescribed (n=232)

Availability of a system to record HS
use (n=232)
Discussion with patients/ consumers on
HS (n=232)

Discussion topic of HS use with
patients/ customers (n=227)

Information sources of HS (n=227)

Barriers limiting discussing HS with
patients/ customers (n=227)

Yes
No
Dietetic
Herbal
Vitamin
Energy drink
Mineral
Food
Sport nutrition
Caplets
Chews/ Gummies
Gel
Liquid
Soft gels
Vegi-caps
Capsule
Drink
Gel caps
Lozenges
Spray
Wafers
Chewable tablets
Drops
Granules
Powder
Tablet
Yes
No
Always
Often
Sometimes
Never
Product effect
Product AE
Product quality
Product price
Internet
Printed material
Multimedia
Literacy
Cultural ethics
Language
Social level

N (%)
232 (54.3%)
195 (45.7%)
94 (40.50%)
149 (34.9%)
221 (64.22%)
46 (19.82%)
132 (30.9%)
84 (36.2%)
86 (37.01%)
126 (54.31%)
128 (55.17%)
46 (19.82%)
102 (43.96%)
160 (68.96%)
112 (48.27%)
151(65.08%)
56 (24.13%)
49 (21.12%)
52 (22.41%)
31 (13.36%)
32 (13.79%)
126 (54.31%)
77 (33.18%)
54 (23.27%)
98 (42.24%)
165 (71.12%)
97 (41.81%)
135 (58.18%)
111 (47.84%)
86 (37.06%)
30 (12.93%)
5 (2.15%)
208 (91.62%)
99 (43.61%)
165 (72.68%)
91 (40.08%)
186 (81.93%)
145 (63.87%)
73 (32.15%)
100 (44.05%)
45 (19.82%)
84 (37.0%)
63 (27.75%)
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Table 4.17 summarises respondents’ experience of HS adverse events. Of the
232 who had prescribed HS, 55 (23.70%) of their patients/ customers had experienced
an adverse event related to HS use. Of these, 39 (70.90%) occasionally or rarely
encountered adverse events while 12 (21.8%) reported frequent encounters. Asthenia
(weakness, lack of strength) was the commonest reported event followed by
gastrointestinal symptoms. Of the 55 respondents who reported experience of patient
adverse events, 24 (44%) never reported them. Only 10 (18%) always reported Patient
adverse events. Most reports were made internally within the practitioner’s
organization, usually to a more senior staff-member. Among the 232 who prescribed
or dispensed HS, only 58 (25%) said they had access to reporting forms at work.
4.2.4 Attitude towards health supplement
Table 4.18 summarises respondents’ attitude towards the reporting of adverse
events associated with HS use. Total 369 respondents (91%) agreed or strongly agreed
that adverse events associated with HS use should be reported to a higher authority.
The most common reasons given for not reporting was not knowing where to report
and difficulty in confirming that an adverse event was related to HS use. There was
good agreement on the importance of reporting and of the likely benefits of setting up
a reporting system. There were concerns about possible legal problems, but most
respondents were confident that they would be able to report an adverse event.
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Table 4.17: Reported adverse event related to health supplement
Reported AE related to HS

N%

Ever experiencing AE related to HS use in
patients/customers during practice (232)

Yes

55 (23.70%)

No

177
(76.29%)

Frequency of encountering AE related to HS use (55)
Once

16 (29.09%)

Occasionally

39 (70.90%)

AE

N%

AE

Abdominal pain

25 (45.45%)

Edema

1 (1.81%)

Alopecia

4 (7.27%)

Headache

14 (25.45%)

Anorexia

5 (9.09%)

Hypotension

2 (3.63%)

Asthenia

55 (100%)

Nausea

22 (40%)

Chest pain

4 (7.27%)

Pain

2 (3.63%)

Convulsion

1 (1.81%)

Pruritus

4 (7.27%)

Dermatitis

7 (12.72%)

Pyrexia

1 (1.81%)

Diarrhea

18 (32.72%)

Sedation

2 (3.63%)

Dizziness

12 (21.81%)

Urticaria

7 (12.72%)

Dyspnea

5 (9.09%)

Vomiting

14 (25.45%)

How often have you
recorded HS AE (55)

Which higher authority did
you report HS AE (31)

Availability of AE
reporting form at the work
(232)

Always

10 (18.18%)

Never

24 (43.63%)

Often

2 (3.63%)

Sometimes

19 (34.54%)

Ministry of Health

3 (9.67%)

Senior physician

8 (25.80%)

Pharmacist in-charge

23 (74.19%)

Yes

58 (25%)

No

138
(59.48%)

Don’t know

36 (15.51%)
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Table 4.18: Descriptive data on healthcare professional’s attitude
Reporting HS
related AE to the
higher authority
(n=427)
Reason of not
reporting AE
(n=427)

Importance of
reporting all AE
of HS (n=330)
Establishment of
AE reporting
system related to
HS use (n=330)
Concerning
about legal
problems of
reporting AE
(n=330)
Feeling confident
when reporting
AE (n=330)

Attitude
Strongly disagree
Disagree
Neutral
Agree
Strongly agree
It’s not important
Don’t know where to report
Don’t know what is AE of HS
Concerned that the report is a false alert
Lack of time to investigate the case
Consider as extra work
Difficulty in confirming AE
No
Only when hospitalisation is needed
Only when it is life threatening
Yes (all)
Definitely beneficial
Not beneficial
Not sure
Somewhat beneficial
Definitely
Definitely not
Not
Not sure
Somewhat
Definitely
Definitely not
Not
Not sure
Somewhat

N (%)
3 (0.7%)
5 (1.2%)
50 (11.7%)
182 (42.6%)
187 (43.8%)
20 (4.7%)
172 (40.3%)
78 (18.3%)
38 (8.9%)
76 (17.8%)
12 (2.8%)
139 (32.6%)
3 (0.90%)
23 (6.96%)
16 (4.84%)
288 (87.27%)
271(82.12%)
1 (0.30%)
24 (7.27%)
34 (10.30%)
104 (31.51%)
21 (6.36%)
33 (10%)
89 (26.96%)
83 (25.15%)
209 (63.33%)
1 (0.30%)
5 (1.51%)
31 (9.39%)
84 (25.45%)

4.2.5 Overall knowledge, attitude and practice
Based on the questions in Table 4.19, a summary score was created for the KAP
of respondents. A correct option scored 1, an incorrect response zero. A total score of
10 was obtainable. For all study participants (427), KAP scores were normally
distributed (see Figure 4.2) with a mean score of 4.85 (standard deviation ± 1.88).
Scores were grouped into three categories: good (>7), fair (5-6) and poor (0-4).
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(Olowokere et al., 2014). Overall, 78 (18.3%) respondents had good KAP, 166 (39%)
had fair KAP, while 166 (40%) had poor KAP.
Table 4.19: Knowledge, attitude, and practice assessment
KAP Items

N% Correct
answer

Knowing what HS are

352 (82.4%)

Whether HS are harmless

244 (56.7%)

Knowledge about adverse events of HS

277 (64.9%)

Definition of reporting system

192 (45.0%)

Knowing any AE reporting system in organization

96 (22.5%)

Knowing to whom reporting AE

112 (26.2%)

Receiving any continuing education on HS

191 (44.7%)

Reading scientific article related to AE of HS in the last 6

189 (44.3%)

months
Receiving training on how to report an AE

108 (25.3%)

Reporting HS related AE to higher authority/personnel

369 (86.42%)
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Figure 4.2: Distribution of healthcare professionals’ knowledge, attitude and practice
score
4.2.6 Factors associated with knowledge, attitude and practice score
Table 4.20 summarises the association between KAP scores and selected sociodemographic factors. Scores were significantly higher among non-UAE nationals
compared to UAE nationals, among physicians and pharmacists compared to other
healthcare practitioners and among practitioners with six or fewer years of experience
compared to those with more than six years of experience. No association was found
between KAP scores and age, marital status, government/private employment status
or graduate/non-graduate educational level.
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Table 4.20: Factors associated with KAP score
KAP Score
Mean

± (SD)

35.43 ±(8.428)

Age

P-Value
0.113

Gender
Male

4.9

±(1.82)

Female

4.76

±(1.92)

0.352

Nationality
UAE national
Non-UAE national

4.14

±(2.1)

0.001

4.98 ±(1.81)

Marital status
Single

4.59 ±(1.81)

Married

4.91 ±(1.91)

0.141

Employment status
Government

4.62

±(2.2)

Private

4.98

±(1.7)

0.051

Occupation
Physicians

5.5 ±(0.264)

Pharmacists

5.1 ±(0.129)

Other healthcare

4.4 ±(0.140)

0.000

Work experience
Six year and less

5.04 ±(1.97)

More than six years

4.6 ±(1.7)

0.017

Education
Graduate

4.78 ±(1.83)

Post Graduate

4.96 ±(1.91)

0.361

4.2.7 Comparisons between occupational groups
Table 4.21 summarises the experience of HS related adverse events among
various occupational sub-groups making up the sample. Most of those reporting
adverse events (46/55, 84%) were pharmacists. Generally, all occupational groups
agreed or strongly agreed that adverse events should be reported.

137
Table 4.21: Experience of health supplement related adverse events among various
occupational sub-groups
All
N=427
Ever experiencing AE
related to HS use in
patients/customers
during practice
Frequency of
encountering AE
related to HS use
Once
Occasionally
Frequency of
recording HS AE
Always
Never
Often
Sometimes

Physician
N= 49

Others
N= 173

N= 232

Pharmacis
t
N=205
N=189

N=18

N=25

55 (23.7%)

46 (24.3%)

4 (22.2%)

5 (20%)

N=55

N=46

N=4

N=5

16
(29.09%)
39
(70.90%)
N=55

13 (28.3%)

0

3 (60%)

33 (71.7%)

4 (100%)

2 (40%)

N=46

N=4

N=5

10
(18.18%)
24
(43.63%)
2 (3.63%)
19
(34.54%)

7 (15.2%)

1(25%)

2 (40%)

22 (47.8%)

1(25%)

1 (20%)

2 (4.3%)
15 (32.6%)

0
2 (50%)

0
2 (40%)

Reporting HS related
AE to higher authority

N= 427

N=205

N=49

N= 173

Strongly disagree

3 (0.7%)

1(0.48%)

0

Disagree
Neutral

5 (1.2%)
50 (11.7%)

0
7 (14.3%)

Agree

182
(42.6%)
187
(43.8%)

1 (0.48%)
21
(10.24%)
96
(46.83%)
86
(41.95%)

2
(11.5%)
4 (2.3%)
22(12.7
%
62(35.8
%
83(47.9
%

Strongly agree

24
(48.9%)
18
(36.7%)
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Chapter 5: Discussion
5.1 Introduction
This dissertation reports findings from two large cross-sectional studies that
were designed and carried out in Dubai to quantify HS use and any related adverse
events. The first study consisted of a computer assisted personal interview conducted
by telephone and involved 1,203 Dubai residents. The study investigated HS
consumption, knowledge and the reporting of any HS related adverse events. The
second study used an on-line questionnaire to assess HS knowledge, HS related
adverse event knowledge, as well as knowledge, attitude and practice (KAP) among
427 Dubai healthcare professionals. The stimulus for this research arose from the
writer’s work with consumer safety in Dubai Municipality, a strongly held belief of
the public health importance of HS use in Dubai and the need to raise awareness among
healthcare professionals to improve patient safety. It is believed that no similar study
has previously been carried out in UAE.

5.2 Key Results
5.2.1 First study: survey among Dubai population
In the general population sample, the prevalence of ever having used HS was
38% and the prevalence of current use was 31%. These levels were similar to findings
from studies in other countries. There are few data on HS use and adverse events in
the UAE. Although in one study, conducted among university students, the
consumption rate of HS was 39%. (Alhomoud et al., 2016). In one recent study
conducted among the female college students in Saudi Arabia 76.6% of the
participants were using HS (Alfawaz et al., 2017). A cross-sectional household survey,
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conducted among Saudi residents of the Riyadh region resulted with 73% of alternative
medicines which includes herbal supplements (Al-faris et al., 2008). The consumption
rate of HS among students in Qatar was 49.6% (Mamtani et al., 2015) while the rate
in the US has been increasing yearly and, in 2009, was 69% (Gahche et al., 2011).
In one of the community based survey study conducted in the rural population
of United States, 61% of the HS using participants were aware that HS products were
not much regulated by controlling authorities and they were getting information about
HS from internet, family / friends, physicians and pharmacists (Owens et al., 2014). In
a study conducted among the US army soldiers, 48% of the respondents had
knowledge about the HS and they were getting it from the leading magazines,
friends/team mates, physicians/ para medical staff or from internet (Tharion et al.,
2004). It is difficult to assess overall knowledge and awareness of HS in the sample,
but about half of HS users had been prescribed HS while 60% had received information
about HS from a pharmacist, suggesting a reasonable level of awareness.
Of the users surveyed, only 13 (3%) reported experiencing adverse events and
most were not serious.
The published literatures, identifies a high risk of adverse events associated with
HS, especially herbal supplements, as they have a higher risk of contaminations, drug
interaction and adulterations. Heavy metal contamination occurs mainly through the
substandard cultivation and manufacturing practices. One study identified that the high
dose consumption of heavy metals can cause several diseases, they may be
carcinogenic or have adverse reproductive effects (Ejeatuluchukwu et al., 2011).
Pesticide residue contamination which is occurring due to excessive use of pesticides
during the cultivation of the herb and from lack of good agriculture practices (GAP).
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Organochlorine pesticide residues which may lead serious health issues if consumed
above the limit, have also been found in a number of Chinese herbal plants cultivated
in China and sold in Hong Kong (Leung et al., 2005)
A number of studies identified the adverse events associated with intended
adulteration of HS for the best result with banned medicinal ingredients or medicinal
ingredient which need medical supervision. In 2009, a division of the US Food and
Drug Administration (FDA), the Internet and Health Fraud Team conducted an internet
survey of HS products intended for sexual enhancement. They found that one third of
such supplements which are marketed as dietary supplements to promote sexual
activity and treat erectile dysfunction, despite having no disclosure of any medicinal
content on the label, nevertheless contained the medicinal ingredient sildenafil, the
active ingredient in Viagra (USFDA, 2009). In Germany, a research carried out by the
government authority controlling HS products (Deutsches Aerzteblatt International)
found 17 incidents of illness with vomiting, arterial hypertension, headache, malaise,
nausea, chest pressure, dyspnea, tachycardia, insomnia and high fever associated with
consumption of Chinese slimming products, such as slimming tea and slimming herbal
capsules which have a banned medical ingredient sibutramine (Muller et al., 2009).
A study conducted in United States by searching the published articles of herbdrug interaction stated that common herbal remedies that produce adverse effects on
the cardiovascular system include St. John’s wort, motherwort, ginseng, gingko biloba,
garlic, grapefruit juice, hawthorn, saw palmetto, danshen, echinacea, tetrandrine,
aconite, yohimbine, gynura, licorice, and black cohosh (Tachjian et al., 2010). In 2001,
the FDA issued warnings and an import alert that herbal products are unsafe if they
contain or are suspected to contain aristolochic acid (USFDA, 2001).
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The literature suggests a rate of adverse events with HS consumption of up to
10%. It was somewhat surprising, therefore, that the rate in this study was only 3%.
One reason for the lower rate found here may be because of the better monitoring and
control of HS availability in the Dubai market-place by the health authorities compared
to other countries with higher reported rates. Other reasons may be because consumers
are more knowledgeable and/or are using HS under pharmacist supervision.
The findings that adverse events often go unreported is noteworthy and may be
linked to the lack of an adverse events monitoring system in Dubai. One FDAcommissioned study estimated that FDA receives less than 1% of all adverse events
associated with dietary supplements. The study suggested that the factors that may
contribute to under-reporting are that many consumers presume supplements to be
safe, use these products without the supervision of a healthcare professional, and may
be unaware that FDA regulates them (DHHS, 2001). This strengthens the case for
raising awareness among consumers of the importance of reporting adverse events to
the appropriate authority and of establishing an HS adverse events monitoring system.
5.2.2 Second study: survey among healthcare professionals
In the healthcare professionals’ survey, although most respondents knew what
HS were and a fair proportion had participated in HS education or read journal articles
about them, the composite knowledge score indicated that only 20% could be
described as having good KAP towards HS use while 43% considered that HS were
harmless. This low level of knowledge is of concern. The findings reported here are
consistent with a study among community pharmacists in Ajman and Sharjah, UAE
(Qassim et al., 2014). These results were also similar to findings in the US and Canada
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where the knowledge towards HS was reported to be unsatisfactory (Kwan et al.,
2006).
Previous studies have likewise obtained results consistent with this view in
which poor knowledge about pharmacovigilance and ADRs reporting was reported
among community pharmacists (Afifi et al., 2014; Vessal et al., 2009; Toklu & Uysal.,
2008; Bawazir, 2006; Li et al., 2004). However, some research findings are contrary
to our results and showed good knowledge about how to report ADRs (Evans et al.,
2006; Zolezzi & Parsotam, 2005; Green et al., 2001). This difference may be due to
different study area, different sample sizes with varied demographic characteristics
and scales.
In a further study in Gujarat, India, it was found that 65% of participants were
knowledgeable about the terminology of adverse drug reactions (ADR) and 63% knew
about the role of the National Pharmacovigilance Centre, but that 60% of community
pharmacists considered all herbal products to be free from ADRs (Rathod & Panchal,
2014). Moreover, several research studies have revealed gaps in information on HS
and adverse event reporting among healthcare professionals (Cellini et al., 2013;
Oshikoya & Awobusuyi, 2009). This poor knowledge about HS may indicate a need
for improved education and training both as part of continuing professional
development and within the basic curriculum.
Nearly all healthcare professionals in this study agreed that reporting HS related
adverse events was necessary, but only 40% said they did not know where to submit
any report. The findings of US study (Cellini et al., 2013) reported that 70% of
healthcare professionals do not know where to report the adverse events associated
with HS.
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Regarding the healthcare professionals knowledge about how and where to
report ADR, our study showed that 60% of respondents were knowledgeable about the
existence of national PV program. This is in accordance with 59.3% of Ting et al.,
(2010) study and 55.9% of Qassim et al., (2014) study, whereas only 28% of
healthcare professionals in SathviK et al., ( 2014) study were knowledgeable about
ADR reporting system in the UAE. However, some research findings are contrary to
our results and showed more knowledge and awareness about local PV system
(Bawazir, 2006; Van et al., 2002; Green et al., 2001). The implications of this factor
results in that ADR go unnoticed and left unreported.
Furthermore, a KAP survey among healthcare professionals in a teaching
hospital in India reported that fewer than half (40%) of the respondents knew how to
report ADRs (Bajaj & Kumar, 2013). A possible explanation for this negative practice
in this study might be due to the fact the most healthcare professionals (77.5%) did not
know to whom to report an adverse event. In addition, most of them (74.7%) had no
training on how to report adverse events. Further, onerous demands of other work
duties coupled within adequate professional conduct compromise the reporting rate of
HS related adverse events. This may cause pharmacists to execute their services in too
short a time. Therefore, there is an essential need for educational interventions among
healthcare professionals to improve their knowledge and increase their reporting rate
of HS.
According to a study performed in Ras Al Khaimah, UAE, 18% of participant
pharmacists indicated that they reported ADR to different set-ups and 6% of them
reported ADR on at least two occasions. Moreover, only 3.6% of community
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pharmacists from Ajman and Sharjah have submitted ADR report to Ministry of Health
or pharmaceutical companies (Osama & Rana, 2014).
About half of the sample prescribed or supplied HS to patients or consumers and,
of these, about a quarter had experience of adverse events in their patients or
consumers. These are lower than the results reported by another study conducted
among military physicians, where 60% observed adverse events in their patients
associated with HS (Cellini et al., 2013). In this study, only about one fifth of those
experiencing an adverse event always reported these events.
Experiences towards HS product related adverse events play an important role
in the perception of ADR and influence how healthcare professionals will report
ADRs. In the sample, the majority reported that they felt confident when reporting an
adverse event, similar to findings in a study conducted among community pharmacists
that assessed their knowledge and attitude about ADR. It showed a positive attitude
towards ADR reporting and that respondents felt that they had an important role to
play in ADR reporting (Qassim et al., 2014).
Findings and reports from other studies have shown that a lack of knowledge
was one of the important factors that prevented healthcare professionals from advising
patients/customers on herbs and herbal preparation use in a positive way (Ghia & Jha,
2013). These findings, however, differ from the findings in this study, where literacy
and language were the most commonly identified barriers limiting discussion of HS
products. Also, a study carried out in Saudi Arabia among community pharmacists
concluded that a lack of time and a lack of reliable resources were the commonly
identified barriers (Al-Arifi, 2013). The differences with the study reported here may
be due to cultural differences.
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5.3 Strengths
An important strength of the first survey was that it used a large random sample
of the general population and, therefore, there can be confidence that the findings are
generalizable to the whole Dubai population. The sampling frame was a list of
households and mobile telephone numbers registered to each of those households.
Lists are regularly updated by the Dubai Statistics Centre. Households were randomly
sampled from each of six geographical areas in Dubai. Telephone numbers were
randomly sampled from each household. The sample obtained mirrors what is known
of the population of Dubai in terms of age, gender, nationality, education and income.
The sample size was estimated before the start of the study and was considered of
adequate power. The questionnaire was adapted from published instruments and
revised by experts to ensure content validity. It was accurately translated into Arabic
and tested to ensure the clarity of the questions and the respondents' ability to provide
accurate answers. Interviewers were trained to increase reliability and reduce
interviewer bias. The CAPI telephone interview helped to ensure a good response rate,
minimise interviewer effects and provided a good level of anonymity. The use of
mobile telephone numbers rather than fixed telephone numbers further minimised
selection bias since response was not open to those who just happened to be at home
when calls were made. Finally, the entry of data directly into the database reduced the
incidence of data entry errors and facilitated rapid data processing and analysis.
The second survey was completed on-line by participants who were invited by
e-mail to take part. Although the e-mail lists were complete and included the entire
target population, as expected, the response rate was low, selection bias affecting the
external validity of the results. Care was taken with the construction of the
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questionnaire and anonymity of the respondents was assured so that there could be
greater confidence in the internal validity of the results. Despite the lower response
rate, the sample obtained still provided adequate power.

5.4 Limitations
There were several limitations to the study. First, as with any cross-sectional
design, it is not possible to infer cause and effect or the direction of any associations
between dependent and independent variables. While there is reasonable confidence
in the generalisability of the results, selection and response bias may affect this. It has
not been possible to compare non-responders with responders to investigate further
this source of bias. Also, since the study was conducted in Dubai, it will not be directly
generalizable to other Emirates. Although based on questionnaires that had been used
in other studies, the questionnaires used in this study had not been separately validated.
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Chapter 6: Conclusion
This study included two cross-sectional surveys. The firststudy was a population
based survey with a cross-sectional design which aimed to measure HS use in Dubai
and the incidence of related adverse events. The survey was conducted by telephone
with the participation of 1,203 residents of Dubai. The study attempted to gather
information on HS consumption, local knowledge of HS, adverse events related to HS
consumption, and the reporting habit of adverse events among the population in Dubai.
The consumption of HS products is common in many countries such as the USA.
As per the findings of this study, however, this is not the case in Dubai, UAE which
has a consumption rate of only 38%. The degree of knowledge of participants about
HS may play a vital role in the reduction of adverse events associated with HS use, as
85.54% of participants in this study who had used HS had knowledge about HS.
The second study was a survey based on a cross-sectional descriptive study using
an on-line questionnaire to assess the levels of knowledge, attitude and practice (KAP)
of Dubai healthcare professionals regarding HS products and any perceived related
adverse events. The inspiration for this cross-sectional study came from a belief in the
importance of raising the awareness of HS and any related adverse events among
healthcare professionals to improve the quality of patient care. Regarding the
healthcare professional survey, improper behaviour towards HS was one of the
markers of poor knowledge. The present study revealed poor knowledge among
healthcare professionals towards HS products and HS product related adverse events.
Health professionals appear to be insufficiently knowledgeable about HS use and
any related risks among their patients/consumers. Health professionals should be
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attentive to any possible adverse health events from the use of such supplements. It is
recommended that physicians and healthcare professionals include questions about the
use of HS when acquiring a medical history from patients/consumers. It is further
recommended that all HS producers clearly label ingredients and any known side
effects of their use. Finally, and importantly, it is recommended that those considering
the use of HS in future should have their lifestyle assessed by a healthcare professional
prior to any such use.
The overall attitude of healthcare professionals was perceived to be relatively
negative. Few included HS in an adverse report to the related authorities as most did
not know to whom to report such an event. This reporting behaviour highlights several
issues and calls for a safety monitoring system for HS products. In addition, it is
possible that consumers fail to tell their physicians or pharmacists about any adverse
events arising from their use of HS. This means that the current situation may not
reveal many HS-related adverse events. There is, therefore, a need for initiatives to
raise awareness among professionals and HS users of an avenue for reporting adverse
events. Ad hoc reporting systems are at present a mainstay of detecting signals of
safety concerns associated with HS. If a suspected adverse event associated with HS
does not reach the appropriate personnel, or if a proper reporting system is not in place,
either through direct patient reporting or through reporting from healthcare
professionals, then patient safety is at risk with resultant important implications for
public health.

6.1 Managerial Implications
It is anticipated that this thesis will make a positive contribution to HS product
research and reform debate in the UAE. By assessing the current consumption rate
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among the population and the levels of knowledge of such products, by exposing some
of the related adverse events and by shedding light on the KAP levels of healthcare
professionals in Dubai, it is felt that an important knowledge gap has been filled. The
resultant recommendations should help to focus future debate and decision making at
the highest level within and among both national and local government departments
and health authorities.

6.2 Research Implications
It is hoped that this study will provide a platform for future HS research in the
UAE. The study may set the scene for an objective approach to a better understanding
of HS products eligible for inclusion in the reporting system. The study also allows
researchers to identify challenges through academic research and to make evidencebased policy recommendations that support reporting system reform activities in the
UAE. In addition, future research may be presented to policy makers at national and
international meetings, seminars and conferences.
In conclusion, this study offers a valuable contribution to HS, KAP, and
reporting system research in the UAE, and allows for international comparisons and
global benchmarking.
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Appendices
Appendix A: Prints of the Population-based Questionnaire
Section A- Demographic Data
Age
Gender
Male □
Marital status
Married □
Nationality
UAE national
□
Occupation
Student □
Health insurance
Yes □
coverage
Income
< 5000
AED □
Education
Less than high
school □
Weight (kg)
Height (cm)

Female □
Single □
Divorced □
Widow □
Non UAE national □ (Specify ……………..)
Employed □

Non-employed □
No □

5000 - <
10000 AED □
High school
□

10000 - < 20000
AED □
Graduate □

Section B- Health and Lifestyle
1
Do you have any allergy?
Yes □ (if yes, please choose from
below options)
Food □
2

Drug □

Aerosol □

4
5

20000 > AED □
Post graduate □

Don’t know □

Contact □

Other □ Specify

How frequently have you visited a doctor in the past 12 months?
□

At least once a
week
3

No □

Retired □

1-3 times a
month

□

Less than
monthly

□

Never

□

Have you ever been diagnosed with any chronic medical condition? (you can choose
more than one answer)
Respiratory disease

No

□

Yes

□

Specify

(…)

Skin disorder
Disease of the digestive
system

No
No

□
□

Yes
Yes

□
□

Specify
Specify

(…)
(…)

Specify
Specify
Specify
Specify

(…)
(…)
(…)
(…)

Diabetes
No
□
Yes
□
Cardiovascular disease
No
□
Yes
□
Cancer
No
□
Yes
□
Other
No
□
Yes
□
Have you taken prescription drugs in the past month?
Yes □ Specify (………)
No □
Do you smoke?
Every day

□

Occasionally

□

In the past □

Don’t know □
Never □
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Section C- Health Supplements Consumption

1
2

Do you know what health supplements are?
Yes □
No □
Have you ever used health supplement? (if your answer is “Currently”, please proceed to
question C4, if your answer is “Never”, please proceed to the last question of the
questionnaire)
Currently □
In the past □
Never □

3

Why did you discontinue using any health supplements? (you can choose more than one
answer)
Allergic reactions □ Serious skin disorders
Cost □ Others □ Specify (…)

4

For how long have you been using / had you used health supplement?
Less than a
More than a month
1-5 years □ > 5 years □ Don't know
month □
but less than a year □
□

□

5

6

How frequently do/did you use health supplement?
Daily or
1-4 times a 1-3 times a
Rarer than
almost daily □ week □
month □
monthly
through
the year □

Seasonally
□

Don't
know □

Which categories of health supplements do /did you use? (you can choose more than one
answer)
Vitamin □
food □

Mineral □
Herbal □
Sport nutrition □
Others □ Specify (…………………)

Energy drink

□

Dietetic

What is the form of the used product(s)? (you can choose more than one answer)
7

Tablet
□
Granules
□

8

Capsule
□

Wafers
□

Powder
□

Drink
□

Spray
□

Lozenges
□

Gel
□
Soft
gels
□

Chews/
Gummy
□
Vegicaps
□

Drops
□

Caplet
□

Gel
caps
□

Liquid
□

Chewable
tablets
□
Don’t
know
□

Which health supplement ingredient(s) do/did you use? (you can choose more than one
answer)
Alfalfa
□ Amino Acids
□ Bee Pollen
□
Bilberry/Eyebright
Caffeine,
□
□ Calcium
□
Combination
Multicomponent
Calcium & Magnesium
□ Calcium & Vitamin □ Cayenne Pepper
□
Chromium
Cimicifuga
Chondroitin
□ (Chromium
□
□
Racemosa
Picolinate)
Conjugated Linolenic
□ Creatine
□ Damiana Folia
□
Acid
Don’t Know
□ Echinacea
□ Ephedra
□
Fish Oils
□ Folate (Folic Acid) □ Fructus Cynosbati □
Gentian, MultiGarlic
□
□ Ginger
□
Component
Glandular Extract,
Ginkgo Biloba
□ Glucosamine
□
□ Multicomponent
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Grape Seed Extract
Iron (Ferrous Xxxate)
L-Cysteine
L-Methionine
Lysine
Methylsulfonyl Methane
Panax Ginseng
Pygeum Africanum
Saw Palmetto (Topical)
Spirulina,
Multicomponent
Tryptophan
Vitamin C (With Or
Without Rose Hips)
Vitamin E,
Multicomponent

10

□

Oxymatrine

□

□
□
□

□
□
□

□

Potassium
Saw Palmetto
Siberian Ginseng
St. John’s Wort,
Multicomponent
Vitamin B12

Vitamin D

□

Vitamin E

□

Vitamins A & D

□

Yohimbe, Alone

□

Zinc (Zinc
Gluconate)

□

Others Specify
(…….)

□

Kelp
Lecithin
Lutein
Magnesium
Morinda Citrifolia
(Noni)
Parsley
Royal Jelly
Selenium
St. John’s Wort

□

Vitamin B6

□
□

□
□
□
□
□
□

Yohimbe,
Multicomponent

9

□

□
□
□
□

Herbal Caffeine,
Alone
L-Carnitine
Licorice
Lycopene
Melatonin

Guarana

□
□
□
□
□

□
□
□
□

□
□

□
□
For what reason do/did you take health supplements? (you can choose more than one
answer)
Body building
Control blood
pressure
Digestive

□
□

Immune booster

□

Memory
improvement
Mood alteration

□

Prevent colds

□

Weight
management

□

□

□

Control aging
Control cholesterol
level
Energy booster

□
□

Control anemia
Detoxify

□
□

□

□

Improve overall
health
Menopausal

□

Hormone
therapy
Insomnia

□

Mental alertness

□

Organ health
Specify
(……………..)
Prevent health
problems Specify
(……………..)
Others
Specify (……..)

□

Pregnancy

□

□

Supplement my
diet

□

□

□

Where do/did you purchase health supplement(s)? (you can choose more than one answer)
Pharmacy □
Clinic □
Gym □
Nutrition shops □
Supermarket □ Other □
Specify (…….….)
How many health supplement products have you ever used?

11
1-2
12

□

3-5

□

6-10

□

> 10

□

Enter the full name of health supplement(s) you have used, including brand name.
Supplement name(s) (……………………….……………….)
Don't know □
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Section D- Information about Health Supplement Products
Who advised you to take health supplements? (you can choose more than one
1
answer)
SelfFriends/
Advertisement
Internet
recommendation
Relatives
□
□
□
□
By prescription
Health care personnel (nurse, etc.)
Other □
□
□
Specify
(………...)

2

3

How many times have health supplements been prescribed for you by your health
care practitioner?
Once □
Twice □
Several times □
Never □
Where do you seek health supplements product information? (you can choose more
than one answer)
Pharmacy □
Physician □
Producer helpline □
Internet □
Government call center □ Relatives / Friends □
Other □ Specify (...)

4

Do you find sufficient information on the label of health supplement products?
Very informative □
Somewhat informative □ Not informative □
Don’t read the label □

5

Do you think nutrition information on health supplement products is useful?
Yes □
No □
Which label information concerns you? (you can choose more than one answer)

6
Ingredients
□
Dietary
sources of
nutrients □
7

Indication
□
Claims □

Prescribed
dosages □
Precautions □

Adverse
Product
reactions □
durability □
Dosing instructions □
None □

Do you follow recommended label information?
Always □
Often □
Sometimes □

Never □
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Section E- Adverse Events Related to Health Supplement Consumption
1

2

Have you ever experienced any adverse event related to health supplement use? (if
no, please proceed to the last question of the questionnaire)
Yes □
No □
Which adverse event of health supplement use have you ever experienced? (you can
choose more than one answer)
Abdominal
pain
Dermatitis

□

Anorexia

□

Anxiety

□

Chest pain

□

Convulsions

□

□

Diarrhea

□

Dizziness

□

Dyspnea

□

Edema

□

Fatigue

□

Hair loss

□

Headache

□

Hypertension

□

Hypotension

□

Muscle
cramping
Sedation

□

Muscle
pain
Tingling

□

Nausea

□

Palpitations

□

Pyrexia

□

□

Urticaria

□

Vomiting

□

Other

□

□

Specify
(……..……...)
What was the severity of the adverse events? (you can choose more than one answer)
3

4

Mild

□

6

Severe □

Life-threatening □

How frequently have you encountered adverse events due to health supplement
consumption?
Once □

5

Moderate □

Occasionally □

Frequently □

What was the onset time of adverse events after consuming health supplement? (you
can choose more than one answer)
Less than 1 hour □
1 hour to 1 day □
More than 1 day □
How was the relation between health supplement consumption and the adverse event
confirmed? (you can choose more than one answer)

Discontinued use ceased the effect □ Not confirmed/personal opinion □
Physician opinion □ Medical diagnosis without lab confirmation □
Clinical test □
7

8

9

10

Which of the health supplement(s) you have used was suspected/confirmed to cause
the adverse event(s)?
Supplement name(s) (…………………….)
Don't know □
When visiting your health care practitioner for any reason, has he/she ever asked you
about your health supplement consumption?
Yes □
No □
How did the adverse event(s) resolve? (you can choose more than one answer) (if you
answered any but not “Hospitalization”, please proceed to question F1)
Discontinued use by personal decision □
Discontinued use by medical advice □
Medical treatment □ Hospitalization □
Resolved spontaneously □
Still
persists □
Other □ Specify (………………..)
How long have you been hospitalized due to the adverse event(s)? (you can choose
more than one answer)
Less than a day □
Few days □
More than a week □
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Section F- Reporting Adverse Events

1

2

3

4

Have you ever informed your physician about your health supplement
consumption?
Yes □
No □
Have you ever reported an adverse event related to health supplement
consumption? (if no, please proceed to the last question of the questionnaire)
Yes □
No □
Where did you report the adverse event(s)? (you can choose more than one
answer)
Pharmacy □ Physician □ Producer helpline □ Internet □ Government call center □
Hospital □
Clinic □
Police □ Others □ Specify ( ……….)
What do you think about the establishment of a surveillance system of adverse
events related to health supplement consumption?
Definitely beneficial □ Somewhat beneficial □ Not sure □ Not beneficial □
Definitely not beneficial□

Appendix B: Risk Assessment Module
Name of the chemical
hazard (Ingredient)

Associated
Risk(s)
with the
ingredient

Severity
(Level of
impact on
the Human
Health)

Probability (The
chances of that risk
happening)

Risk Score
(Risk score,
found by
combining
impact and
probability on
the risk
matrix)

Average impact
SUM (Risk
Impact values)/
number of risks
in same category

Average
probability SUM
(Risk Probability
values)/ number
of risks in same
category

Alfalfa

Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with heavy metals
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with heavy metals
Pesticides residue
Short-term
toxicity

Negligible
Low
Low
Low
Low

Low
Low
High
High
Low

Low
Medium
High
High
Medium

(1+2+2+2+2)/5
=
1.8
Low

(1+1+3+3+1)/5 =
1.8

Negligible
Low
Low
Negligible
Negligible

Low
Low
Medium
Low
Low

Low
Medium
Medium
Low
Low

(1+2+2+1+1)/5
=
1.4
Negligible

(1+2+2+1+1)/5 =
1.4

Negligible
Negligible

Low
Medium

Low
Low

(1+1+2+1+1)/5
=

(1+1+2+1+1)/5 =
1.2

Bilberry/ eyebright

Garlic

Risk Score
(Risk score,
found by
combining
average
impact and
average
probability
on the risk
matrix)
Medium

Medium

Low

Low

Low

176

Name of the chemical
hazard (Ingredient)

Ginkgo Biloba

Grape Seed Extract

Associated
Risk(s)
with the
ingredient

Severity
(Level of
impact on
the Human
Health)

Probability (The
chances of that risk
happening)

Risk Score
(Risk score,
found by
combining
impact and
probability on
the risk
matrix)

Average impact
SUM (Risk
Impact values)/
number of risks
in same category

Average
probability SUM
(Risk Probability
values)/ number
of risks in same
category

Long-term
toxicity
Interactions of
food/drugs
Contamination
with heavy metals
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with heavy metals
Pesticides residue
Short-term side
effects
Long-term
toxicity
Interactions of
medications
Contamination of
heavy metals
Pesticides residue

Low
Negligible
Negligible

Medium
Low
Low

Medium
Low
Low

1.2
Negligible

Negligible
Low
Moderate
Low
Negligible

Low
Medium
Medium
High
Low

Low
Medium
High
High
Low

(1+2+3+2+1)/5
=
1.8
Low

(1+2+2+3+1)/5 =
1.8

Negligible
Negligible
Low
Negligible
Low

Low
Low
Low
Low
Low

Low
Low
Medium
Low
Medium

(1+1+2+1+2)/5
=
1.4
Negligible

(1+1+1+1+1)/5 =
1

Risk Score
(Risk score,
found by
combining
average
impact and
average
probability
on the risk
matrix)

Low

Medium

Medium

Low

Low
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Name of the chemical
hazard (Ingredient)

Associated
Risk(s)
with the
ingredient

Severity
(Level of
impact on
the Human
Health)

Probability (The
chances of that risk
happening)

Risk Score
(Risk score,
found by
combining
impact and
probability on
the risk
matrix)

Average impact
SUM (Risk
Impact values)/
number of risks
in same category

Average
probability SUM
(Risk Probability
values)/ number
of risks in same
category

Panax Ginseng

Short-term side
effects
Long-term sideeffects
Interactions of
medications
Contamination of
heavy metals
Pesticides residue

Low
Low
Low
Low
Low

Low
Low
Medium
Low
Low

Medium
Medium
Medium
Medium
Medium

(2+2+2+2+2)/5
=
2
Low

(1+1+2+1+1)/5 =
1.2

Short-term side
effects
Long-term side
effects
Interactions of
medications
Contamination of
heavy metals
Pesticides residue
Short-term
toxicity
Long-term
toxicity

Negligible
Negligible
Moderate
Negligible
Negligible

Low
Low
Medium
Low
Low

Low
Low
High
Low
Low

(1+1+3+1+1)/5
=
1.4
Negligible

(1+1+2+1+1)/5 =
1.2

Low
Low
Negligible
Negligible

Low
Low
Low
Low

Medium
Medium
Low
Low

(2+2+1+1+2)/5
=
1.6
Low

(2+2+1+1+2)/5 =
1.6

Siberian Ginseng

Pygeum Africanum

Risk Score
(Risk score,
found by
combining
average
impact and
average
probability
on the risk
matrix)
Medium

Low

Low

Low

Medium

Medium
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Name of the chemical
hazard (Ingredient)

Saw Palmetto

L-Cysteine

Associated
Risk(s)
with the
ingredient

Severity
(Level of
impact on
the Human
Health)

Probability (The
chances of that risk
happening)

Risk Score
(Risk score,
found by
combining
impact and
probability on
the risk
matrix)

Average impact
SUM (Risk
Impact values)/
number of risks
in same category

Average
probability SUM
(Risk Probability
values)/ number
of risks in same
category

Interactions of
food/drugs
Contamination
with heavy metals
Pesticides residue
Short-term side
effects
Long-term side
effects
Interactions of
medications
Contamination of
heavy metals
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs, drug
sensitivity
Contamination
with Heavy
Metals
Pesticide Residue

Low

Low

Medium

Low
Moderate
Moderate
Low
Low

Low
Medium
Medium
Low
Low

Medium
High
High
Medium
Medium

(2+3+3+2+2)/5
= 2.4

(1+2+2+1+1)/5 =
1.4

Low

Low

Negligible
Low
Moderate
Moderate
Low

Medium
Medium
Medium
Medium
Low

Medium
Medium
High
High
Medium

(1+2+3+3+2)/5
= 2.2

(2+2+2+2+1)/5 =
1.8

Low

Medium

Risk Score
(Risk score,
found by
combining
average
impact and
average
probability
on the risk
matrix)

Medium

Medium
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Name of the chemical
hazard (Ingredient)

Associated
Risk(s)
with the
ingredient

Severity
(Level of
impact on
the Human
Health)

Probability (The
chances of that risk
happening)

Risk Score
(Risk score,
found by
combining
impact and
probability on
the risk
matrix)

Average impact
SUM (Risk
Impact values)/
number of risks
in same category

Average
probability SUM
(Risk Probability
values)/ number
of risks in same
category

L-Methionine

Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with toxicants.
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with toxicants
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs

Negligible
Moderate
Moderate
Moderate
Low

Low
Low
Medium
Low
Low

Low
Medium
High
Medium
Medium

(1+3+3+3+2)/5
= 2.4

(1+1+2+1+1)/5 =
1.2

Low

Low

Negligible
Low
Low
Low
Low

Low
Medium
Medium
Low
Low

Low
Medium
Medium
Medium
Medium

(1+2+2+2+2)/5
= 1.8

(1+2+2+2+2)/5 =
1.8

Low

Medium

Negligible
Negligible
Negligible
Negligible
Negligible

Low
Low
Low
Low
Low

Low
Low
Low
Low
Low

(1+1+1+1+1)/5
= 1

(1+1+1+1+1)/5
= 1

Negligible

Low

Lysine

Methylsulfonyl Methane

Risk Score
(Risk score,
found by
combining
average
impact and
average
probability
on the risk
matrix)

Medium

Medium

Low
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Name of the chemical
hazard (Ingredient)

Chromium
(ChromiumPicolinate)

Tryptophan

Vitamin C

Associated
Risk(s)
with the
ingredient

Contamination
with heavy metals
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with toxicants
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with toxicants
Pesticides residue
Short-term
toxicity
Long-term
toxicity

Severity
(Level of
impact on
the Human
Health)

Probability (The
chances of that risk
happening)

Risk Score
(Risk score,
found by
combining
impact and
probability on
the risk
matrix)

Average impact
SUM (Risk
Impact values)/
number of risks
in same category

Average
probability SUM
(Risk Probability
values)/ number
of risks in same
category

Negligible
Moderate
Moderate
Moderate
Low

Low
Medium
Low
Low
Medium

Low
High
Medium
Medium
Medium

(1+3+3+3+2)/5
= 2.4

(1+2+1+1+2)/5
= 1.4

Low

Low

Negligible
Moderate
Moderate
Moderate
Low

Low
Medium
High
High
Medium

Low
High
High
High
Medium

(1+3+3+3+2)/5
= 2.4

(1+2+3+3+2)/5
= 2.2

Low

Medium

Negligible
Low
Low
NA

Low
High
Medium
NA

Low
High
Medium
NA

(1+2+2)/3
= 1.67

(1+3+2)/3
= 2

Low

Medium

Risk Score
(Risk score,
found by
combining
average
impact and
average
probability
on the risk
matrix)

Medium

Medium

Medium
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Name of the chemical
hazard (Ingredient)

Amino Acids

Caffeine

Creatine

Associated
Risk(s)
with the
ingredient

Severity
(Level of
impact on
the Human
Health)

Probability (The
chances of that risk
happening)

Risk Score
(Risk score,
found by
combining
impact and
probability on
the risk
matrix)

Average impact
SUM (Risk
Impact values)/
number of risks
in same category

Average
probability SUM
(Risk Probability
values)/ number
of risks in same
category

Interactions of
food/drugs
Contamination
with toxicants
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with toxicants
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with toxicants
Pesticides residue
Short-term
toxicity

NA

NA

NA

Negligible
Low
Low
NA
NA

Low
Low
Medium
NA
NA

Low
Medium
Medium
NA
NA

(1+2+2)/3
= 1.67

(1+1+2)/3
= 1.33

Low

Low

Negligible
High
Low
NA
NA

Low
Medium
Medium
NA
NA

Low
EXTREME
Medium
NA
NA

(1+4+2)/3
= 2

(1+2+2)/3
= 1.67

Low

Medium

Negligible
Negligible

Low
Low

Low
Low

(1+1+2)/3
= 1.33

(1+1+2)/3
= 1.33

Risk Score
(Risk score,
found by
combining
average
impact and
average
probability
on the risk
matrix)

Medium

Medium
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Name of the chemical
hazard (Ingredient)

Folate (Folic Acid)

Gentian

Associated
Risk(s)
with the
ingredient

Severity
(Level of
impact on
the Human
Health)

Probability (The
chances of that risk
happening)

Risk Score
(Risk score,
found by
combining
impact and
probability on
the risk
matrix)

Long-term
toxicity
Interactions of
food/drugs
Contamination
with toxicants
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with toxicants
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with toxicants
Pesticides residue

Low
NA
NA

Medium
NA
NA

Medium
NA
NA

Negligible
Negligible
Low
NA
NA

Low
Low
Medium
NA
NA

Low
Low
Medium
NA
NA

Moderate
Moderate
High
Moderate
High

Medium
Medium
Medium
High
Medium

High
High
High
High
Extreme

Average impact
SUM (Risk
Impact values)/
number of risks
in same category

Average
probability SUM
(Risk Probability
values)/ number
of risks in same
category

Risk Score
(Risk score,
found by
combining
average
impact and
average
probability
on the risk
matrix)

Negligible

Low

Low

(1+1+2)/3
= 1.33

(1+1+2)/3
= 1.33

Low

Negligible

Low

(3+3+4+3+4)/5
= 3.4

(2+2+2+3+2)/5
= 2.2

Moderate

Medium

High
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Name of the chemical
hazard (Ingredient)

Associated
Risk(s)
with the
ingredient

Severity
(Level of
impact on
the Human
Health)

Probability (The
chances of that risk
happening)

Risk Score
(Risk score,
found by
combining
impact and
probability on
the risk
matrix)

Average impact
SUM (Risk
Impact values)/
number of risks
in same category

Average
probability SUM
(Risk Probability
values)/ number
of risks in same
category

Lecithin

Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with toxicants
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with toxicants
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs

Negligible
Negligible
Negligible
Low
Low

Low
Low
Low
Low
Medium

Low
Low
Low
Medium
Medium

(1+1+1+2+2)/5
= 1.4

(1+1+1+1+2)/5
= 1.2

Negligible

Low

Negligible
Low
Low
Low
Low

Low
Low
Low
Medium
Medium

Low
Medium
Medium
Medium
Medium

(1+2+2+2+2)/5
= 1.8

(1+1+1+2+2)/5
= 1.4

Low

Low

Negligible
Low
Low
Low
Medium

Low
Low
Medium
Low
Medium

Low
Medium
Medium
Medium
High

(1+2+2+2+3)/5
= 2

(1+1+2+1+2)/5
= 1.4

Low

Low

Lutein

Royal Jelly

Risk Score
(Risk score,
found by
combining
average
impact and
average
probability
on the risk
matrix)

Low

Medium

Medium
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Name of the chemical
hazard (Ingredient)

Selenium

Vitamin B6

Vitamin D

Associated
Risk(s)
with the
ingredient

Contamination
with heavy metals
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with heavy metals
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with toxicants
Pesticides residue
Short-term
toxicity
Long-term
toxicity

Severity
(Level of
impact on
the Human
Health)

Probability (The
chances of that risk
happening)

Risk Score
(Risk score,
found by
combining
impact and
probability on
the risk
matrix)

Average impact
SUM (Risk
Impact values)/
number of risks
in same category

Average
probability SUM
(Risk Probability
values)/ number
of risks in same
category

Low
Moderate
Moderate
Moderate
High

Low
Medium
Medium
Medium
Medium

Medium
High
High
High
Extreme

(2+3+3+3+4)/5
= 3

(1+2+2+2+2)/5
= 1.8

Moderate

Medium

Negligible
Negligible
Negligible
NA
NA

Medium
Medium
High
NA
NA

Low
Low
Medium
NA
NA

(1+1+1)/3
= 1

(2+2+3)/3
= 2.33

Negligible

Medium

Negligible
Negligible
Low
NA

High
High
Medium
NA

Medium
Medium
Medium
NA

(1+1+2)/3
= 1.33

(3+3+2)/3
= 2.67

Negligible

High

Risk Score
(Risk score,
found by
combining
average
impact and
average
probability
on the risk
matrix)

High

Low

Medium
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Name of the chemical
hazard (Ingredient)

Glucosamine

L-Carnitine

Potassium

Associated
Risk(s)
with the
ingredient

Severity
(Level of
impact on
the Human
Health)

Probability (The
chances of that risk
happening)

Risk Score
(Risk score,
found by
combining
impact and
probability on
the risk
matrix)

Average impact
SUM (Risk
Impact values)/
number of risks
in same category

Average
probability SUM
(Risk Probability
values)/ number
of risks in same
category

Interactions of
food/drugs
Contamination
with toxicants
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with toxicants
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with toxicants
Pesticides residue
Short-term
toxicity

NA

NA

NA

Negligible
Low
Moderate
Negligible
Negligible

Medium
Medium
Medium
Medium
Medium

Low
Medium
High
Low
Low

(1+2+3+1+1)/5
= 1.6

(2+2+2+2+2)/5
= 2

Low

Medium

Negligible
Low
Negligible
Negligible
Negligible

High
Low
Medium
Medium
Medium

Medium
Medium
Low
Low
Low

(1+2+1+1+1)/5
= 1.2

(3+1+2+2+2)/5
= 2

Negligible

Medium

Negligible
Negligible

Low
Medium

Low
Low

(1+1+2)/3
= 1.33

(1+2+2)/3
= 1.67

Risk Score
(Risk score,
found by
combining
average
impact and
average
probability
on the risk
matrix)

Medium

Low
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Name of the chemical
hazard (Ingredient)

Vitamin B12

Vitamin E

Associated
Risk(s)
with the
ingredient

Severity
(Level of
impact on
the Human
Health)

Probability (The
chances of that risk
happening)

Risk Score
(Risk score,
found by
combining
impact and
probability on
the risk
matrix)

Long-term
toxicity
Interactions of
food/drugs
Contamination
with toxicants
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with toxicants
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with toxicants
Pesticides residue

Low
NA
NA

Medium
NA
NA

Medium
NA
NA

Negligible
Negligible
Low
NA
NA

Medium
Medium
Medium
NA
NA

Low
Low
Medium
NA
NA

Negligible
Negligible
Negligible
NA
NA

Low
Medium
High
NA
NA

Low
Low
Medium
NA
NA

Average impact
SUM (Risk
Impact values)/
number of risks
in same category

Average
probability SUM
(Risk Probability
values)/ number
of risks in same
category

Risk Score
(Risk score,
found by
combining
average
impact and
average
probability
on the risk
matrix)

Negligible

Medium

Low

(1+1+2)/3
= 1.33

(2+2+2)/3
= 2

Negligible

Medium

(1+1+1)/3
= 1

(1+2+3)/3
= 2

Negligible

Medium

Low

Low
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Name of the chemical
hazard (Ingredient)

Associated
Risk(s)
with the
ingredient

Severity
(Level of
impact on
the Human
Health)

Probability (The
chances of that risk
happening)

Risk Score
(Risk score,
found by
combining
impact and
probability on
the risk
matrix)

Average impact
SUM (Risk
Impact values)/
number of risks
in same category

Average
probability SUM
(Risk Probability
values)/ number
of risks in same
category

Vitamins A & D

Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with toxicants
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with toxicants
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs

Negligible
Low
Low
NA
NA

Low
High
Medium
NA
NA

Low
High
Medium
NA
NA

(1+2+2)/3
= 1.67

(1+3+2)/3
= 2

Low

Medium

Negligible
Low
Negligible
NA
NA

High
Medium
Medium
NA
NA

Medium
Medium
Low
NA
NA

(1+2+1)/3
= 1.33

(2+2+1)/3
= 1.67

Negligible

Medium

Low

Low
Negligible
Low
Low
Moderate

Medium
Low
Low
Medium
Medium

Medium
Low
Medium
Medium
High

(2+1+2+2+3)/5
= 2

(2+1+1+2+2)/5
= 1.6

Medium

Low

Medium

Zinc

Bee Pollen

Risk Score
(Risk score,
found by
combining
average
impact and
average
probability
on the risk
matrix)

Medium
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Name of the chemical
hazard (Ingredient)

Spirulina

Echinacea

Glandular Extract

Associated
Risk(s)
with the
ingredient

Contamination
with heavy metals
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with heavy metals
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with heavy metals
Pesticides residue
Short-term
toxicity
Long-term
toxicity

Severity
(Level of
impact on
the Human
Health)

Probability (The
chances of that risk
happening)

Risk Score
(Risk score,
found by
combining
impact and
probability on
the risk
matrix)

Average impact
SUM (Risk
Impact values)/
number of risks
in same category

Average
probability SUM
(Risk Probability
values)/ number
of risks in same
category

Low
Low
Low
Moderate
Low

Low
Low
Low
High
Low

Medium
Medium
Medium
High
Medium

(2+2+2+3+2)/5
= 2.2

(1+1+1+3+1)/5
= 1.4

Low

Low

Low
High
High
Low
Negligible

Medium
Low
Low
Low
Low

Medium
High
High
Medium
Low

(2+4+4+2+1)/5
= 2.6

(2+1+1+1+1)/5
= 1.2

Moderate

Low

High
High
High
NA

High
High
Low
NA

Extreme
Extreme
High
NA

(4+4+4)/3
= 4

(3+3+1)/3
= 2.33

High

Medium

Risk Score
(Risk score,
found by
combining
average
impact and
average
probability
on the risk
matrix)

Medium

Medium

Extreme
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Name of the chemical
hazard (Ingredient)

Guarana

Kelp

Morinda Citrifolia

Associated
Risk(s)
with the
ingredient

Severity
(Level of
impact on
the Human
Health)

Probability (The
chances of that risk
happening)

Risk Score
(Risk score,
found by
combining
impact and
probability on
the risk
matrix)

Interactions of
food/drugs
Contamination
with heavy metals
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with heavy metals
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with heavy metals
Pesticides residue
Short-term
toxicity

NA

NA

NA

Low
Low
Moderate
Low
Low

Medium
Medium
Medium
Low
Low

Medium
Medium
High
Low
Low

Moderate
Moderate
Moderate
Low
Low

Low
Low
Low
Low
Low

Medium
Medium
Medium
Medium
Medium

Negligible
Negligible

Low
Low

Low
Low

Average impact
SUM (Risk
Impact values)/
number of risks
in same category

Average
probability SUM
(Risk Probability
values)/ number
of risks in same
category

(2+2+3+2+2)/5
= 2.2

(2+2+2+1+1)/5
= 1.6

Low

Medium

(3+3+3+2+2)/5
= 2.6

(1+1+1+1+1)/5
= 1

Moderate

Low

(1+1+2+1+2)/5
= 1.4

(1+1+1+1+1)/5
= 1

Risk Score
(Risk score,
found by
combining
average
impact and
average
probability
on the risk
matrix)

Medium

Medium
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Name of the chemical
hazard (Ingredient)

Parsley

St. John’s Wort

Associated
Risk(s)
with the
ingredient

Severity
(Level of
impact on
the Human
Health)

Probability (The
chances of that risk
happening)

Risk Score
(Risk score,
found by
combining
impact and
probability on
the risk
matrix)

Average impact
SUM (Risk
Impact values)/
number of risks
in same category

Average
probability SUM
(Risk Probability
values)/ number
of risks in same
category

Risk Score
(Risk score,
found by
combining
average
impact and
average
probability
on the risk
matrix)

Long-term
toxicity
Interactions of
food/drugs
Contamination
with heavy metals
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with heavy metals
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with heavy metals
Pesticides residue

Low
Negligible
Low

Low
Low
Low

Medium
Low
Medium

Negligible

Low

Low

Negligible
Negligible
Moderate
Negligible
Moderate

Low
Low
Low
Low
Low

Low
Low
Medium
Low
Medium

(1+1+3+1+3)/5
= 1.8

(1+1+1+1+1)/5
= 1

Low

Low

Moderate
Moderate
High
Low
Low

Medium
Medium
High
Low
Low

High
High
Extreme
Medium
Medium

(3+3+4+2+2)/5
= 2.8

(2+2+3+1+1)/5
= 1.8

Moderate

Medium

Medium

High
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Name of the chemical
hazard (Ingredient)

Associated
Risk(s)
with the
ingredient

Severity
(Level of
impact on
the Human
Health)

Probability (The
chances of that risk
happening)

Risk Score
(Risk score,
found by
combining
impact and
probability on
the risk
matrix)

Average impact
SUM (Risk
Impact values)/
number of risks
in same category

Average
probability SUM
(Risk Probability
values)/ number
of risks in same
category

Cayenne Pepper

Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with heavy metals
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with heavy metals
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs

Low
High
Moderate
Low
Negligible

Medium
Low
Medium
Low
Low

Medium
High
High
Medium
Low

(2+4+3+2+1)/5
= 2.4

(2+1+2+1+1)/5
= 1.4

Low

Low

Low
High
High
Low
Negligible

Low
Low
Medium
Low
Low

Medium
High
Extreme
Medium
Low

(2+4+4+2+1)/5
= 3

(1+1+2+1+1)/5
= 1.2

Moderate

Low

Low
High
Moderate
Moderate
Low

Medium
Low
Medium
Medium
Low

Medium
High
High
High
Medium

(2+4+3+3+2)/5
= 2.8

(2+1+2+2+1)/5
= 1.6

Moderate

Medium

Cimicifuga Racemosa

Damiana Folia

Risk Score
(Risk score,
found by
combining
average
impact and
average
probability
on the risk
matrix)

Medium

Medium

High
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Name of the chemical
hazard (Ingredient)

Ephedra

Fructus Cynosbati

Ginger

Associated
Risk(s)
with the
ingredient

Contamination
with heavy metals
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with heavy metals
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with heavy metals
Pesticides residue
Short-term
toxicity
Long-term
toxicity

Severity
(Level of
impact on
the Human
Health)

Probability (The
chances of that risk
happening)

Risk Score
(Risk score,
found by
combining
impact and
probability on
the risk
matrix)

Average impact
SUM (Risk
Impact values)/
number of risks
in same category

Average
probability SUM
(Risk Probability
values)/ number
of risks in same
category

Low
High
High
High
Low

Medium
Medium
Medium
Medium
Low

Medium
Extreme
Extreme
Extreme
Medium

(2+4+4+4+2)/5
= 3.2

(2+2+2+2+1)/5
= 1.8

Moderate

Medium

Negligible
Moderate
Moderate
Moderate
Low

Medium
Low
Medium
Low
Low

Low
Medium
High
Medium
Medium

(1+3+3+3+2)/5
= 2.4

(2+1+2+1+1)/5
= 1.4

Low

Low

Negligible
Low
Moderate
Negligible

Low
Low
Low
Low

Low
Medium
Medium
Low

(1+2+3+1+2)/5
= 1.6

(1+1+1+1+1)/5
= 1

Low

Low

Risk Score
(Risk score,
found by
combining
average
impact and
average
probability
on the risk
matrix)

High

Medium

Medium
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Name of the chemical
hazard (Ingredient)

Licorice

Lycopene

Melatonin

Associated
Risk(s)
with the
ingredient

Severity
(Level of
impact on
the Human
Health)

Probability (The
chances of that risk
happening)

Risk Score
(Risk score,
found by
combining
impact and
probability on
the risk
matrix)

Average impact
SUM (Risk
Impact values)/
number of risks
in same category

Average
probability SUM
(Risk Probability
values)/ number
of risks in same
category

Interactions of
food/drugs
Contamination
with heavy metals
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with heavy metals
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with heavy metals
Pesticides residue
Short-term
toxicity

Low

Low

Medium

Negligible
Negligible
Low
Moderate
Negligible

Low
Low
Medium
Medium
Low

Negligible
Negligible
Low
Negligible
Negligible

Low
Low

Risk Score
(Risk score,
found by
combining
average
impact and
average
probability
on the risk
matrix)

Low
Low
Medium
High
Low

(1+1+2+3+1)/5
= 1.6

(1+1+2+2+1)/5
= 1.4

Low

Low

Medium

Low
Low
Medium
Low
Low

Low
Low
Medium
Low
Low

(1+1+2+1+1)/5
= 1.2

(1+1+2+1+1)/5
= 1.2

Low

Negligible

Low

Low
High

Medium
High

(2+2+3)/3
= 2.33

(1+3+2)/3
= 2

Medium
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Name of the chemical
hazard (Ingredient)

Oxymatrine

Yohimbe

Associated
Risk(s)
with the
ingredient

Severity
(Level of
impact on
the Human
Health)

Probability (The
chances of that risk
happening)

Risk Score
(Risk score,
found by
combining
impact and
probability on
the risk
matrix)

Long-term
toxicity
Interactions of
food/drugs
Contamination
with heavy metals
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with heavy metals
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with heavy metals
Pesticides residue

Moderate
NA
NA

Medium
NA
NA

High
NA
NA

Low
Negligible
Negligible
Negligible
Negligible

Medium
Low
Low
Low
Low

Medium
Low
Low
Low
Low

High
High
High
Moderate
Moderate

High
High
High
Medium
Medium

Extreme
Extreme
Extreme
High
High

Average impact
SUM (Risk
Impact values)/
number of risks
in same category

Average
probability SUM
(Risk Probability
values)/ number
of risks in same
category

Low

Medium

(2+1+1+1+1)/5
= 1.2

(2+1+1+1+1)/5
= 1.2

Negligible

Low

(4+4+4+3+3)/5
= 3.6

(3+3+3+2+2)/5
= 2.6

High

High

Risk Score
(Risk score,
found by
combining
average
impact and
average
probability
on the risk
matrix)

Low

Extreme
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Name of the chemical
hazard (Ingredient)

Associated
Risk(s)
with the
ingredient

Severity
(Level of
impact on
the Human
Health)

Probability (The
chances of that risk
happening)

Risk Score
(Risk score,
found by
combining
impact and
probability on
the risk
matrix)

Average impact
SUM (Risk
Impact values)/
number of risks
in same category

Average
probability SUM
(Risk Probability
values)/ number
of risks in same
category

Calcium

Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with heavy metals
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with heavy metals
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs

Negligible
Low
Moderate
NA
NA

Low
Low
Medium
NA
NA

Low
Medium
High
NA
NA

(1+2+3)/3
= 2

(1+1+2)/3
= 1.33

Low

Low

Negligible
Low
Moderate
NA
NA

Low
Low
Medium
NA
NA

Low
Medium
High
NA
NA

(1+2+3)/3
= 2

(1+1+2)/3
= 1.33

Low

Low

Negligible
Low
Low
Moderate
NA

Low
Low
Low
Low
NA

Low
Medium
Medium
Medium
NA

(1+2+2+3)/4
= 2

(1+1+1+1)/4
= 1

Low

Low

Magnesium

Chondroitin

Risk Score
(Risk score,
found by
combining
average
impact and
average
probability
on the risk
matrix)
Medium

Medium

Medium
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Name of the chemical
hazard (Ingredient)

Conjugated Linolenic Acid

Fish Oils

Associated
Risk(s)
with the
ingredient

Contamination
with heavy metals
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with heavy metals
Pesticides residue
Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with heavy metals
Pesticides residue

Severity
(Level of
impact on
the Human
Health)

Probability (The
chances of that risk
happening)

Low
Moderate
Moderate
Low
NA

Medium
Low
Medium
Low
NA

Negligible
Moderate
Moderate
Moderate
Moderate

Medium
Low
Medium
Medium
Medium

Risk Score
(Risk score,
found by
combining
impact and
probability on
the risk
matrix)

Medium
Medium
High
Medium
NA

Low
Medium
High
High
High

Average impact
SUM (Risk
Impact values)/
number of risks
in same category

Average
probability SUM
(Risk Probability
values)/ number
of risks in same
category

(2+3+3+2)/4
= 2.5

(2+1+2+1)/4
= 1.5

Moderate

Medium

(1+3+3+3+3)/5
= 2.6

(2+1+2+2+2)/5
= 1.8

Moderate

Medium

Risk Score
(Risk score,
found by
combining
average
impact and
average
probability
on the risk
matrix)

High

High
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Name of the chemical
hazard (Ingredient)

Associated
Risk(s)
with the
ingredient

Severity
(Level of
impact on
the Human
Health)

Probability (The
chances of that risk
happening)

Risk Score
(Risk score,
found by
combining
impact and
probability on
the risk
matrix)

Average impact
SUM (Risk
Impact values)/
number of risks
in same category

Average
probability SUM
(Risk Probability
values)/ number
of risks in same
category

Iron

Short-term
toxicity
Long-term
toxicity
Interactions of
food/drugs
Contamination
with heavy metals
Pesticides residue

Low
High
Moderate
Low
Negligible

Medium
Low
Medium
Medium
Low

Medium
High
High
Medium
Low

(2+4+3+2+1)/5
= 2.4

(2+1+2+2+1)/5
= 1.6

Low

Medium

Risk Score
(Risk score,
found by
combining
average
impact and
average
probability
on the risk
matrix)
Medium
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Appendix C: Risk Assessment Matrix

NEGLIGIBLE 1
small/unimportant not likely
to have a major effect on
Human Health

Probability

LOW 1
risk has rarely been a
problem
MEDIUM 2
risk most likely occurs
with this ingredient
HIGH 3
risk will occur and
associated with the use
of this ingredient

LOW 2
minimal
importance has an
effect on Human
and impact on
health

Severity
MODERATE 3
serious/important will affect the
human health
significantly/suffers serious
injuries/requires immediate
action

HIGH 4
maximum importance could
result in disaster/death/serious
injuries or toxicity

LOW
1

MEDIUM
2

MEDIUM
3

HIGH
4

LOW
2

MEDIUM
4

HIGH
6

EXTREME
8

MEDIUM
3

HIGH
6

HIGH
9

EXTREME
12
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Negligible coded as (1) for small/unimportant that not likely to have a major effect on
human health, Low coded as (2) for an effect on human and impact on the health/requires
medical treatment, Moderate coded as (3) for serious/important that will affect the human
health significantly/suffers serious injuries requires immediate action, High coded as (4) for
maximum importance that could result in disaster/death/serious injuries or toxicity.

The probability of the risk matrix was ranging from Low coded as (1) for risk has
rarely been a problem, Medium coded as (2) for This risk will most likely occur with this
ingredient, and High coded as (3) for the risk will occur and associated with the use of this
ingredient/possibly multiple times, and has occurred in the past.
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Appendix D: Individual Ingredient Overall Risk Score
Alfalfa scored low as an average score of severity level of impact on the human
health, and scored medium as an average score of probability level of chances of that
risk happening (Soto-Zarazúa et al., 2016; CPSS, 2015). The final score was medium.

Bilberry/ eyebright scored negligible as an average score of severity level of
impact on the human health, and scored low as an average score of probability level
of chances of that risk happening (Rouhi-Boroujeni et al., 2015; CPSS 2015). The final
score was low.

Garlic scored negligible as an average score of severity level of impact on the
human health, and scored low as an average score of probability level of chances of
that risk happening (EMA, 2016; Nethathe & Russell, 2014; CPSS, 2015). The final
score was low.

Ginkgo Biloba scored low as an average score of severity level of impact on
the human health, and scored medium as an average score of probability level of
chances of that risk happening (Edwards et al., 2015; Diamond & Bailey, 2013;
Nethathe & Russell, 2014; CPSS, 2015). The final score was medium.

Grape Seed Extract scored negligible as an average score of severity level of
impact on the human health, and scored low as an average score of probability level
of chances of that risk happening (UMMC, 2015; Nieto-García et al, 2014; CPSS,
2015). The final score was low.

Panax Ginseng scored low as an average score of severity level of impact on
the human health, and scored low as an average score of probability level of chances
of that risk happening (Lee et al., 2012; Kiefer & Pantuso, 2003; Popovich et al., 2011;
Nethathe & Russell, 2014; CPSS, 2015). The final score was medium.

Siberian Ginseng scored negligible as an average score of severity level of
impact on the human health, and scored low as an average score of probability level
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of chances of that risk happening (Cicero et al., 2004; Kiefer & Pantuso, 2003; CPSS,
2015). The final score was low.

Pygeum Africanum scored low as an average score of severity level of impact
on the human health, and scored medium as an average score of probability level of
chances of that risk happening (Moyad, 2014; CPSS, 2015). The final score was
medium.

Saw Palmetto scored low as an average score of severity level of impact on the
human health, and scored low as an average score of probability level of chances of
that risk happening (Avins et al., 2013; CPSS, 2015). The final score was medium.

L-Cysteine scored low as an average score of severity level of impact on the
human health, and scored medium as an average score of probability level of chances
of that risk happening (McGavigan et al., 2015; CPSS, 2015). The final score was
medium.

L-Methionine scored low as an average score of severity level of impact on the
human health, and scored low as an average score of probability level of chances of
that risk happening (Tapia-Rojas et al., 2015; CPSS, 2015). The final score was
medium.

Lysine scored low as an average score of severity level of impact on the human
health, and scored medium as an average score of probability level of chances of that
risk happening (Huang et al., 2016; CPSS, 2015). The final score was medium.

Methylsulfonyl Methane scored negligible as an average score of severity level
of impact on the human health, and scored low as an average score of probability level
of chances of that risk happening (Johansson et al., 1998; CPSS, 2015). The final score
was low.

Chromium (Chromium Picolinate) scored low as an average score of severity
level of impact on the human health, and scored low as an average score of probability
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level of chances of that risk happening (Thompson et al., 2013; Sun et al., 2015; CPSS,
2015). The final score was medium.

Tryptophan scored low as an average score of severity level of impact on the
human health, and scored medium as an average score of probability level of chances
of that risk happening (Oketch-Rabah et al., 2016; CPSS, 2015). The final score was
medium.

Vitamin C scored low as an average score of severity level of impact on the
human health, and scored medium as an average score of probability level of chances
of that risk happening (NIH, 2016; Costa et al., 2015; Jemaa et al., 2017; Nađpal et al.,
2016; NIH, 2016; CPSS, 2015). The final score was medium.

Amino Acids scored low as an average score of severity level of impact on the
human health, and scored low as an average score of probability level of chances of
that risk happening (Zhenyukh et al., 2017; CPSS, 2015). The final score was medium.

Caffeine scored low as an average score of severity level of impact on the
human health, and scored medium as an average score of probability level of chances
of that risk happening (Gurley et al., 2015; Campana, 2014; Jabbar & Hanly, 2013;
CPSS, 2015). The final score was medium.

Creatine scored negligible as an average score of severity level of impact on
the human health, and scored low as an average score of probability level of chances
of that risk happening (Dickinson et al., 2014; CPSS, 2015). The final score was low.

Folate (Folic Acid) scored negligible as an average score of severity level of
impact on the human health, and scored low as an average score of probability level
of chances of that risk happening (Manshadi et al., 2014; Zhao et al., 2014; CPSS,
2015). The final score was low.

Gentian scored moderate as an average score of severity level of impact on the
human health, and scored medium as an average score of probability level of chances
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of that risk happening (Akileshwari et al., 2012; Huang et al., 2015; CPSS, 2015). The
final score was high.

Lecithin scored negligible as an average score of severity level of impact on
the human health, and scored low as an average score of probability level of chances
of that risk happening (Chen et al., 2015; CPSS, 2015). The final score was low.

Lutein scored low as an average score of severity level of impact on the human
health, and scored low as an average score of probability level of chances of that risk
happening (Olmedilla-Alonso et al., 2014; CPSS, 2015). The final score was medium.

Royal Jelly scored low as an average score of severity level of impact on the
human health, and scored low as an average score of probability level of chances of
that risk happening (Karaca et al., 2010; CPSS, 2015). The final score was medium.

Selenium scored moderate as an average score of severity level of impact on
the human health, and scored medium as an average score of probability level of
chances of that risk happening (Yang & Jia, 2014; CPSS, 2015). The final score was
high.

Vitamin B6 scored negligible as an average score of severity level of impact
on the human health, and scored medium as an average score of probability level of
chances of that risk happening (Zhang et al., 2013; CPSS, 2015). The final score was
low.

Vitamin D scored negligible as an average score of severity level of impact on
the human health, and scored high as an average score of probability level of chances
of that risk happening (Reis et al., 2009; CPSS, 2015). The final score was medium.

Glucosamine scored low as an average score of severity level of impact on the
human health, and scored medium as an average score of probability level of chances
of that risk happening (Jacobs et al., 2013; CPSS, 2015). The final score was medium.
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L-Carnitine scored negligible as an average score of severity level of impact
on the human health, and scored medium as an average score of probability level of
chances of that risk happening (Serban et al., 2016; CPSS, 2015). The final score was
low.

Potassium scored negligible as an average score of severity level of impact on
the human health, and scored medium as an average score of probability level of
chances of that risk happening (Chatterjee et al., 2010; CPSS, 2015). The final score
was low.

Vitamin B12 scored negligible as an average score of severity level of impact
on the human health, and scored medium as an average score of probability level of
chances of that risk happening (Gröber et al., 2013; CPSS, 2015). The final score was
low.

Vitamin E scored negligible as an average score of severity level of impact on
the human health, and scored medium as an average score of probability level of
chances of that risk happening (Ledesma et al., 2011; CPSS, 2015). The final score
was low.

Vitamins A & D scored low as an average score of severity level of impact on
the human health, and scored medium as an average score of probability level of
chances of that risk happening (Ergin et al., 2013; CPSS, 2015). The final score was
medium.

Zinc scored negligible as an average score of severity level of impact on the
human health, and scored medium as an average score of probability level of chances
of that risk happening (Plum et al., 2010; CPSS, 2015). The final score was low.

Bee Pollen scored low as an average score of severity level of impact on the
human health, and scored medium as an average score of probability level of chances
of that risk happening (Petersen, 1977; CPSS, 2015). The final score was medium.
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Spirulina scored low as an average score of severity level of impact on the
human health, and scored low as an average score of probability level of chances of
that risk happening (Pilkington & CAM-Cancer Consortium, 2015; Karkos et al.,
2010; UMMC, 2013; CPSS, 2015). The final score was medium.

Echinacea scored moderate as an average score of severity level of impact on
the human health, and scored low as an average score of probability level of chances
of that risk happening (Karsch‐Völk et al., 2014; Lawrenson et al., 2014; CPSS, 2015).
The final score was medium.

Glandular Extract scored high as an average score of severity level of impact
on the human health, and scored medium as an average score of probability level of
chances of that risk happening (Hadayer & Schaal, 2016; Gangwar et al., 2015; CPSS,
2015). The final score was extreme.

Guarana scored low as an average score of severity level of impact on the
human health, and scored medium as an average score of probability level of chances
of that risk happening (da Costa Krewer et al., 2014; CPSS, 2015). The final score was
medium.

Kelp scored moderate as an average score of severity level of impact on the
human health, and scored low as an average score of probability level of chances of
that risk happening (Barton & McLean, 2013; Rosen et al., 2014; CPSS, 2015). The
final score was medium.

Morinda Citrifolia scored negligible as an average score of severity level of
impact on the human health, and scored low as an average score of probability level
of chances of that risk happening (Assi et al., 2015; CPSS, 2015). The final score was
low.

Parsley scored low as an average score of severity level of impact on the human
health, and scored low as an average score of probability level of chances of that risk
happening (Khosravan et al., 2017; CPSS, 2015). The final score was medium.
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St. John’s Wort scored moderate as an average score of severity level of impact
on the human health, and scored medium as an average score of probability level of
chances of that risk happening (Knuppel & Linde, 2004; Cui & Zheng, 2016;
Hohmann et al., 2016; CPSS, 2015). The final score was high.

Cayenne Pepper scored low as an average score of severity level of impact on
the human health, and scored low as an average score of probability level of chances
of that risk happening (Nantakornsuttanan et al., 2016; CPSS, 2015). The final score
was medium.

Cimicifuga Racemosa scored moderate as an average score of severity level of
impact on the human health, and scored low as an average score of probability level
of chances of that risk happening (Wuttke & Seidlová-Wuttke, 2015; CPSS, 2015).
The final score was medium.

Damiana Folia scored moderate as an average score of severity level of impact
on the human health, and scored medium as an average score of probability level of
chances of that risk happening (Avelino-Flores et al., 2015; CPSS, 2015). The final
score was high.

Ephedra scored moderate as an average score of severity level of impact on the
human health, and scored medium as an average score of probability level of chances
of that risk happening (Council for Responsible Nutrition, 2003; CPSS, 2015). The
final score was high.

Fructus Cynosbati scored low as an average score of severity level of impact
on the human health, and scored low as an average score of probability level of chances
of that risk happening (Andersson et al., 2012; CPSS 2015). The final score was
medium.

Ginger scored low as an average score of severity level of impact on the human
health, and scored low as an average score of probability level of chances of that risk
happening (Kafeshani, 2015; CPSS, 2015). The final score was medium.

208
Licorice scored low as an average score of severity level of impact on the
human health, and scored low as an average score of probability level of chances of
that risk happening (Qiao et al., 2014; Hruby et al., 2013; CPSS, 2015). The final score
was medium.

Lycopene scored negligible as an average score of severity level of impact on
the human health, and scored low as an average score of probability level of chances
of that risk happening (Selvan et al., 2014; Viuda-Martos et al., 2014; CPSS, 2015).
The final score was low.

Melatonin scored low as an average score of severity level of impact on the
human health, and scored medium as an average score of probability level of chances
of that risk happening (Hartz et al., 2015; CPSS, 2015). The final score was medium.

Oxymatrine scored negligible as an average score of severity level of impact
on the human health, and scored low as an average score of probability level of chances
of that risk happening (Lu et al., 2015; CPSS, 2015). The final score was low.

Yohimbe scored high as an average score of severity level of impact on the
human health, and scored high as an average score of probability level of chances of
that risk happening (NIH, 2016; Wongkrajang et al., 2014; CPSS, 2015). The final
score was extreme.

Calcium scored low as an average score of severity level of impact on the
human health, and scored low as an average score of probability level of chances of
that risk happening (Quinn et al., 2013; CPSS, 2015). The final score was medium.

Magnesium scored low as an average score of severity level of impact on the
human health, and scored low as an average score of probability level of chances of
that risk happening (Hruby et al., 2013; CPSS, 2015). The final score was medium.
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Chondroitin scored low as an average score of severity level of impact on the
human health, and scored low as an average score of probability level of chances of
that risk happening (UMMC, 2015; CPSS, 2015). The final score was medium.

Conjugated Linolenic Acid scored moderate as an average score of severity
level of impact on the human health, and scored medium as an average score of
probability level of chances of that risk happening (Koba & Yanagita, 2014; CPSS,
2015). The final score was high.

Fish Oils Acid scored moderate as an average score of severity level of impact
on the human health, and scored medium as an average score of probability level of
chances of that risk happening (Mason & Sherratt, 2016; CPSS, 2015). The final score
was high.

Iron scored low as an average score of severity level of impact on the human
health, and scored medium as an average score of probability level of chances of that
risk happening (Aigner et al., 2015; CPSS, 2015). The final score was medium.
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Appendix E: Information Sheet A
Title of project: Health supplement use and related adverse events in Dubai
You are being invited to take part in a research study. Before you decide it is
important for you to understand why the research is being done and what it will
involve. Please take time to read the following information carefully and discuss it
with others if you wish. Ask us if there is anything that is not clear or if you would like
more information. Take time to decide if you wish to take part.
Several of several chemicals within the content of health supplement products
(HS) may affect human health by inducing certain adverse events. Previous studies
found that consumers are generally unaware regarding HS risks, its associated adverse
events and proper reporting process to concerned authorities. This study aims to
conduct a population based cross-sectional survey to identify the prevalence of HS
consumption in the population of Dubai and the adverse events related to HS
consumption. It is up to you to decide to take part or not. If you decide to take part you
are still free to withdraw at any time and without giving a reason. The information and
opinions you provide will be kept strictly confidential and used only for research
purposes. Your name and details cannot be linked to this survey and will not be
identified in any report/publication. The completion and submission of the electronic
questionnaire indicates the agreement for participation and acts as signature of the
consent form.
The study is sponsored by the College of Medicine and Health Sciences of the
United Arab Emirates University as well as Dubai Municipality and reviewed by the
Al Ain Medical District Human Research Ethics Committee.

For any further information regarding the study, please contact:

Naseem M. R. Abdulla
Tel: +971 45035554
E-mail: nmrafee@gmail.com
5 March 2015
Thank you very much for participating in the study.
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Appendix F: Prints of the healthcare professionals questionnaire
Section A. Demographic Data
Age
Gender
Marital status

Male

□

Female

□

Married □

Single □

Divorced □

Widow □

Nationality
Employment
status
Title
Work
experience
Insurance
coverage
Education

Drop down list in on-line questionnaire
Government □
Physician □

Private □

Self-employed □

Specialized physician □

Assistant pharmacist □

Pharmacist □

Other □ Specify (…………...…)

Less than 1 year □
5-6 years □

1-2 years □

3-4 years □

More than 6 years □
Yes

Graduate □

□ No □
Post graduate □
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Section B. Knowledge
1
2
3

4

5

6

7

8

9

Do you know what health supplements are?

Yes

□

No □

Don’t know □
Please, list as many health supplements as you can.

(…………………..)

Do you agree with the statement that health

Yes

supplements?
Please, list as many adverse events of health

D

on’t know □

supplements are harmless?
Do you know about adverse events of health

□ No □

□ No □

Yes

D

on’t know □
(…………………..)

supplements as you can.
Do you know what surveillance system is?

Yes

□ No □

Don’t know □

Do you know about any existing surveillance system

Yes □ Specify

in the UAE?

(……) No □

Do you know about any adverse event reporting system

Yes □ Specify

in your institution/organization?

(……) No □

Do you know to whom you can report an adverse

Yes

□

No □

event?
Have you ever received any continuing education on
health supplement products?

No □ Electronic
learning □ Product
orientation
(Principle) □

10

Official training
courses □ Other □
Specify (…)
11

12

Have you read a scientific article related to adverse

Yes

□

No □

Yes

□

No □

events of health supplements in the last 6 months?
Have you ever received training on how to report an
adverse event?

213
Section C. Practice

1

2

3

Do you sell/prescribe/dispense any
health supplements at practice site?
(if your answer is “No”, please
proceed to section D)

□

Yes

No □

Which type of health supplements do
you usually
prescribe/advice/dispense? (you can
choose more than one answer)

Dietetic □ Energy drink
□ Food □ Herbal □

Which form of health supplements
do you usually
prescribe/advice/dispense?

Caplets □ Capsule □ Chewable □
tablets

(you can choose more than one
answer)

Mineral □ Sport
nutrition □ Vitamin □ Other □
Specify (……….)

Chews/ □
Gummy

Drink

□ Drops □

Gel

□ Gel caps □ Granule □

Liquid

□ Lozenges □ Powder □

Soft gels □

Spray

□ Tablet □

Vegicaps □ Wafers □ Don’t □
know
4

Do you have a system to record
health supplements use?

Yes □

No □

Always □

5

How often do you discuss health
supplement products use with your
patients/customers? (if your answer
is “Never”, please proceed to
question C9)

6

What is the topic of discussion about
health supplement products use with
your patients/customers? (you can
choose more than one answer)

Internet □ Printed material □

7

Which of the following health
supplement products information
sources are helpful in caring for your
patients/customers? (you can choose
more than one answer)

8

What are the barriers that limit
discussing health supplement

Literacy □

Often □

Sometimes □ Never □

Product effect □ Product adverse
event □ Product quality □ Product
price □ Other □ Specify (…….…)

Multimedia □ Other □
Specify (…….…)
Cultural ethics □
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products with your
patients/customers? (you can choose
more than one answer)

Language □ Social level □

Yes □

9

Have you ever experienced an
adverse event related to health
supplement consumption in
patients/customers during your
practice? (if your answer is “No”,
please proceed to question C14)

10

How frequently have you
Once □ Occasionally (monthly
encountered adverse events related to or rarer) □ Frequently (every
health supplement consumption?
week) □

11

What was the adverse event?
(you can choose more than one
answer)

Other □

Specify (…….…)

No □

Abdominal Alopecia
pain □
□

Anorexia □

Asthenia □ Chest
pain □

Convulsion
□

Dermatitis Diarrhea Dizzines
□
□
s□
Dyspnea □ Edema □

Headach
e□

Hypotensi Nausea □ Pain □
on □
Pruritus □ Pyrexia
□

Sedation
□□

Urticaria □ Vomiting
□

12

13

How often have you recorded health
supplements adverse events? (if your
answer is “Never”, please proceed to
question C14)
To which higher authority/ personnel
did you report health supplement
adverse events? (you can choose
more than 1 answer)

Always □

Often □

Sometimes □

Never □

Ministry of Health □
Senior physician □
Pharmacist in-charge □
Other □ Specify (………)

14

Is adverse event reporting form
available when you are at the job of
prescribing/dispensing medicines to
the patients/customers?

Yes □

No □

Don’t Know□
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Section D. Attitude
You report health supplements related
1

adverse events to the higher

Strongly agree □ Agree □ Neutral □
Disagree □

Strongly disagree □

authority/personnel.
It’s not important □ Don’t know where
to report □ Don’t know what is

2

What is the reason if you

adverse event of health supplement □

don’t/wouldn’t report an adverse

Concerned that the report is a false

event?

alert □ Lack of time to investigate the

(you can choose more than one

case at work □ Consider as extra work

answer)

(not your concern) □ Difficulty in
confirming/distinguishing the adverse
event □ Other Specify (…..……) □

3

4

Do you think it is important to report

Yes (all) □ Only when hospitalisation

all adverse events of health supplement

is needed □ Only when it is life

products?

threatening □ No □

What do you think about the

Definitely beneficial □ Somewhat

establishment of a surveillance system

beneficial □ Not sure □ Not

of adverse events related to health

beneficial □ Definitely not beneficial □

supplement consumption?

5

Are you concerned about legal

Definitely □

Somewhat □

problems of reporting an adverse

Not sure □ Not □

Definitely not □

event?
6

Do/would you feel confident when

Definitely □

Somewhat □

reporting an adverse event?

Not sure □ Not □ Definitely not □
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Appendix G: Information Sheet B
Title of project: Healthcare Professionals’ Knowledge, Attitude and Practice of
Health Supplement Products Related Adverse Events

You are being invited to take part in a research study. Before you decide it is
important for you to understand why the research is being done and what it will
involve. Please take time to read the following information carefully and discuss it
with others if you wish. Ask us if there is anything that is not clear or if you would like
more information. Take time to decide if you wish to take part. Several chemicals
within the content of health supplement product (HS) may affect human health by
inducing certain adverse events. Previous studies found that consumers are generally
unaware regarding HS risks, its associated adverse events and proper reporting process
to concerned authorities. More, many healthcare professionals have inadequate
knowledge, attitude and practice (KAP) on the issue. This study aims to conduct a
cross-sectional survey to identify the level of KAP among healthcare professionals in
the Emirate of Dubai.
It is up to you to decide if to take part. If you decide to take part you are still
free to withdraw at any time and without giving a reason. The information and opinions
you provide will be kept strictly confidential and used only for research purposes. Your
name and details cannot be linked to this survey and will not be identified in any
report/publication. The completion and submission of the electronic questionnaire
indicates the agreement for participation and acts as signature of the consent form.
The study is sponsored by the College of Medicine and Health Sciences of the
United Arab Emirates University as well as Dubai Municipality and reviewed by the
Al Ain Medical District Human Research Ethics Committee.

For any further information regarding the study, please contact:
Naseem M. R. Abdulla
Tel: +971 45035554
E-mail: nmrafee@gmail.com
March 2015
Thank you very much for participating in this study.
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